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Abstract 
 
To date, only five fluorinated natural products have been identified. These were isolated from 
both plants and bacteria. The bacterium Streptomyces cattleya has the ability to biosynthesise 
fluoroacetate and 4-fluoro-L-threonine. The first enzyme discovered to be capable of 
catalysing a C-F bond from fluoride ion, the fluorinase, was identified from S. cattleya in 2002 
and is involved in the first step in the biosynthesis of fluorometabolites. The complete 
metabolic pathway of fluoroacetate and 4-fluoro-L-threonine in S. cattleya was elucidated 
utilising a variety of different techniques. 
 
Recently, genome studies revealed the presence of four new fluorinase enzymes from 
different bacterial species. Cultures of one of these species, named Streptomyces sp. MA37, 
showed the production of new unidentified fluorometabolites. Over-expression of the FdrC 
gene from Streptomyces sp. MA37 was performed, and enzymatic assays of the FdrC enzyme 
allowed the conversion of 5-fluoro-5-deoxy-ribose to (2R,3S,4S)-5-fluoro-2,3,4-
trihydroxypentanoic acid. Identification of (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid 
as a new fluorometabolite was then confirmed by synthetic synthesis.  
 
Nucleocidin, an antibiotic containing fluorine, was isolated in 1957 from the soil bacterium, 
Streptomyces calvus. Since its isolation, attempts at re-establishing nucleocidin producing 
cultures have proven unsuccessful. The biosynthesis of nucleocidin involves a C-F bond-
forming enzyme unique to Streptomyces calvus. Production of a commercial strain from Pfizer 
was established and isotopic labelling studies with different labelled glycerols were completed. 
Pulse feeding experiments with (2R)-[1-2H2]-glycerol, (2S)-[1-2H2]-glycerol, glycerol-1,1,2,3,3-d5 
and [2-13C]-glycerol proved to be successful. Concomitantly, synthesis of highly pure putative 
substrates for the fluorinating enzyme was carried out. Unfortunately, cell-free extract experiments 
were achieved, but results from these were not conclusive.  
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1. Introduction 
 
1.1. Metabolism 
 
1.1.1. Catabolism and anabolism 
 
The word metabolism comes from the Greek “metabolē”, which means “change”. Metabolism 
refers to all chemical reactions involved in maintaining the living state of the cells within an 
organism. Biochemical transformations, which are enzymatically catalysed, allow cells to: 
grow, duplicate, maintain their structures and adapt to the environment. Enzymes are a crucial 
component of cellular metabolism, as they are responsible for mediating essential 
biotransformations, within the cell. They catalyse kinetically favoured reactions, which require 
energy, by coupling them to spontaneous reactions that release energy.1 The chemical 
reactions of metabolism can be organised into metabolic pathways and the regulation of these 
different pathways can also be carried out by enzymes, often in response to external signals. 
Some of these metabolic pathways are interconnected, leading to elaborate complexity.2  
Metabolism is heavily reliant on the availability of nutrients, which are broken down in order to 
provide the energy essential to run cellular processes.1 However, the types of nutrients that 
can be digested vary from one living organism to another. Despite this, a large variety of 
nutrients are capable of being utilised by most organisms, such as: animals, plants, and 
bacteria, and these are derived from three types of compounds: amino acids, carbohydrates 
and lipids. Metabolism is also involved in the elimination of nitrogenous waste such as 
ammonia, urea and uric acid.3  
Each biochemical reaction involved in metabolism can be divided into two categories: 
catabolism and anabolism. Catabolism involves the breakdown of large organic molecules to 
obtain energy and small components needed by anabolic reactions. These catabolic reactions 
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are very different for each organism, and depend on many factors such as their energy and 
carbon sources.4 Anabolism comprises the biosynthesis of all compounds required by the cell. 
In order to do this, the cell uses the energy released along with the small precursors made 
during catabolism. Anabolism contains three major steps; the first involves the biosynthesis of 
precursors e.g. amino acids, nucleotides, etc. The second usually involves the activation by 
ATP of these precursors and finally the last step involves the assembly of these activated 
precursors into more complex molecules such as proteins, lipids, polysaccharides and nucleic 
acids.5    
 
Scheme 1. Scheme showing interconnection between catabolism and anabolism. 
1.1.2. Primary and secondary metabolites 
 
Metabolites are small molecules that are considered to be either intermediates or products of 
cell metabolism. Metabolites possess various functions and can be divided into two classes: 
primary and secondary metabolites. Primary metabolites are fundamental to all cells e.g. DNA, 
proteins, lipids, etc. They are universal and responsible for the vital functions within in a cell 
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and as such are involved in the generation of energy, growth, cellular reproduction, breakdown 
of waste products and synthesis of cellular components.6  
Secondary metabolites are not necessary for the survival of the cell, and are often specific to 
a particular subspecies or even individual organism. They include polyketides, terpenoids, 
alkaloids, etc. and thus fulfil a variety of different roles within the cell, acting as: antibiotics, 
toxins, pigments, etc.6 Secondary metabolites are derived from the assembly of building 
blocks produced by primary metabolism. Primary and secondary metabolisms are closely 
connected. However, the metabolic pathways of secondary metabolites differ from organism 
to organism. Consequently, the range of natural products produced in nature is very diverse 
and these molecules contribute to a wide structural diversity.7  
1.2. Soil bacteria 
 
1.2.1. A large diversity 
 
Bacteria are single-celled organisms, typically 1 µm in length. This small size however, is 
compensated for by the vast number of bacteria in the soil; approximately 40 million bacterial 
cells can be found in one gram of soil.8 Moreover, soil is a habitat for the largest distribution 
of the world’s biodiversity. Bacteria are able to reproduce very quickly by binary fission and 
consume organic matter from their environment in order to make nutrients necessary for this. 
Such nutrients are also taken up by plants or different organisms. Despite having a 
comprehensive affiliation, the links between soil bacteria and other organisms, such as plants, 
are complex and often difficult to interpret.  
Soil bacteria can be divided into four different groups, the first of which represents the majority; 
the decomposer bacteria. They are named as such because they consume simple carbon 
compounds, for instance, most decomposers can breakdown pesticides and pollutants. The 
second group are the mutualists, because they form an intimate partnership with plants. 
Pathogens compose the third group of soil bacteria and they are responsible for the formation 
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of a gall, which is an abnormal plant growth. The last group contains bacteria that consume 
compounds of nitrogen, sulfur or hydrogen instead of carbon in order to obtain their energy. 
All bacteria from these four groups execute important processes related to water dynamics 
and nutrient cycling.9,10  
1.2.2. Streptomyces bacteria 
 
Most antibiotics in clinical use are isolated from Actinomycetes.11 The abundance of microbial 
antibiotics from this source can be explained by the limited presence of specific nutrients in 
soil. The competition between soil bacteria for these nutrients increases the production of their 
secondary metabolites, which include antibiotics.12 Therefore antibiotic production is used as 
a defence strategy by bacteria in order to ensure survival in a competitive environment. It has 
been argued that secondary metabolites act upon specific receptors in competing 
organisms.13 Among soil bacteria the largest antibiotic-producing genus are the 
Streptomycetes.14 Streptomyces are Gram-positive bacteria that grow in various 
environments, and are characterised by a rich secondary metabolism. Moreover, the 
antimicrobial secondary metabolites produced by Streptomyces tend to be of low molecular 
weight with complex chemical structures. The production of antibiotics is specific for each 
species, depending upon their external environments.15 Production of a given metabolite 
usually begins in response to a lack of or presence of a particular nutrient in the culture 
medium and tends to occur over a narrow time window, prior to events such as sporulation. 
Some examples of antibiotics discovered from different Streptomyces bacteria are shown 
below in Scheme 2.  
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Figure 1. Antibiotics isolated from Streptomyces bacteria. 
Streptomyces bacteria form spores with very limited mobility. After spore germination, 
vegetative hyphae grow and then aerial hyphae with new spores are formed as coiled threads 
at the terminus. Finally, the layers of hyphae can differentiate into chains of spores. Each 
different stage of the Streptomyces’ life cycle are described in Scheme 2.15 Due to the limited 
availability of nutrients Streptomyces secrete antimicrobial secondary metabolites in order to 
protect their resources and to eliminate competing organisms.12    
 
Scheme 2. Streptomyces life cycle. 
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1.2.2.1. Streptomyces cattleya 
 
The soil bacterium S. cattleya, discovered in 1976, has the ability to produce the antibiotic 
thienamycin 4 (Figure 2). S. cattleya presents a recognizable phenotype, as it appears with 
purple spores as shown below in Figure 3. Thienamycin 4 was the first of a series of naturally 
occurring β-lactam antibiotics to be found with a carbapenem ring system.16 This antibiotic 
presented with good activity against both Gram-positive and Gram-negative bacteria. Its mode 
of action is similar to that of penicillin, operating via disruption of cell wall biosynthesis. 
Thienamycin 4 was isolated using extensive purification procedures and its structure was 
elucidated in 1979, however, isolation of this antibiotic proved to be very difficult due to its 
instability.16  
 
Figure 2. Structure of thienamycin 4. 
 
Figure 3. Photography of Streptomyces cattleya. 
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Thienamycin 4 is not the only β-lactam antibiotic produced by S. cattleya, indeed this soil 
bacterium has the ability to biosynthesise two other β-lactam antibiotics namely cephamycin 
C 5 and penicillin N 6 (Figure 4).17 Cephamycin C 5 is a very efficient antibiotic against 
anaerobic microbes.  
 
Figure 4. Antibiotics isolated from Streptomyces cattleya. 
1.2.2.2. Streptomyces calvus 
 
In the 1950s a soil bacterium called S. calvus was isolated in India. Unlike S. cattleya, S. 
calvus displays a “bald” phenotype deficient in the formation of aerial mycelium and spores, 
as shown below in Figure 5. It is well established that the inability to sporulate can decrease 
the production of secondary metabolites in Streptomycetes. Despite a lack of aerial mycelium, 
this soil bacterium is able to produce two related antibiotics, adiposin 1 7 and adiposin 2 8 
(Figure 6), which are α-glucosidase inhibitors.18  
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Figure 5. Photography of Streptomyces calvus. 
 
Figure 6. Antibiotics isolated from Streptomyces calvus. 
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1.3. Halogenated natural products 
 
1.3.1. Brominated, iodinated and chlorinated natural products 
 
Over 4000 halogenated natural products have been isolated and structurally characterised.19 
Most natural organohalogens contain chlorine or bromine atoms, with iodinated and 
fluorinated much rarer by comparison; with just over 100 iodinated natural products isolated 
so far.19 Natural products containing halogen atoms exhibit a wide range of important bioactive 
roles.20 Moreover, these natural products are produced by a variety of organisms such as 
plants, soil and marine bacteria, mammals, etc. Some examples of brominated, chlorinated 
and iodinated natural products with very different bioactivities are shown below in Figure 7. 
Fluorinated natural products will be described later in this chapter. 
 
Figure 7. Examples of halogenated natural products. 
1.3.2. Biological halogenation with chlorine, bromine and iodine 
 
Biological halogenation is achieved by three different mechanisms, via; a halide anion (X-), a 
cationic halonium ion species (X+) or a radical (X·).21 However most biological halogenations 
use either oxidative or radical reactions to generate formal electrophilic (X+) or radical (X·) 
species from the corresponding chloride, bromide or iodide ions.  
The main mechanism of biological halogenation is via the formation of a reactive hypohalite 
species through oxidation of the halide.21 This strategy allows the formation of carbon-halogen 
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bonds between an electron-rich carbon centre and an electron-deficient hypohalite. Numerous 
enzymes are responsible for this type of biological halogenation such as haloperoxidases and 
halogenases.21 In this section only biological halogenation concerning bromine, chlorine and 
iodine are detailed. Biological fluorination will be discussed in further details in the next section.    
A large number of iron-dependent enzymes were discovered from various organisms, which 
are able to biocatalyse radical halogenation.22 These enzymes are called non-haem-iron 
halogenases, and they are able to promote halogen-carbon bond formation with an 
unactivated sp3 carbon, such as a methyl group. They catalyse radical halogenation only in 
the presence of molecular oxygen, α-ketoglutarate and a chloride or bromide ion, which initially 
affords the formation of halo-Fe(IV)-oxo species 13. The next step proceeds via the 
abstraction of a hydrogen radical from the substrate to produce an Fe(III) species 14. Finally, 
the last step in this halogenation mechanism is the formation of halogen-carbon bond, 
promoting the reduction of the iron centre which returns to the ferrous oxidation state, as 
shown below in Scheme 3.23  
 
Scheme 3. Catalytic cycle of Fe-dependent halogenases. 
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Despite the existence of these non-haem-iron halogenases, which catalyse radical 
halogenation, most biological halogenation is achieved via cationic halonium ions (X+). The 
first halogenating enzyme to be isolated was a heme-iron haloperoxidase from the fungus 
Caldariomyces fumago.24 The mechanism of this enzyme was subsequently elucidated and is 
shown below in Scheme 4. During the first step peroxide binds to the resting FeIII-porphyrin 
complex 17, generating 18. The intermediate FeIV-oxo species 19 is then formed by water 
elimination, and is intercepted by halide to form FeIII-hypopalite species 20. Finally, the 
halogenation step can be achieved by two different routes; it can either be carried out directly 
from the FeIII-hypohalite species or hypohalous acid can be released from 20 and the 
halogenation reaction takes place away from the Fe centre.25  
 
Scheme 4. Mechanism of heme-iron haloperoxidase. 
Studies of biological halogenation in marine environments have revealed the presence of a 
second subclass of haloperoxidase enzymes, which utilise a vanadium co-factor.26 The mode 
of action of these vanadium haloperoxidase, shown below in Scheme 5, is very similar to that 
of the iron haloperoxidase mechanism. Indeed, it begins with the binding of peroxide to the 
vanadium centre to form an oxo-peroxo-V(V) species 22. This species 22 is an activated 
intermediate that is intercepted by halide in order to generate the hypohalite ion 23. Finally the 
nucleophilic substrate reacts with the hypohalite ion 23 to establish the halogen-carbon 
bond.27  
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Scheme 5. Formation of the hypohalite 23 by vanadium haloperoxidase. 
Most recently, another type of electrophilic enzymatic halogenation was discovered using 
flavin as a co-factor. During flavin catalysed halogenation, FADH2 24 reacts with peroxide to 
form an oxidised flavin intermediate 25, as shown below in Scheme 6. The halide ion is then 
oxidised by this flavin intermediate 25 to give hypohalous acid, which consequently reacts with 
the substrate.28 
 
Scheme 6. Mechanism of flavin catalysed halogenation. 
The last known process of biological halogenation is via a nucleophilic halide (X-).21 One 
example of this mechanism was recently discovered from Salinispora tropica. This SAM-
dependent chlorinase is responsible for the chlorination step during the biosynthesis of the 
natural product salinosporamide A 11, which was described in Figure 7. This enzyme transfers 
a chloride anion to the 5’-carbon atom of the S-adenosylmethionine 27a substrate to form 5-
chloroadenosine 28, as shown in Scheme 7. The first step of this mechanism involves the 
desolvatation of the chloride by replacement of hydrogen bonds to water with hydrogen bonds 
to amino acid residues within the enzyme active site. The desolvated chloride then attacks the 
5’-carbon atom of the sulfonium centre, displacing methionine 29, to generate 5’-
chloroadenosine 28 in a SN2 type reaction.29   
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Scheme 7. Formation of a chlorine-carbon bond mediated by the chlorinase. 
1.3.3. Fluorination techniques 
 
1.3.3.1. Fluorine: properties, effects and applications 
 
Elemental fluorine was prepared for the first time in 1886 by Henri Moissan, who was 
subsequently granted the Nobel Prize in 1906 for his work. Fluorine is an exceptional atom 
amongst the halogens in several respects. Firstly, it is the smallest of the halogens (its van 
der Waal’s radius is close to that of hydrogen and the hydroxyl group) and it is the most 
electronegative of all of the elements. Therefore the fluorine-carbon bond is highly polarised, 
which provides it with a substantial ionic character. It is very unlikely to form a positive 
fluorinium ion. The only natural isotope of fluorine is fluorine-19 with a spin quantum number 
(I) of ½, the same as hydrogen. This property is useful for NMR spectroscopy, which allows 
the detection of fluorine in biological systems. Physical properties of fluorine and hydrogen 
atoms are compared below in Figure 8.  
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X 
Bond 
dissociation 
energy 
(kcal/mol) 
Bond length 
(Å) 
Van der 
Waal’s radius 
(Å) 
Electronegativity 
(Pauling scale) 
F 106 1.38 1.47 4.0 
H 104 1.09 1.20 2.2 
 
Figure 8. Comparison of physical properties of fluorine and hydrogen. 
All of the properties discussed previously explain why substitution of a hydrogen or hydroxyl 
group with a fluorine atom in a molecule can be highly profitable. This type of substitution does 
not induce significant conformational changes, because the bond lengths and van der Waal’s 
radius are very similar. However, it generates impactful electronic effects because of fluorine’s 
high electronegativity. Fluorine can also form a weak hydrogen bond by acting as a hydrogen 
bond acceptor.30 Aromatic and olefinic fluorine atoms are weaker hydrogen bond acceptors 
than aliphatic fluorine atoms. Therefore, in order to investigate substrate-enzyme interactions, 
fluorine atom replacing hydroxyl group is a method widely used.31  
The electronegativity of fluorine can change the pKa of functional groups depending on the 
position of the fluorine atom. For instance, acetic acid has a pKa of 4.8 and trifluoroacetic acid 
has a pKa of 0.2. Introduction of a fluorine atom close to carboxyl or phosphate group tends 
to increase their acidity, but its close proximity decreases the basicity of amino groups. All 
these changes can provoke significant consequences in substrate/enzyme binding, 
particularly when binding efficiency is sensitive to acidity.  
By definition, a fluorine atom is not a good leaving group because of the high bond dissociation 
energy of the fluorine-carbon bond. However, its ease of hydration favours hydrogen fluoride 
elimination (HF) under specific conditions. For instance when a fluorine atom is located vicinal 
to an acidic hydrogen, elimination of hydrogen fluoride can occur under both acidic and basic 
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conditions. This strategy has been significantly investigated in the production of enzyme 
inhibitors known as suicide substrates.32  
For instance, methyl ketone substrates have proven to be inhibitors of the acetylcholinesterase 
enzyme. Fluorinated ketone analogues have shown better efficiency as inhibitors through 
formation of a stable hemiketal with the active site serine residue.33 Fluoro ketone substrate 
analogues are also inhibitors of protease enzymes when replacing NH with a CF2 moiety. 
Fluorinated amide mimetic 35 can undergo the same nucleophilic attack from the enzyme; 
however, cleavage cannot occur as it does with the amide, see scheme 8. 
 
Scheme 8. Example of an enzyme inhibition by a fluorinated analogue.  
The introduction of a fluorine atom or trifluoromethyl group into a molecule tends to change its 
lipophilicity. Fluorination often increases the lipophilicity, which makes the organocompound 
more fat soluble. However, this is not general; for instance, introduction of a fluorine atom in 
α position to carbonyl compounds lowers the lipophilicity.34 These properties of the fluorine 
atom and the effects caused by hydrogen-to-fluorine substitutions reinforce why fluorine is 
considered a low-risk, and potential high impact substituent. Appropriate introduction of a 
fluorine atom during drug optimisation can improve efficacy. Nowadays around one fifth of all 
drugs in the market contain at least one fluorine atom. Indeed, the structures of two 
blockbuster drugs contain fluorine substituents as shown below in Figure 9.     
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Figure 9. Blockbuster drugs containing fluorine substituents. 
Atorvastatine 39, also known as Lipitor, is a lipid lowering agent which is used for prevention 
of cardiovascular disease. It is an inhibitor of HMG-CoA reductase which is an enzyme in the 
liver responsible for the production of cholesterol.35 Sofosbuvir 40 is a drug blockbuster which 
is used for the treatment of hepatitis C. This prodrug 40 is metabolised to an active antiviral 
agent that acts as an inhibitor of viral RNA synthesis.36    
Fluorine substituents are not only used in medicinal chemistry but are also found in numerous 
other applications. Indeed, production of fluorinated organic compounds for industrial 
application began in the 1930s with the preparation of chlorofluorocarbons as refrigerants.37 
The major turning point for the development of industrial fluoroorganic chemistry was the 
Manhattan project during the 1940s. This project was launched in the context of War World II 
for the production of weapons. From the 1950s more civilian applications of industrial 
fluoroorganic chemistry were developed such as in pharmaceuticals. Nowadays the 
fluorochemical industry is involved in a wide range of different fields of application, such as: 
fluoropolymers, agrochemicals, fluorosurfactants, liquid crystals, etc. Some examples of these 
are shown below in the Figure 10.  
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Figure 10. Examples of fluorinated compounds used in industry. 
Polytetrafluoroethylene 41, also known as TeflonTM, is a fluoropolymer which is used for many 
different applications. It was discovered accidentally in 1938 by Roy Plunkett.38 Most 
applications of Teflon involve wiring in aerospace and computer applications; however it can 
also be used in cookware such as coating non-stick frying pans. Bifenthrin 42 is an insecticide 
from the family of pyrethroids, which are harmless to humans, but are toxic to insects.39 This 
particular insecticide is primarily used against the red imported fire ant by acting on the insect’s 
neuromuscular system.40 Perfluorooctanesulfonic acid 43 is a fluorosurfactant which is utilised 
across various industries, such as: commercial aviation (hydraulic fluid), fire retardant flames 
industry, semiconductor industry, etc.41,42 
1.3.3.2. Fluorination reactions 
 
Despite the fact that the fluorine atom is widely used and considered as a crucial substituent 
for industrial applications, it is still very difficult to introduce fluorine into organic compounds. 
Fluorine gas was utilised as the first technique for fluorination and is still used today despite 
safe handling challenges. Due to the rigorous safety considerations of this technique, many 
novel fluorinating reagents have been developed in the last half-century. Organic reactions 
that create a C-F bond can be carried out via two different processes: electrophilic and 
nucleophilic fluorination.43  
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1.3.3.2.1. Electrophilic fluorination 
 
Cationic fluorine species cannot be formed because of the high electronegativity of fluorine, 
however, numerous species that contain an electrophilic source of fluorine have been recently 
developed. Reactivity of these electrophilic fluorinating reagents is based on a nitrogen-
fluorine bond. The first type of these reagents to become wide-spread on the market was the 
N-fluoropyridinium salts e.g. 44-46 of Umemoto.44 These reagents can react with most 
nucleophilic substrates and can be tuned by modifying the pyridinium ring with different 
functional groups as shown below in Figure 11.   
 
Figure 11. Structures of different N-fluoropyridinium salts. 
A second type of electrophilic fluorinating reagent is the N-fluorosulfonamides. The most 
widely used reagent of this class is N-fluorobenzenesulfonimide 48, also known as NFSI. An 
enantioselective organocatalytic electrophilic fluorination of aldehydes with NFSI was 
developed by MacMillan and co-workers, as shown below in Scheme 9.45 The aldehyde 47 
reacts with the chiral amine 50 forming a chiral enamine, which then reacts with NFSI 48 
forming α-fluoroaldehyde which was immediately reduced to fluoroalcohol 49 with NaBH4 
because of its inherent instability.  
 
Scheme 9. Enantioselective fluorination by MacMillan. 
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The most widely used electrophilic fluorinating reagent Selectfluor 52 was developed by 
Banks, along with many of its derivatives (F-TEDA-X).46 Selectfluor 52 is a commercially 
available reagent which is very stable and widely used in organic chemistry for numerous 
applications.47 The oxidation potential of these F-TEDA-X reagents can be tuned by 
modification at the nitrogen substitution using electron-withdrawing substituents. Some 
structures of this type of electrophilic fluorinating reagents are shown below in Figure 12.  
 
Figure 12. Structures of electrophilic fluorinating reagents. 
1.3.3.2.2. Nucleophilic fluorination 
 
Fluoride ion was the first source of nucleophilic fluorine, and can be found as alkali fluorides 
such as: NaF, KF, LiF and CsF. LiF is the least reactive of these alkali fluorides, because of 
the decrease in both nucleophilicity and solubility observed when ionic strength increases. In 
order to increase the solubility of these fluorinating reagents in organic solvents crown ethers 
can be used in combination with alkali metal fluorides, such as KF-18-crown-6 54.48 However, 
a fluoride ion can form very strong hydrogen bonds which lowers its nucleophilicity, whereas 
its high basicity can often lead to elimination reactions. Therefore, additional fluorinating 
reagents based around the fluoride ion were developed, such as tetrabutylammonium fluoride 
53 (TBAF).49 The tetrabutylammonium counter ion increases the solubility of the fluoride ion, 
which in turn increases the reactivity of TBAF 53 as a fluorinating reagent. All of these 
nucleophilic fluorinating reagents can react with activated alcohols such as mesylates, 
tosylates, triflates, halides, etc.  
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Figure 13. Structures of TBAF 53 and KF-18-crown-6 54. 
Another important source of nucleophilic fluorine is based on anhydrous hydrogen fluoride 
(HF), a toxic colourless gas which necessitates rigorous safety considerations. This explains 
why substantial efforts were made to form stable hydrogen fluoride liquid reagents, such as 
HF-pyridine 55 and triethylamine tris(hydrogen fluoride) 56 (Et3N.3HF),  as shown below in 
Figure 14. HF-pyridine 55 is an acidic nucleophilic fluorinating reagent which was synthesised 
by Olah in 1973 as a 70% w/w solution of HF in pyridine.50 Triethylamine tris(hydrogen fluoride) 
56 is a neutral reagent which is more stable to elevated temperatures than HF-pyridine 55.  
 
Figure 14. Structures of HF.pyridine 55 and triethylamine tris(hydrogen fluoride) 56. 
In the 1970’s, due to the harsh conditions employed during the use of anhydrous hydrogen 
fluoride, safer nucleophilic fluorinating reagents were developed.51 These reagents are easier 
to handle and sulfur-based, such as diethylaminosulfur trifluoride (DAST) 57 and Deoxofluor® 
58 as shown below in Figure 15. These three nucleophilic fluorinating reagents are used for 
the deoxofluorination of alcohols.  
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Figure 15. Structures of DAST 57 and Deoxofluor® 58. 
Both DAST 57 and Deoxofluor® 58 exist in equilibrium between their neutral and activated 
form with a fluoride counter ion. The lone pair of the alcohol attacks the sulfur atom of the 
activated form of DAST 57 or Deoxofluor® 58, which causes the liberation of fluoride ion. This 
fluoride ion can then attack the electrophilic centre of the recently formed activated alcohol in 
order to give the fluorinated product.   
 
Scheme 10. General mechanism of fluorination of alcohol with DAST 57 or Deoxofluor® 58. 
More recently, other sulfur-based fluorinating reagents such as XtalFluor-E® 59, XtalFluor-
M® 60 and FluoleadTM 61 were developed in 2010.52,53 XtalFluor-E® 59 and XtalFluor-M® 60 
are more stable and easier to handle than DAST 57 and Deoxofluor® 58. Moreover, these 
reagents are safer because they do not generate free-HF. FluoleadTM 61 also proved to have 
a very high thermal stability. This reagent 61 also showed a resistance to aqueous hydrolysis 
which is a significant advantage in fluorine chemistry.  
 
Figure 16. Structures of XtalFluor-E® 59, XtalFluor-M® 60 and FluoleadTM 61. 
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1.3.3.3. Biological fluorination 
 
Despite progress in the development of new fluorinating reagents, most require harsh 
conditions to react. This has led to a greater interest concerning fluorination methods found in 
nature. In contrast to biological halogenation with bromine, iodine and chlorine, which can be 
performed by electrophilic, nucleophilic or radical reactions, biological fluorination is a very 
rare phenomenon in nature. One reason for this is that fluorination in nature can be achieved 
only via a nucleophilic reaction, as fluoride cannot be oxidised by haloperoxidases to generate 
radical and cationic fluorine. Indeed, fluorine’s redox potential is too high for coupling to known 
oxidations in living cells, such as haloperoxidase enzymes, as shown below in Figure 17.21  
 I Br Cl H2O2 F 
Redox 
potential (V) 
+0.54 +1.08 +1.36 +1.77 +2.87 
 
Figure 17. Redox potentials of halogens and peroxide. 
The level of fluoride in sea water is very low, at approximately 1.3 ppm. On the other hand, 
fluorine is the most abundant of the halogens in the Earth’s crust.54 Nevertheless, most fluorine 
in nature exists as insoluble fluoride minerals, such as fluorite (CaF2) and cryolite (Na3AlF6) 
(Figure 18). Therefore, these fluoride minerals cannot be used by living organisms. Moreover, 
fluoride ion is a poor nucleophile in aqueous systems because it is highly hydrated and 
consequently this hydration shell reduces its nucleophilicity. As mentioned previously, the 
fluorine atom is very small so it forms numerous and strong hydrogen bonds with water 
molecules. Thus fluorine biochemistry has hardly evolved in nature. Despite all these 
disadvantages, a small number of discoveries have been made concerning biological 
fluorination.  
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Figure 18. Photographies of cryolite and fluorite. 
1.3.3.3.1. Glycosidase mutants 
 
The first two examples for the enzymatic formation of a carbon-fluorine bond were reported 
with two different modified glycosidases. Glycosidase enzymes are responsible for the 
hydrolysis of glycosidic bonds in complex sugars. These enzymes are widespread in nature 
and are involved in numerous functions, such as: degradation of biomass, pathogenesis 
mechanisms, anti-bacterial defence strategies, etc. The mechanism of these glycosidase 
enzymes involve two steps; firstly a carboxylate group from an amino acid residue in the active 
site behaves as a nucleophile and attacks the anomeric centre generating a glycosyl enzyme 
intermediate. In the second step another carboxylate group acts as a base and deprotonates 
water, affording hydrolysis of the intermediate as shown below in Scheme 11. 
 
Scheme 11. General mechanism of glycosidase. 
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Examples of these two enzymes were engineered by site directed mutagenesis from two 
different bacteria, Agrobacterium sp. and Cellulomonas fimi.55,56 These mutations replaced the 
glutamate residue within the active site of the glycosidases with alternate residues such as 
glycine, serine or alanine. The first enzyme, β-glucosidase from Agrobacterium sp., was 
engineered with a serine residue in place of the native glutamate residue within the active site. 
It was found that in the presence of inorganic fluoride and 2,4-dinitrophenyl β-glycoside, the 
engineered enzyme showed very high activity.55,56 A proposed mechanism suggested that 
fluoride attacks the anomeric alcohol and transglycosylation occurs via transitory formation of 
glucosyl fluoride as depicted in Scheme 12.   
 
Scheme 12: Proposed mechanism for transglycosylation by Agrobacterium sp. β-glucosidase. 
A second range of mutants was prepared from Cellulomonas fimi by substitution of the 
glutamate residue in the active site by an alanine residue. Due to the absence of the 
carboxylate group which should act as a base, deglycosylation did not take place causing the 
glycosyl enzyme intermediate to accumulate in the media. It was also discovered that in the 
presence of high concentrations [~2M] of inorganic fluoride the anomeric carbon can be 
attacked by fluoride anion giving β-mannosyl fluoride, as depicted in Scheme 13.  
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Scheme 13. Proposed mechanism for transglycosylation by Cellulomonas fimi β-mannosidase. 
1.3.3.3.2. Fluorinase enzyme 
 
Despite the fact that the enzymatic synthesis of a carbon-fluorine bond was first reported with 
mutant glycosidases, the fluorinating activity of these enzymes was not native. The first, and 
unique, native fluorinating enzyme was discovered in 2002 from a soil bacterium named 
Streptomyces cattleya.57 This enzyme was given the common name “fluorinase” and S-
adenosyl methionine 27a was identified as the substrate. SAM 27a is converted to 5’-
fluorodeoxyadenosine 62a (FDA) (Scheme 14), which is immediately turned over towards the 
biosynthesis of other fluorometabolites.  
 
Scheme 14. Reaction of the fluorinase enzyme. 
Following purification, the structure of the fluorinase enzyme was elucidated by X-ray 
diffraction.58 The fluorinase exists as a dimer of trimers, containing three active sites with which 
the substrate SAM 27a can bind. The locations of these active sites are rather unusual, in that 
they are located at the subunit interfaces. X-ray structures of the fluorinase with the substrate 
SAM 27a and also the product FDA 62a bound, revealed that the ribose rings of the bound 
substrate and product possess an unusually ring planar structure (Figure 19).56  
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Figure 19. Representation of FDA 62a and methionine 29 bound to the active site of fluorinase.  
An experiment, probing the stereochemistry with SAM 27b bearing deuterium at the 5’-pro-S 
site, revealed that the fluorination reaction occurs with an inversion of configuration (Scheme 
15), consistent with a SN2 mechanism.59 Crystallographic58 and theoretical studies60 indicated 
that the fluoride ion was desolvated within the enzyme, allowing hydrogen bonds with three 
amino acid residues within the active site to be established. Furthermore, there is an 
electrostatic interaction between the negatively charged fluoride ion and the positively charged 
sulfonium atom in SAM 27a.61 All of these factors contributed to stabilising the transition state, 
and consequently lowering the activation barrier.60 
 
Scheme 15. The fluorination reaction with an inversion of configuration. 
The fluorinase mediates the equilibrium between SAM 27a and the products FDA 62a and 
methionine 29, favouring the products (Scheme 15). The enzyme has high substrate 
specificity, and as such only a small number of substrates have been shown to bind to its 
27 
 
active site. 5’-Chloro-5’-deoxyadenosine 28 (ClDA) is an example. The fluorinase also 
displayed chlorinase activity. Indeed, the enzyme catalysed the conversion of SAM 27a to 
ClDA 28, in the presence of inorganic chloride, in which the equilibrium lies heavily in favour 
of SAM 27a (Scheme 16).62 This observation has been particularly useful in the development 
of fluorinase mediated fluorination strategies, as ClDA derivatives are easier to synthesise 
than SAM derivatives. 
 
Scheme 16. Chlorinase activity of fluorinase. 
1.4. Fluorometabolites 
 
1.4.1. Fluoroacetate 63a 
 
Fluoroacetate 63a is the most common fluorinated natural product, and was first isolated by 
Marais in 1943 from a South African plant named Dichapetalum cymosum.63,64 Due to the 
presence of fluoroacetate 63a this small shrub was considered as a hazard to livestock in the 
Transvaal since the 1830s, and as such was known under the name of “gifblaar” which means 
“poison leaf”.65 This plant proved to be very difficult to exterminate, because of its persistent 
root system. During the spring, the young leaves are particularly toxic and contain 
approximately 2500 mg kg-1 dry wt of fluoroacetate 63a.  
 
Figure 20. Structure of fluoroacetate 63a. 
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After the first isolation of fluoroacetate 63a, this toxin was found to be produced by other 
species of Dichapetalaceae such as D. braunii in Tanzania.66 Fluoroacetate producers have 
not only been found in the African continent. A Brazilian species called Palicourea margravii, 
which is a shrub, is able to biosynthesise this toxin in high concentration (5000 mg kg-1 dry wt) 
in its seeds. However, Australia remains the country with the highest number of plants 
producing fluoroacetate 63a. Indeed more than 35 plant species were found in Western 
Australia with high concentrations of the toxin. Gastrolobium bilobum and Oxylobium 
parviflorum are both examples of Australian plants which accumulate high levels of 
fluoroacetate 63a. Despite the fact that all of these fluoroacetate plant producers have different 
origins, they are all found within tropical weather regions. However, the biosynthetic pathway 
of fluoroacetate 63a in plants has not been elucidated yet.  
In 1986, the first microorganism able to produce fluoroacetate 63a in the presence of inorganic 
fluoride was discovered.67 This microorganism is a soil bacterium named Streptomyces 
cattleya. The production of this fluorinated natural product was detected fortuitously during the 
optimisation for the production of the antibiotic thienamycin 4. The complete metabolic 
pathway of fluoroacetate 63a in S. cattleya was subsequently fully elucidated and will be 
described later on.  
1.4.2. Fluorocitrate 64 
 
The toxicity of fluoroacetate 63a is explained by the fact that it is absorbed into a living cell 
and then converted in vivo to fluorocitrate 64. This metabolic conversion from fluoroacetate 
63a to fluorocitrate 64 was referred to as the “lethal synthesis” by Peters.68 During this “lethal 
synthesis”, fluoroacetate 63a is converted to fluoroacetyl coenzyme A 65 by enzymes which 
usually accept acetate as their natural substrate.69 Fluoroacetyl coenzyme A 65 subsequently 
enters into the Krebs cycle where a condensation reaction with oxaloacetate is catalysed by 
citrate synthase forming fluorocitrate 64. This reaction is stereospecific since only the (2R, 
3R)-fluorocitrate 64 is produced. The first step of this condensation is the selective abstraction 
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of the 2-pro-S hydrogen. The second step is the attack at the Si-face of the carbonyl group of 
oxaloacetate which brings about an overall inversion of configuration at the fluoromethyl group 
of fluoroacetyl coenzyme A 65.70  
 
Scheme 17. Biosynthesis of fluorocitrate 64. 
The toxicity of fluorocitrate 64 can be partially attributed to the fact that it is a competitive 
inhibitor of the aconitase enzyme.71 Aconitase is the subsequent enzyme after citrate synthase 
on the Krebs cycle, which usually catalyses the interconversion of citrate and isocitrate. The 
exact mechanism for the inhibition of aconitase by fluorocitrate 64 has not yet been fully 
elucidated, but a proposed mechanism was described after the reporting of an X-ray structure 
where 4-hydroxy-trans-aconitate remained tightly bound to the enzyme.72 The first step begins 
by dehydration of fluorocitrate 64 to generate fluoro-cis-aconitate 66. Hydrolysis of the double 
bond of fluoro-cis-aconitate 66 leads to the displacement of fluoride resulting in the production 
of 4-hydroxy-trans-aconitate 67 as shown below in Scheme 18. However, the toxicity of 
fluorocitrate 64 cannot solely be explained by inhibition of the aconitase enzyme. The major 
toxicity of fluorocitrate 64 is due to the fact it binds covalently to a citrate carrier protein inside 
the mitochondria. This binding causes the inhibition of tricarboxylic acid transport which leads 
to the death of the cell.73,74       
 
Scheme 18. Proposed mechanism for the inhibition of the aconitase by fluorocitrate 64. 
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To avoid autotoxicity from fluorocitrate 64, plants and microorganisms have developed several 
mechanisms, one of which, among plants producing fluoroacetate 63a, is to compartmentalise 
fluoroacetate 63a in vacuoles or sacs remote from the mitochondria. It was also suggested 
that in some plants the citrate synthase enzyme has a lower affinity for fluoroacetyl coenzyme 
A 65. The only known mechanism of defence from fluorocitrate 64 in microorganisms was 
discovered in S. cattleya. One gene from S. cattleya’s genome has the ability to encode for a 
fluoroacetyl-CoA thioesterase. This enzyme allows the hydrolysis of fluoroacetyl coenzyme A 
65 as described below in Scheme 19.75 After enzyme acylation, a proton is abstracted by a 
histidine residue forming the enolate 69. After deacylation of the enolate 69, a ketene 
intermediate 70 is formed, followed by hydrolysis affording fluoroacetate 63a.    
 
Scheme 19. Hydrolysis of fluoroacetyl coenzyme A 65 to fluoroacetate 63a. 
1.4.3. ω-Fluorofatty acids 
 
In plants, such as the West African shrub Dichapetalum toxicarium, fluoroacetate can be 
further metabolised to toxic ω-fluorofattyacids. These fluorofatty acids are produced in the 
seeds, comprising about 3% of the seed oil and represents 80% of fluoroorganic compounds 
biosynthesised by the plant.76,77 Further investigation using GC/MS technology revealed that 
plants can produce a large range of ω-fluorofattyacids, such as: ω-fluorooleic acid 72, ω-
fluoropalmitic acid 73, ω-fluorocapric acid 74, etc. All of these ω-fluorofattyacids isolated were 
found to be more toxic than fluoroacetate 63a due to their higher lipid solubility, which 
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facilitates transport across cell membranes. It is thought that plants evolved to produce ω-
fluorofattyacids as a mechanism of defence against predators such as herbivore animals.  
 
Figure 21. Examples of natural ω-fluorofattyacids. 
The metabolic pathway of these ω-fluorofattyacids is identical to the conventional biosynthesis 
of fatty acids. Due to the high structural similarity to the natural substrate of the fatty acid 
synthase enzyme, fluoroacetyl coenzyme A 65 undergoes a condensation with malonyl-acyl 
carrier protein.78 In the biosynthesis of ω-fluorooleic acid 72, conversion from fluorostearoyl-
ACP to ω-fluorooleic-ACP is catalysed by a nonspecific stearoyl desaturase. ω-Fluorooleic 
acid 72 is generated by a final hydrolysis as described in Scheme 20. All fluorofatty acids 
isolated contained the fluorine atom at the ω-position. This can be explained by the fact that 
the enzymes involved in the fatty acid biosynthesis have very narrow substrate specificity, only 
accepts fluoroacetyl coenzyme A 65 as a starter unit and as such fluorinated malonyl-CoA is 
not accepted.    
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Scheme 20. Biosynthesis of ω-fluorooleic acid 72. 
1.4.4. 4-Fluoro-L-threonine 77a 
 
As described previously, the soil bacterium Streptomyces cattleya has the ability to produce 
fluoroacetate 63a, along with another fluorinated natural product, 4-fluoro-L-threonine 77a. 
They are produced in a 2:1 ratio. Indeed, during optimisation for the production of the β-lactam 
antibiotic thienamycin 4 by S. cattleya, the fluorinated 4-fluoro-L-threonine 77a, was identified 
and isolated in 1986.67 This was discovered fortuitously from a culture contaminated with 
inorganic fluoride in the medium. The structure shown in Figure 22 of this single stereoisomer 
was confirmed by asymmetric synthesis. The biological activity of fluorothreonine 77a was 
investigated and revealed it to exhibit antimicrobial activity against a variety of bacteria most 
probably due to its ability to act as an antimetabolite of L-threonine. Following this finding, 25 
species from the genus Streptomyces were cultured in the presence of inorganic fluoride ion. 
Over half of these species were able to uptake fluoride ion, however no fluorinated natural 
products were detected by 19F-NMR.79  
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Figure 22. Structure of 4-fluoro-L-threonine 77a. 
1.4.5. Nucleocidin 78a 
 
In 1957 the soil bacterium Streptomyces calvus was isolated in India. Interestingly, S. calvus 
has the ability to biosynthesise nucleocidin 78a, the only fluorinated nucleoside discovered.80 
Nucleocidin 78a is a nucleoside sulfonamide antibiotic containing a fluorine atom located at 
the 4’-carbon of the adenosine unit, as shown in Figure 23. Nucleocidin 78a exhibits a wide 
range of antibacterial activity against gram-positive and gram-negative bacteria, including 
some pathogenic bacteria, in addition to its efficiency against trypanosomes.80 However, due 
to its high toxicity, nucleocidin 78a never became a clinical antibiotic. This fluorinated natural 
product is unique because it is the only fluorosugar derivative discovered in nature.  
 
2.  
Figure 23. Structure of nucleocidin 78a. 
Nucleocidin 78a, along with the analogous nucleoside antibiotics ascamycin and 
dealanylascamycin,81 constitute a class of antibiotics that share a common structure, each 
containing a sulfonamide group at the ribose-C5’ position. This class of antibiotic is known to 
inhibit protein biosynthesis in human cells by interfering with the ribosome-dependent 
translation process.82 However, the biosynthetic mechanism of nucleocidin 78a for inhibiting 
protein biosynthesis has yet to be elucidated.  
Several structures were initially proposed for nucleocidin 78a, but it was not until 1969 that it 
was recognised to contain a fluorine atom.83 This confusion lay in the unusual coupling 
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patterns in the 1H-NMR spectrum, which are due to 19F-1H couplings. Assignment of the D-ribo 
configuration was confirmed by the total synthesis of nucleocidin 78a in 1976.84 Nucleocidin 
78a appeared to be the first example of a furanose sugar bearing a functional substituent at 
C-4. The fact that the fluorine atom was attached to the C-4 of the ribose ring suggested that 
the biosynthesis of nucleocidin 78a does not involve the fluorinase enzyme using SAM 27a, 
but rather, has a unique fluorination enzyme. However, the biosynthesis of nucleocidin 78a is, 
as of yet, completely unknown and thus requires further investigation.  
 
Microbial large-scale production of nucleocidin 78a was not established due to very low titres 
(1-5 mg/L) and poor reproducibility. Since 1957, re-isolation of nucleocidin 78a from publically 
available culture collections has been unsuccessful.  
1.5. Studies of metabolic pathways 
 
1.5.1. Different techniques 
 
The first technique commonly used for the elucidation of a metabolic pathway involves the use 
of putative precursors containing isotopic labels such as: 13C, 2H, 3H, 15N, etc. Radioisotopes 
can be detected by scintillation counting, however, a high degree of radiochemical purity is 
important to avoid errors from cross-contamination. Moreover, this technique does not reveal 
much in the way of regiochemical information, unless chemical degradation studies are 
employed. Stable isotopes have been used much more frequently due to the increasing 
sensitivity of analytical techniques available, such as GC/MS.  
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Isotope 
Relative natural 
abundance, % 
Half-life 
2H 0.015 stable 
3H < 0.001 12 years 
13C 1.1 stable 
14C < 0.001 5700 years 
18O 0.2 stable 
15N 0.37 stable 
32P < 0.001 14 days 
 
Figure 24. Properties of isotopes. 
13C-NMR is used to detect incorporation of an administered 13C labelled putative precursor, 
since heavy atom induced shifts. The development of 2H-NMR has also allowed the selective 
detection of incorporated deuterium into the metabolite under investigation. Deuterium 
labelling is approximately 60 times more sensitive than 13C labelling, however 2H spectra often 
present with poor resolution since 1H vibrates at higher frequency (400 MHz) than 2H. Another 
reason that explains its lower sensitivity is the quadrupolar nature of deuterium nucleus.  
The advantage in the study of the biosynthesis of fluorinated natural products is that isotope 
incorporations can be detected by 19F-NMR, without the need to purify the labelled 
fluorometabolites. However, in the presence of incorporated 2H or 13C the fluorine signals are 
shifted due to a heavy isotope effect. Incorporation of deuterium geminal to a fluorine atom 
causes an isotope shift of approximately 0.6 ppm to a lower frequency compared to the 
reference fluorine signal. This effect is additive, therefore two geminal deuterium atoms induce 
a more pronounced shift of about 1.2 ppm compared to that of the original fluorine signal. The 
shift induced by a deuterium atom bound geminal to the fluorine is considerably smaller (0.15-
0.35 ppm according to the angle).   
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The use of labelled intermediates is also exploited with cell-free extracts. Cell-free extract 
experiments allow the study of co-factor requirements and substrate specificity. Indeed, 
putative intermediates, which can be chemically synthesised, are added to the cells in order 
to identify if they are involved in the biosynthesis of the desired metabolites.  
Mutations to the genome of a particular organism of interest can be induced by numerous 
processes such as the treatment of cells with: UV-light, X-ray beams or chemical mutagens. 
These mutations can cause the accumulation of intermediates by blocking certain stages of 
the metabolic pathway. These mutations are induced at the genetic level by altering or 
knocking out gene enzymes.   
1.5.2. Metabolic pathway of fluoroacetate and fluorothreonine in S. cattleya 
 
1.5.2.1. Examples of feeding experiments in Streptomyces cattleya 
 
The bacterium Streptomyces cattleya has been cultured in a medium with 20% D2O. This 
produced fluorometabolites with a range of deuterium isotopomers. The 19F{H}-NMR spectrum 
of the supernatant of a resting cell experiment revealed each shift induced by deuterium 
incorporation, as shown in Figure 25 (Figure taken from M. R. Amin’s thesis).85 This spectrum 
revealed the production of two labelled fluoroacetates. The signal of the monodeuterated 
fluoroacetate is shifted upfield (α-shift) by approximately 0.6 ppm. Due to the additive nature 
of deuterium incorporation, the signal of the dideuterated fluoroacetate is shifted upfield (2x α-
shift) by ~1.2 ppm. Considering fluorothreonine, the first upfield shifted peak resulted from a 
β-shift of around 0.2 ppm due to the presence of a deuterium atom at the C-3 position of 
fluorothreonine. The second upfield shifted peak is shifted about 0.6 ppm compared to the 
reference signal, due to the α-shift. The third upfield shifted peak of about 0.8 ppm 
corresponds to double label incorporation at positions the C-3 and C-4, which results from a 
combined α + β-shift. The last peak at the highest field is due to a 2x β-shift of about 1.2 ppm.       
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Figure 25. 19F{1H}-NMR spectrum of the supernatant from resting cells of S. cattleya incubated with 
20% of D2O (M. R. Amin’s thesis, University of Durham, 1996). 
 
Feeding experiments using 2H- and 13C- metabolic precursors such as glycolate, glycine, 
serine, pyruvate, succinate, etc, suggested that only one fluorination enzyme is involved in the 
biosynthesis of both fluoroacetate 63a and fluorothreonine 77a.86-88 Indeed both fluorinated 
natural products showed similar incorporations of the labelled precursors. Feeding 
experiments with synthetic [2,2-2H2]fluoroacetaldehyde proved that fluoroacetaldehyde 79 is 
the branching point in the metabolic pathway of fluoroacetate 63a and fluorothreonine 77a.89  
1.5.2.2. Detection and purification of the fluorinase 
 
Cell free extract experiments were carried out using cells resuspended in a specific TAPS 
buffer (100 mM, pH 7.8) supplemented with potassium bicarbonate, magnesium chloride and 
potassium fluoride. Nucleotides such as ATP, UTP, GTP and CTP were administered to cell-
free extracts and those experiments were incubated at 37 °C. After incubation of ATP in these 
cell-free extracts, four different fluorinated compounds were observed by 19F-NMR: 
fluoroacetate 65, fluorothreonine 77a, 5’-fluoro-5’-deoxyadenosine 62a (FDA) and 5’-fluoro-
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5’-deoxyinosine 80 (FDI).90 Control experiments were performed on cell-free extracts 
incubated without the presence of potassium bicarbonate, magnesium chloride, potassium 
fluoride or ATP. Such experiments were only successful in producing fluoroacetate 63a, 
fluorothreonine 77a, 5’-fluoro-5’-deoxyadenosine 62a (FDA) and 5’-fluoro-5’-deoxyinosine 80 
(FDI) in the presence of KF, ATP and MgCl2. Magnesium chloride is very important because 
it stabilises the structure of ATP. At first, the triphosphate group of ATP was considered as a 
potential leaving group which could be attacked by a fluoride ion to form the product of the 
enzyme reaction named FDA 62a.  
However, after further investigations, it was established that addition of the amino acid L-
methionine 29 enhanced the production of the fluorinated organocompounds observed 
previously. This observation suggested that ATP might not be the substrate for the fluorinating 
enzyme. Indeed, SAM 27a was then explored as the substrate for the fluorination reaction, as 
it is derived from ATP and L-methionine 29 by the action of SAM synthase. A cell-free extract 
experiment with SAM 27a in place of ATP produced the same result. This experiment 
suggested that SAM 27a is the natural substrate for enzymatic fluorination as shown in 
Scheme 21.   
At first, FDI 80 was thought to be an intermediate in the biosynthesis of fluoroacetate 63a and 
fluorothreonine 77a. After further investigation, it was proven that FDI 80 is not an intermediate 
but a metabolic shunt product of FDA 62a. This side-product 80 is generated by the action of 
a deaminase enzyme which is known to be involved in purine degradation.     
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Scheme 21. Cell-free extract experiments with ATP. 
The fluorinase was purified to homogeneity in a four step protocol (ammonium sulphate 
addition; hydrophobic column; gel-filtration chromatography; anion exchange 
chromatography) to purify the fluorinase enzyme with the molecular mass of approximately 
180-190 kDa.90 Consequently, over-expression of the fluorinase for X-ray crystallography 
studies became a priority. From analysis of the wild-type protein, a partial amino acid 
sequence was acquired by Edman degradation. This was used by Dr. Spencer from the 
University of Cambridge to design PCR primers and the fluorinase gene was then located and 
cloned into Escherichia coli in order to over-express this enzyme.58 This method allowed for 
efficient purification of the enzyme. 
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ORF Length (amino acids) Annotated function 
flA 299 Fluorinase 
flB 299 
Purine nucleoside 
phosphorylase 
flC 397 MFS permease 
flD 216 Dehalogenase/Phosphatase 
flE 222 
DNA binding regulatory 
protein 
flF 185 
DNA binding regulatory 
protein 
flG 234 
DNA binding regulatory 
protein 
flH 467 Na+/H+ antiporter 
flI 489 Homocysteine lyase 
flJ 131 
DNA binding regulatory 
protein 
flK 139 Thioesterase/Acyltransferase 
flL 225 
DNA binding regulatory 
protein 
 
Figure 26. The Spencer cluster. 
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1.5.2.3. Metabolic pathway of fluorometabolites in S. cattleya 
 
An aldehyde dehydrogenase, which is responsible for the oxidation from fluoroacetaldehyde 
79 to fluoroacetate 63a, was purified from S. cattleya homogenates.91 This NAD+-dependent 
enzyme is ten-fold more specific for fluoroacetaldehyde 79 over acetaldehyde. Upon 
incubation of a cell-free extract of S. cattleya with fluoroacetaldehyde 79, L-threonine and 
pyridoxal 5’-phosphate (PLP), production of fluorothreonine 77a was enhanced. When the 
assay was carried out in the absence of L-threonine and PLP, there was no detection of 
fluorothreonine 77a by 19F-NMR. These experiments allowed for the identification and 
purification of a PLP-dependent fluorothreonine transaldolase.  
 
Scheme 22. Metabolism of fluoroacetaldehyde 79. 
The Schiff base was proposed to react with fluoroacetaldehyde 79 in an aldol-type reaction to 
afford the product fluorothreonine 77a as shown in Scheme 23.92 This PLP enzyme was found 
to be different from other related enzymes because glycine was not accepted as a substrate.  
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Scheme 23. Proposed mechanism for the enzymatic formation of fluorothreonine 77a by threonine 
aldolase. 
After investigation of the fluorinase enzyme, the fate of FDA 62a was explored. Due to its 
similar structure to adenosine, enzymes that metabolise adenosine were examined. One of 
these enzymes was a purine nucleoside phosphorylase (PNP), which was incubated with FDA 
62a resulting in the displacement of the adenine base by phosphate at the anomeric carbon. 
This enzymatic assay revealed the conversion of FDA 62a to 5-deoxy-5-fluoro-α,D-ribose 1-
phosphate 81 (FDRP), as illustrated in Scheme 24. FDRP 83 was subsequently incubated in 
cell-free extract experiments of S. cattleya and production of fluoroacetate 63a was observed, 
proving that FDRP 81 is a common intermediate in the biosynthesis of fluoroacetate 63a and 
fluorothreonine 77a.93  
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Scheme 24. The PNP reaction. 
5-S-Methyl-5-thioribose-1-phosphate 83 (MTRP) is a well-established intermediate of the 
methionine salvage pathway and was found to be a close analogue to FDRP 81. This is a 
common primary metabolic pathway which regenerates L-methionine 29 from waste by-
products of SAM 27a. Within this pathway, MTRP 83 is converted to 5-methylthioribulose-1-
phosphate 84 (MTRPuIP) via ring opening of the hemiacetal group of the ribose ring to form 
an acyclic keto-sugar under the action of an MTRP isomerase as shown in Scheme 25.  
 
Scheme 25. MTRP isomerase in the methionine salvage pathway. 
By homology, it was thought that a similar isomerase could accept FDRP 81 as a substrate 
and convert it to a 5-fluoro-5-deoxyribulose-1-phosphate 85 (FDRuIP). Moreover, ribulose 
phosphate compounds are well-known substrates for aldolase enzymes, creating aldehyde 
intermediates through a retro-aldol reaction. Therefore, fluoroacetaldehyde 79 could be 
generated from FDRuIP 85 by the action of a similar aldolase. FDRP 81 was incubated in cell-
free extract experiments of Streptomyces cattleya and a new fluorinated compound was 
observed by 19F-NMR. This proved to be FDRuIP 85 by GC-MS analysis after derivatisation 
of the reaction mixture with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA).94 PCR 
amplification of genomic DNA from S. cattleya, using primers generated from conserved 
regions of two different Streptomyces MTRP isomerases, led to the discovery of a similar gene 
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in the genome of S. cattleya. This gene was amplified, cloned into and over-expressed in E. 
coli. The protein obtained was able to convert FDRP 81 to FDRuIP 85.        
 
Scheme 26. Isomerase in the biosynthesis of fluoroacetate 63a and fluorothreonine 77a in S. cattleya. 
After isolation of FDRuIP 85 as an intermediate, it remained to carry out further investigations 
into how FDRuIP 85 was converted to fluoroacetaldehyde 79. Ribulose phosphate analogues 
of FDRuIP are known to undergo a retro-aldol reaction which is catalysed by DHAP-dependent 
aldolases. Two aldolases (fructose 1,6-bisphosphate aldolase and putative fuculose 1-
phosphate aldolase) were found in S. cattleya. The first enzyme produced an incorrect 
diastereoisomer in assays and the second could not be purified from cell-free extract 
experiments in S. cattleya.95  
 
Scheme 27. The aldolase reaction. 
However, a putative fuculose aldolase from S. coelicolor was over-expressed, along with all 
of the other enzymes (fluorinase, PNP, isomerase and fluoroacetaldehyde transaldolase) 
involved in the biosynthesis of fluorinated natural products. In the presence of various co-
factors and reactants, this experiment produced fluorothreonine 77a and indicated that an 
aldolase is responsible for the generation of fluoroacetaldehyde 79.96 Though the aldolase 
from S. cattleya is yet to be isolated and purified. The complete metabolic pathway of 
fluoroacetate 63a and fluorothreonine 77a is described in Scheme 28.  
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Scheme 28. Metabolic pathway of fluoroacetate 63a and fluorothreonine 77a. 
The complete genome of S. cattleya was elucidated in 2011. This genome contains a linear 
chromosome of 6.28 Mb (5822 genes) and a linear mega-plasmid of 1.81 Mb (1747 
genes).97,98 The genes involved in the biosynthesis of fluoroacetate 63a and fluorothreonine 
77a are not all located in close proximity. The transaldolase and the putative aldolase are 
located on the megaplasmid, whereas the “Spencer cluster” containing the flA gene is located 
on the chromosome. The full genome map of S. cattleya is depicted in Figure 23, with the 
fluorinase gene identified as flA and the PNP gene identified as flB. In order to confirm the six 
enzymes involved in the metabolic pathway of fluoroacetate 63a and fluorothreonine 77a, 
specific gene knock-out mutant strains of S. cattleya of all the revelant genes were prepared 
and production of fluorometabolites was analysed. During analysis of the knock-outs of each 
of the first four enzymes of the metabolic pathway, no production of fluorometabolites was 
observed. However, the knock-out mutant of the threonine transaldolase showed production 
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of fluoroacetate 63a only, confirming the branch point of the fluorometabolite biosynthesis 
pathway.99  
 
Figure 27. The full genome map of S. cattleya. 
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1.6. Conclusions and project aims  
 
 
The secondary metabolism of Streptomyces offers a wide range of natural products, many of 
which have found potential application in various fields, particularly in the pharmaceutical 
industry.15 To date, over 4000 halogenated natural products have been isolated from various 
sources in nature. However, among all these halogenated natural products, only five contain 
a fluorine atom.  
The rarity of fluorinated natural products can be explained by the fact that biological 
fluorination can only proceed via a nucleophilic fluoride ion. Indeed, cationic and radical 
fluorine cannot be generated in nature.21 Fluoride in aqueous medium is a poor nucleophile 
due to its hydrogen bonding with water, which creates a tight hydration shell around the anion. 
Therefore, the desolvation of the fluoride ion, which requires energy, is necessary for 
nucleophilic fluorination in nature.  
Due to the unique properties of the fluorinated natural products, investigations into new 
fluorometabolite producing bacteria were conducted. Recently, the production of new and 
unidentified fluorinated natural products by a soil bacterium named Streptomyces sp. MA37 
was observed. Therefore, the initial aim of this work was the identification of these new 
fluorometabolites by both total synthesis and enzyme assay, as discussed in Chapter 2. 
Due to the complexity within secondary metabolism, several techniques have been developed 
in order to elucidate the metabolic pathways involved. Until now, the biosynthesis of 
fluoroacetate 63a and fluorothreonine 77a in Streptomyces cattleya represented the only fully 
elucidated metabolic pathway of fluorometabolites. The elucidation of this divergent metabolic 
pathway allowed for the discovery and isolation of the only known native fluorinating enzyme, 
the fluorinase.  
Significant efforts have previously been deployed towards the discovery of a novel native 
fluorinating enzyme. According to the structure of nucleocidin 78a produced by Streptomyces 
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calvus, its biosynthesis is based on a different fluorinating enzyme than the previously 
discovered fluorinase. The aims of this second project was the elucidation of the metabolic 
pathway to nucleocidin 78a by conducting feeding experiments as described in Chapter 3. 
The second objective was to perform cell-free extract experiments for the determination of the 
native substrate for this new fluorinating enzyme, as reported in Chapter 4. 
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2. Identification of new fluorometabolite from Streptomyces 
sp. MA37 
 
2.1. Analogues of the fluorinase enzyme 
 
2.1.1. Four new fluorinase enzymes from different bacterial species 
 
In 2014, four new fluorinase enzymes were isolated from the bacterial species; Streptomyces 
sp. MA37, Nocardia brasiliensis, Actinoplanes sp. N902-109 and Streptomyces xinghaiensis 
NRRL B-24674.1,2 These fluorinases were identified through the mining of publically available 
databases of bacterial genomes and each shared high homology (>80%) with the fluorinase, 
isolated from S. cattleya.1  
 
N. brasiliensis is a species of Nocardia, a genus of Gram-positive, rod-shaped bacteria, which 
mimics fungi by forming small branching filaments. Like most bacteria, Nocardia can be found 
across the world where the soil is rich with organic matter. Some species of Nocardia are 
harmless to humans; however most are responsible for nocardiosis, an infectious disease 
which can be acquired by either inhalation or, more rarely, through traumatic introduction. This 
disease affects either the lungs (pulmonary nocardiosis) or the whole body (systemic 
nocardiosis).3,4 Consequently, it can be fatal for patients with weak immune systems, for 
example: children, the elderly and immunocompromised people. In 2012, the genome 
sequence of this hospital pathogen became publically available.5,6 Comparative genome 
analysis showed a new fluorinase enzyme which possessed 81% similarity to the fluorinase 
from S. cattleya. Unfortunately, cultures of N. brasiliensis in the lab were not able to produce 
either fluoroacetate 63a or 4-fluoro-L-threonine 77a, suggesting that this new fluorinase 
enzyme possesses a latent activity within this organism.1  
 
56 
 
Actinoplanes sp. N902-109 is a bacterium possessing aerial mycelia and spherical, motile 
spores.7 As with N. brasiliensis, the full genome sequence of Actinoplanes sp. N902-109 has 
been sequenced, and this became publically available in 2013.8,9 A fluorinase gene was 
identified within the genome, and this was subsequently over-expressed in E. coli.1 The 
enzyme possessed 80% similarity to the fluorinase enzyme from S. cattleya.10 Unfortunately, 
the organism was not placed in the public domain so it has not been determined whether this 
soil bacterium is capable of producing fluoroacetate 63a or 4-fluoro-L-threonine 77a in culture; 
however the over-expressed enzyme was found to be a functional fluorinase.1 
 
Streptomyces xinghaiensis NRRL B-24674 is a marine bacterium isolated in 2009 around 
Xinghai Bay, in Dalian, China.11,12 Its full genome was sequenced in 2011 and this showed the 
presence of a fluorinase gene sharing a high sequence identity (84%) to that of S. cattleya.2 
Fermentation of Streptomyces xinghaiensis NRRL B-24674 in the presence of inorganic 
fluoride was carried out but did not show fluorometabolites production. However, when this 
marine bacterium was incubated in the presence of potassium fluoride and artificial sea salt, 
the production of fluoroacetate 63a was observed.2 Streptomyces xinghaiensis NRRL B-
24674 is the only microorganism from the marine environment known to produce a fluorinated 
natural product.  
 
Additionally, a fourth fluorinase was discovered from the bacterium Streptomyces sp. MA37, 
isolated from a soil sample collected in Legon, Ghana, Dr. Kwaku Kyeremeh from the 
University of Ghana and Dr. Deng from the University of Aberdeen. The full genome sequence 
of this soil bacterium was determined in 2011, revealing that its fluorinase possessed 87% 
similarity to the fluorinase from S. cattleya. Cultures of S. sp. MA37 grown by Dr. Deng from 
the University of Aberdeen showed the production of fluoroacetate 63a and 4-fluoro-L-
threonine 77a, along with novel, as yet unidentified, fluorometabolites, as described in Figure 
2.1  
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Figure 1. Photograph of Dr. Deng (second from left) in Ghana where Streptomyces sp. MA37 was 
found. 
These findings suggested that the unknown fluorometabolites observed from S. sp. MA37 
cultures, were produced via a metabolic pathway related to that of fluoroacetate 63a and 4-
fluoro-L-threonine 77a. Additionally it was found that the concentration of fluoroacetate 63a 
and 4-fluoro-L-threonine 77a was greater than that observed for the other unidentified 
fluorinated natural products. The chemical shifts of 4-fluoro-L-threonine 77a and the 
unidentified fluorometabolites are in a similar region of the 19F-NMR spectrum, suggesting 
common fluoromethyl groups. Moreover, 4-fluoro-L-threonine 77a and the other unidentified 
fluorinated natural products share the same multiplicity with different coupling constants. 
Therefore, it was suggested these unidentified fluorometabolites have the same metabolic 
origin as fluoroacetate 63a and 4-fluoro-L-threonine 77a but there is a divergence creating two 
competing metabolic pathways (Figure 2).  
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Figure 2. 19F-NMR spectrum of an extract of Streptomyces sp. MA37 culture. 
2.1.2. Genetic and kinetic studies 
 
The amino acid sequences of the newly discovered fluorinase enzymes revealed that all of 
the active site residues were highly conserved. The three fluorinase enzymes from S. sp. 
MA37, N. Brasiliensis, Actinoplanes sp. N902109 were overexpressed in E. coli and were 
shown to be capable of catalysing the reaction between fluoride anion and SAM 27a forming 
the product FDA 62a. However, all were identified as slow enzymes, with turnover numbers 
(kcat) of less than 0.3 min-1, as described below in Figure 3.1 The three newly identified 
enzymes possess close kcat values, each of which were a little higher than that of the fluorinase 
isolated from S. cattleya. The catalytic efficiency (kcat/Km) is a constant that indicates the 
relative efficiencies. It was found that new fluorinase enzymes are all very slow such as that 
of Streptomyces cattleya.  
 
 
 
 
 
fluoroacetate 63a 4-fluoro-L-threonine 77a 
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SAM Km 
(µM) 
Turnover number 
kcat (min-1) 
Catalytic efficiency 
kcat/Km (mM-1min-1) 
S. cattleya 29.2 0.083 2.84 
S. sp. MA37 82.4 0.262 3.18 
N. Brasiliensis 27.8 0.122 4.40 
Actinoplanes sp. 
N902109 
45.8 0.204 4.44 
 
Figure 3. Kinetic data of the four fluorinase enzymes. 
The organisation of the biosynthetic genes responsible for fluorometabolite production by the 
four species, Streptomyces cattleya, Streptomyces sp. MA37, Nocardia brasiliensis and 
Actinoplanes sp. N902-109, was investigated (see Figure 4, image reproduced from O’Hagan 
et al.1). The genome maps of all three bacteria, from which the new fluorinase enzymes were 
discovered, shared high homology to fluorometabolite biosynthetic genes found in S. cattleya. 
In Figure 4, gene maps are centred around the fluorinase encoding gene flA. The genes 
encoding the FDRP isomerase and the fluorothreonine transaldolase are both located remote 
from the Spencer cluster in S. cattleya. However, in the three other organisms these genes 
were found to be located close to the gene encoding for the fluorinase, suggesting a greater 
evolutionary regulation of fluorometabolite biosynthesis.  
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Figure 4. Fluorometabolite biosynthesis gene organisations in S. cattleya, S. sp. MA37, N. brasiliensis, 
Actinoplanes sp. N902109. 
 
2.2. Analogy between Streptomyces sp. MA37 and Salinospora 
tropica 
 
2.2.1. A chlorinated natural product: salinosporamide A 11 
 
The full genome sequence of S. sp. MA37 was found to possess a high homology with that of 
Salinispora tropica and Salinispora arenicola. These marine bacteria, which are found in 
ocean sediments, are known to biosynthesise the anticancer agent, salinosporamide A 11, as 
shown below in Figure 5.  
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Figure 5. Structure of salinosporamide A 11. 
Salinosporamide A 11 was isolated in 2003 and has exhibited potent cancer cell 
cytotoxicity.13,14 This chlorinated natural product belongs to a family of compounds collectively 
called salinosporamides, each of which contains a densely functionalised γ-lactam-β-lactone 
ring structure.15 Its structure was confirmed by single-crystal X-ray diffraction analysis,13 and 
it is very similar to clasto-lactacystin-β-lactone, also known as omuralide 87 (see Figure 6), 
which was the first inhibitor of the proteasome discovered. The proteasome is a multicatalytic 
proteinase complex which is responsible for most nonlysosomal protein degradation within a 
living cell. Omuralide 87 specifically inhibits the proteolytic activity of the 20S subunit of the 
proteasome, without interfering with the other protease activities.      
 
Figure 6. Structure of omuralide 87. 
Due to the structural similarity between omuralide and salinosporamide A 11, the latter was 
investigated as a potential inhibitor of the proteasome. This study revealed that 
salinosporamide A 11 is 35 times more potent than omuralide 87.16 This chlorinated natural 
product 11 contains a cyclohexene substituent, which suggested perhaps that the inhibition 
mechanism of the proteasome by salinosporamide A 11 was different from the mechanism of 
action of omuralide 87. Indeed, the mechanism of this inhibition was revealed to be based on 
inhibition of all three proteolytic functions by covalent binding to the active site threonine 
residues of the 20S proteasome.13 Three years after its discovery, salinosporamide A 11 
62 
 
entered phase I in human clinical trials for the treatment of multiple myeloma, which is a cancer 
of plasma cells.   
2.2.2. Metabolic pathway of salinosporamide A 11 
 
Salinosporamide A 11 is a chlorinated natural product and the enzyme responsible for the 
chlorination step during its biosynthesis was identified in 2008.16 This enzyme shares a 
moderate homology of 30% to the fluorinase enzyme isolated from Streptomyces cattleya, 
and exhibits a very high substrate specific towards the specific halide ions, principally chloride 
ion, as fluoride ion cannot be utilised by this enzyme. This chlorinase enzyme is responsible 
for the conversion of SAM 27a and chloride ion to 5’-chloro-5’-deoxyadenosine 28 (ClDA), in 
an equivalent manner to the function of the fluorinase enzyme, as shown below in Scheme 1.  
 
Scheme 1. Formation of a chlorine-carbon bond by the chlorinase enzyme. 
Knockout experiments using Salinispora tropica were performed where the gene encoding the 
chlorinase was mutated and rendered inoperable.16 Incubation of FDA 62a or 5-fluoro-5-
deoxyribose 88 (FDR) in chlorinase-knockout mutant of S. tropica revealed the production of 
fluorosalinosporamide A,17 a fluorinated analogue of salinosporamide A 11, subsequently the 
biological activity and cytoxicity of fluorosalinosporamide A were evaluated. Its inhibition 
efficiency was half that of chlorosalinosporamide A 11, and its cytotoxicity was reduced by a 
factor of 20, as stated in Figure 7.17 Consequently, a S. tropica mutant was designed in which 
the gene encoding the chlorinase enzyme was chromosomally substituted with the gene 
encoding the fluorinase enzyme from S. cattleya. The mutant organism showed the production 
of fluorosalinosporamide A.18 
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Proteasome inhibition 
(nM) 
Cytotoxicity (nM) 
salinosporamide A 11 0.7 9.5 
fluorosalinosporamide A 1.5 210 
 
Figure 7. IC50 values for proteasome inhibition and cytotoxicity. 
In 2009, the complete metabolic pathway of the chlorinated building block of salinosporamide 
A 11 was determined by a combination of gene deletions and chemical complementation 
experiments using putative intermediates.19 The biosynthesis of the chlorinated building block 
involves 8 steps, beginning with the conversion of SAM 27a to ClDA 28 by a chlorinase 
enzyme. ClDA 28 is then transformed into 5-deoxy-5-chloro-D-ribose-1-phosphate 89 (ClDRP) 
by SalT, a purine nucleoside phosphorylase (PNP) responsible for the displacement of the 
purine moiety by phosphate group. In contrast to the biosynthesis of fluorometabolites in S. 
cattleya, ClDRP 89 undergoes hydrolysis of its phosphate group affording 5-chloro-5-
deoxyribose 90 (ClDR). Oxidation of the anomeric alcohol of ClDR 90 is followed by an 
elimination reaction generating a chlorinated α-ketoacid 92 which is then subjected to 
oxidative decarboxylation producing the corresponding CoA derivative 94. The latter 94 
undergoes an elimination reaction followed by hydrogenation affording the chlorinated 
intermediate 96 as described below in Scheme 2.  
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Scheme 2. Metabolic pathway of salinosporamide A 11. 
2.2.3. Aims of the project 
 
Comparison of the genomes of S. sp. MA37 and S. tropica revealed that they share high 
homology, especially for genes involved in the biosynthesis of the chlorinated intermediate 96; 
SalN, SalM and SalQ. Genome studies of the Streptomyces sp. MA37 strain showed the 
presence of a FdrA gene that is thought to encode a metal-dependent phosphoesterase, which 
shares 56% sequence identity with SalN of the salinosporamide gene cluster. Moreover, FdrB 
and FdrC genes also share high sequence identities with SalH (68% identity) and SalM (69% 
identity) and are predicted to encode a hydroxy-acid dehydratase and a chain dehydrogenase, 
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respectively. Therefore, based on information obtained from the investigation of 
salinosporamide A 11 biosynthesis, a metabolic pathway of the new fluorometabolites found 
in S. sp. MA37 (which require further structural and biosynthetic investigation) was proposed, 
as shown in Scheme 3. 5-Deoxy-5-fluoro-D-ribose-1-phosphate 81 was assumed to be a 
common intermediate to fluoroacetate 63a, 4-fluoro-L-threonine 77a and the new, as yet 
unidentified, fluorometabolites.   
 
 
Scheme 3. Proposed metabolic pathway of new fluorometabolites in S. sp. MA37. 
 
The enzyme FdrC was over-expressed by Dr. Long Ma from the University of St Andrews by 
designing a plasmid containing both an antibiotic resistance gene and the desired gene 
encoding for FdrC. Over-expression of the FdrC enzyme was accomplished, employing the 
same conditions used for the over-expression of fluorinase.20 
The initial aim of this project was to carry out enzyme assays with FdrC. In order to achieve 
this, the synthesis of FDR 88 was required. Absolute stereochemistry of the product of the 
enzyme FdrC catalysed reaction was verified through the chemical synthesis of (2R,3S,4S)-
5-fluoro-2,3,4-trihydroxypentanoic acid 98. Fluorolactone 97 was also prepared by synthesis, 
in order to investigate whether the enzyme FdrC catalyses the conversion of this lactone 97 
to fluorocarboxylic acid 98.  
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2.3. Synthesis of putative substrates of the FdrC enzyme  
 
2.3.1. Synthesis of 5-fluoro-5-deoxyribose 88 
 
An initial aim was to synthesise FDR 88. This was accomplished by following a procedure 
developed by Li et al., (Scheme 4).21 After preparation of FDR 88, it was envisaged that the 
anomeric alcohol could be oxidized giving fluororibolactone 97, which would then be subject 
to base-mediated hydrolysis to afford fluorocarboxylic acid 98. 
 
Scheme 4. Retrosynthetic strategy to FDR 88 by Li et al.21  
In order to synthesis FDR 88, an acetal protection of the 2’- and 3’-hydroxyl groups of D-ribose 
103 was accomplished using acetone and DMP in the presence of catalytic perchloric acid. 
This was followed by methanolysis of the anomeric hydroxyl-group via addition of MeOH to 
the acidic mixture.22 Acetonide 102 was isolated in 44% yield. Tosylation of the primary 
hydroxyl group of the ribose 102 was then achieved with a good conversion using tosyl 
chloride in dry pyridine. This reaction mixture was then purified by column chromatography 
affording 101 in 83% yield, as illustrated in Scheme 5.  
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Scheme 5. Protection of D-ribose 103 and tosylation of 102. 
Fluorination of tosylate 101 was achieved using an excess of TBAF 53 (5 eq.) in dry 
acetonitrile. The conversion was improved by increasing the reaction temperature from room 
temperature to reflux (22% to 44%). In an effort to further optimise this conversion, the reaction 
was carried out using a range of TBAF 53 concentrations; however both the yield and the 
conversion could not be further improved. This fluorination reaction was monitored by 19F-
NMR and after three days the conversion did not progress beyond 66%. Deprotection to reveal 
the hydroxyl groups of 100 was then achieved utilising aqueous sulphuric acid. The reaction 
mixture was quenched by addition of BaCO3, filtered and the product freeze-dried to give a 
mixture of α and β anomers of FDR 88 in 0.4:1 ratio (Scheme 6). This material was subjected 
to enzymatic assay studies with FdrC enzyme and the results will be described later in section 
2.4.  
 
Scheme 6. Synthesis of FDR 88. 
In 2015, a mild and selective deoxyfluorination reagent with increased stability, with respect 
to conventional reagents, was reported. PyFluor 104 was prepared from 2-mercaptopyridine. 
2-Mercaptopyridine is oxidised with aqueous sodium hypochlorite to form 2-pyridinesulfonyl 
chloride, and was then treated with potassium bifluoride to afford PyFluor 104.23 This reagent 
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claims to be a viable and inexpensive alternative to the reagents such as DAST 57 due to its 
selectivity against elimination and ease of reaction work-ups. Fluorination reactions with 
PyFluor 104 typically require a longer reaction time, along with the use of strong bases such 
as DBU and MTBD. A mode of action for PyFluor 104 has been proposed and is shown below 
in Scheme 7.  
 
Scheme 7. Proposed mechanism of fluorination reaction with PyFluor 104. 
PyFluor 104 was used for the optimisation of the synthesis of FDR 88. Indeed, this reagent 
allows the fluorination of acetonide 102, in the presence of MTBD as a base, in a very good 
yield (82%) as depicted in Scheme 8. The overall yields of both strategies are approximately 
75% but activation of the 5-hydroxyl of 102 into tosylate 101 was not necessary with the direct 
use of PyFluor 104.   
 
Scheme 8. Fluorination reaction with PyFluor 104. 
2.3.2. Synthesis of (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid 98 from 
5-fluoro-5-deoxyribose 88 
 
With FDR 88 in hand, oxidation at the anomeric position was completed by employing bromine 
in water. At neutral pH, previous kinetic studies indicated that the mechanism of such 
oxidations involve the formation of hypobromous acid.24-26 These mild conditions allow the 
selective oxidation of the anomeric alcohol of FDR 88 as illustrated in Scheme 9. 19F-NMR of 
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the crude product revealed the formation of the fluororibolactone 97 along with other 
unidentified side-products. Purification of the mixture by C-18 cartridge or ion exchange 
column proved to be difficult. 
 
Scheme 9. Mechanism of oxidation of α and β FDR 88 with Br2. 
It was therefore decided to carry out a one pot reaction with direct hydrolysis of fluorolactone 
97 in aqueous LiOH in the hope that purification of the newly formed carboxylic acid 98 could 
be more readily achieved (Scheme 10).27 This approach proved somewhat successful; 
however the fluorocarboxylic acid 98 was contaminated with side products, which could not 
be readily purified using a C-18 cartridge or ion exchange column.  
 
Scheme 10. Synthesis approach to fluorometabolite 98. 
2.3.3. Synthesis of (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid 98 
 
Due to the challenge in purifying (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid 98, an 
alternative approach was utilised, in which oxidation of the anomeric alcohol of the ribose ring 
was carried out before the fluorination reaction as illustrated in Scheme 11. The last two steps 
of this new strategy, which are acetal deprotection and ring-opening hydrolysis, are known to 
allow for a less challenging purification when compared to purifications involved in the previous 
strategy. 
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Scheme 11. Second retrosynthetic strategy to fluorometabolite 98.  
The 2’- and 3’-hydroxyl groups of D-ribose 103 were subjected to acetonide protection, using 
DMP in the presence of a catalytic amount of PTSA in acetone.28 Only the β anomer 110 was 
obtained in low yield after purification by column chromatography. Oxidation of the anomeric 
alcohol was then achieved with iodine in DCM in the presence of potassium carbonate, 
affording 109 in good yield, as shown below in Scheme 12. This reaction, along with the 
oxidation using bromine in water, was chemoselective as only the anomeric alcohol was 
oxidised.   
 
Scheme 12. Protection of D-ribose 103 and chemoselective oxidation of 110. 
Fluorination of the acetonide protected lactone 109 with Deoxofluor® 58 in DCM, at room 
temperature, afforded the protected fluorolactone 108 in good yield.29 In contrast to the first 
strategy; this route did not require formation of the tosylate as a leaving group. Indeed, the 
overall yield of the tosylation and the fluorination in the previous strategy was 37%. To 
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conclude, this strategy proved to be quicker, shorter and the yield of the fluorination step 
improved significantly. The yield of this fluorination reaction was improved from 52% to 87% 
by using the reagent PyFluor 104 instead of Deoxofluor® 58, as described previously in 
Scheme 7.  
 
Scheme 13. Fluorination of 109 and deprotection of acetonide 108. 
Moreover the crystal structure of the fluorinated compound 108 was determined by X-ray 
crystallography (Figure 8). The structure revealed that the fluorine atom adopts a gauche 
conformation relative to the oxygen in the ring and an endo conformation with respect to the 
ribose ring system. According to the previous studies by Buissonneaud et al.30, this endo 
conformation can be explained by the fact that the fluorine atom is partially electronegatively 
charged and the carbon C-1 is partially electropositively charged, therefore there is an 
electrostatic interaction between these two atoms. The acetonide 108 was then deprotected 
using TFA in water to afford pure fluorolactone 97. After work up there was still some residual 
TFA observable by 19F-NMR and as such several co-evaporations with Et2O were required to 
remove all of the remaining TFA (Scheme 13).  
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Figure 8. X-ray crystal structure of fluorolactone 108. 
Finally, the hydrolysis of fluororibolactone 97 was explored using aqueous LiOH (Scheme 
14).27 After purification, the 19F-NMR revealed the presence of fluoride anion in addition of the 
desired product 98.  
 
Scheme 14. Final step of the synthesis of the novel fluorometabolite 98. 
In order to confirm that the synthetic fluorocarboxylic acid 98 exactly correlated to the 
fluorometabolite observed from S. sp. MA37 cultures, a spiking experiment was carried out, 
as shown below in Figure 9. 19F-NMR of a culture of S. sp. MA37 after 19 days revealed an 
increased presence of new fluorometabolites. Among them there was a peak at -233.30 ppm. 
This 19F-NMR sample was then spiked with the synthetically prepared fluorocarboxylic acid 
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98, and 19F-NMR revealed that the peak at -233.30 ppm had increased. This experiment 
confirmed that fluorocarboxylic acid 98 is a fluorometabolite of S. sp. MA37.  
 
Figure 9. 19F{1H}-NMR spiking experiment of Streptomyces sp. MA37 culture after 19 days in D2O 
(blue) and after adding synthetic fluorometabolite 98 in D2O (red). 
 
 
 
 
 
 
 
 
fluoroacetate 63a 
fluoroacetate 63a 
4-fluoro-L-threonine 77a 
4-fluoro-L-threonine 77a fluorocarboxylic acid 98 
+ synthetic material 
 
 
 
fluorocarboxylic acid 98 
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2.4. Enzymatic assays of FdrC enzyme  
 
2.4.1. Identification of FDR 88 as a key intermediate 
 
ClDRP 89 is the last intermediate in salinosporamide A 11 biosynthesis which possesses a 
corresponding fluorinated analogue (FDRP 81) within the metabolic pathway of fluoroacetate 
63a and fluorothreonine 77a in Streptomyces cattleya. Therefore, it was hypothesised that 
FDRP 81 is the branching point for the biosynthesis of fluoroacetate 63a, fluorothreonine 77a 
and the new fluorometabolites in Streptomyces sp. MA37.  
To investigate this hypothesis, the role of FDR 88 in the biosynthesis of these unknown 
fluorometabolites was examined. FDR 88, which was prepared by synthesis, was incubated 
in a cell-free extract of Streptomyces sp. MA37 and monitored by 19F-NMR. The spectrum 
obtained was very different from that of whole cell incubations in the presence of inorganic 
fluoride. The resulting 19F-NMR spectrum showed a dominance of fluoroacetate 63a and 
fluorothreonine 77a over the seven fluorometabolites produced by this organism. Indeed, in 
this new experiment signals of some of the ‘minor fluorometabolites’ had increased and 
subsequently signals corresponding to fluoroacetate 63a and fluorothreonine 77a had 
diminished, as shown below in Figure 10.20 This indicates that FDR 88 may be an intermediate 
of some of the new fluorometabolites of Streptomyces sp. MA37. However, it did not 
upregulate the biosynthesis of fluoroacetate 63a and fluorothreonine 77a.      
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Figure 10. 19F-NMR spectroscopic analysis of fluorometabolites:                                                         
(A) in the supernatant of culture from Streptomyces sp. MA37.                                                            
(B) in the cell free extract of MA37 strain incubated with FDR 88. 
 
2.4.2. Enzyme assays 
 
With FDR 88 in hand, it became an objective to determine whether the FdrC enzyme is able 
to utilise FDR 88 as a substrate. Subsequently, over-expression of a codon-optimized 
synthetic gene for FdrC in E. coli, including a His6 tag and a TEV protease cleavage site was 
performed in our laboratory by Dr. Long Ma. After purification of the coded protein, the 
molecular weight of this isolated FdrC enzyme was estimated to be approximately 31 kDa.31  
Enzyme assays with the FdrC enzyme using various conditions were carried out and 
monitored by 19F-NMR spectroscopy. The enzyme reaction of FdrC in the presence of FDR 
88 without any co-factors did not show any conversion. Incubation of FdrC enzyme with FDR 
88 and NADP+ still resulted in no observable turnover. However, the enzymatic reaction in the 
presence of FDR 88 and NAD+ revealed a complete conversion of FDR 88 to a new 
organofluorine compound at -233.15 ppm with the same multiplicity (dt) by 19F-NMR. This 
result revealed that the FdrC enzyme is a NAD+-dependent enzyme. According to the 
fluoroacetate 63a 4-fluoro-L-threonine 77a 
β-anomer FDR 88 
α-anomer FDR 88 
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proposed metabolic pathway of salinosporamide A 11 in Salinospora tropica (see Scheme 2), 
fluorocarboxylic acid was thought to be formed via a multi-step FdrC enzyme catalysed 
reaction. This reaction can reasonably proceed in two steps: firstly oxidation of the anomeric 
alcohol to lactone 97, followed by a ring opening hydrolysis. Incubation of fluorolactone 97 
with the FdrC enzyme in the presence of NAD+ revealed the appearance of FHPA 98 as 
indicated by 19F-NMR but there was no obvious presence of fluorolactone 97, suggesting an 
instantaneous hydrolysis. In addition to this, enzymatic reaction products along with bacterial 
culture products were derivatised with N-methyl-N-trimethylsilyl trifluroacetamide (MSTFA) 
and analysed by GC-MS in the James Hutton Institute by Dr. Thomas Shepherd. The same 
protocol was followed for the derivatisation of the synthetic fluorocarboxylic acid 98 that 
showed an identical fragmentation and retention time, proving that they are both the same 
fluorometabolite. All these results are summarised in Figure 11 and Figure 12.31 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. GC-MS fragmentation analysis of MSTFA treated extract showing the mass spectrum and 
fragmentation pattern of FHPA (TMS)4. 
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Figure 12. 19F-NMR spectroscopic analysis of:  
(A) 19F{1H}-NMR of FdrC after overnight incubation with FDR 88 at 37 °C.  
(B) 19F{1H}-NMR of the FdrC enzymatic reaction after overnight incubation with NADP+ and FDR 88 at 
37 °C. 
(C) 19F{1H}-NMR of the FdrC enzymatic reaction after overnight incubation with NAD+ and FDR 88 at 
37 °C. 
(D) 19F{1H}-NMR of FdrC enzymatic reaction after overnight incubation with NAD+ and fluorolactone 97 
at 37 °C. 
(E) 19F{1H}-NMR of aqueous solution of 97 after overnight incubation at 37 °C.  
(F) 19F-NMR of synthetic fluorolactone 97. 
Left insert: the enzymatic reaction; right insert: the GC-MS fragmentation pattern of FHPA 98. 
 
Kinetic studies with FdrC enzyme carried out in our laboratory by Dr. Long Ma, demonstrated 
that FdrC has a higher affinity for D-ribose 103 over FDR 88 as indicated by the Michaelis 
contant (Km) values. However, both substrates are oxidised with a very similar efficiency 
(kcat/Km) as shown below in Figure 13.20  
 
 
88
88                                                                    
98                                                                    
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Km 
(µM) 
Turnover number 
kcat (min-1) 
Catalytic efficiency 
kcat/Km (µM-1min-1) 
D-ribose 0.84 0.32 0.38 
FDR 2.73 0.58 0.21 
 
Figure 13. Kinetic data of FdrC enzyme.31 
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2.5. Conclusion 
 
In conclusion, identification of FHPA 98 as a new fluorometabolite was achieved by 
synthesis. Its biosynthesis was revealed to eminate from branching of the established 
metabolic pathway to fluoroacetate 63a and 4-fluoro-L-threonine 77a.  Genetic studies 
revealed the presence of a gene cluster containing three genes (FdrA, FdrB and FdrC) 
which share high homology with genes involved in the biosynthesis of salinosporamide 
A 11 in Salinospora tropica. Over-expression of the FdrC gene was carried out by Dr. 
Long Ma, and enzymatic assays of the FdrC enzyme demonstrated that FDR 88 is a 
substrate for the enzyme. FdrC enzyme is responsible for the oxidation of the anomeric 
alcohol to give fluorolactone 97, followed by hydrolysis generating FHPA 98. Synthetic 
synthesis of FHPA 98 allowed the confirmation of the absolute stereochemistry of the 
product of FdrC enzyme reaction. Moreover, GC-MS analysis was achieved after 
derivatisation of synthetic FHPA 98 and derivatisation of the product of the enzymatic 
assay. This demonstrated that they are indeed the same compound by retention time 
and fragmentation pattern. All of these experiments demonstrate that FHPA 98 is a 
new fluorinated natural product of Streptomyces sp. MA37 and the first novel 
fluorinated natural product to be identified in over two decades. 
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3. Isotopic labelling studies into nucleocidin 78a 
 
3.1. Introduction 
 
 
3.1.1. Previous studies 
 
Since the initial discovery and isolation of nucleocidin 78a from Streptomyces calvus in 1957,1 its 
subsequent production has proved challenging. First of all, nucleocidin 78a production is difficult 
to observe, this is primarily due to the low titre during the cultivation of S. calvus, which is 
approximately 1 mg in 1 L. Moreover, the biosynthesis of nucleocidin 78a by S. calvus is very 
unpredictable, and publically deposited strains appear to have lost the ability to produce 
nucleocidin 78a altogether.2-4 Moreover, S. calvus is known to have a “bald” phenotype because 
of its lack of spores, and thus is defficient in the synthesis of secondary metabolites.  
 
3.  
Figure 1. Structure of nucleocidin 78a. 
Over the last 50 years, extensive investigations have been carried out to elucidate the biosynthesis 
of nucleocidin 78a.2-4 However, these studies have proved challenging due to the low level or lack 
of production. As a result, subsequent investigations have focused on revealing the reasons 
behind this inconsistent production. Firstly, it has been widely accepted, though not without some 
opposition, that the formation of spores and aerial mycelium in Streptomyces is crucial for the 
production of secondary metabolites.5 The absence of spores from Streptomyces calvus in solid 
media has been postulisated to be one reason for its seemingly unpredictable nucleocidin 78a 
production.  
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Furthermore, several studies have reported that certain mutations within the rpoB gene, which is 
known to encode the RNA polymerase β-subunit protein, favoured the production of secondary 
metabolites in Streptomyces.6 In one study, a wild-type strain of S. calvus underwent mutation of 
the rpoB gene by ultraviolet light irradiation,2 this mutant strain was then observed to exhibit 
resistance to rifampicin, which is known to inhibit transcription by binding to the β-subunit of RNA 
polymerase.7 The production of antibiotics, including nucleocidin 78a, was revealed to be 
enhanced in this mutant strain.2  
 
In 2013, genome sequencing of wild-type S. calvus identified a mutation in the bldA gene.3 The 
bld genes are crucial for initiating aerial hyphae development and sporulation in solid media. 
The bldA gene is responsible for encoding a tRNA which is important for the translation of 
mRNA involved in nucleocidin 78a biosynthesis. Correction of this mutation in the bldA gene, 
by complementation of a wild-type strain of S. calvus with a functional copy, allowed for the 
restoration of the production of nucleocidin 78a.4  
3.1.2. Production of nucleocidin 78a 
 
For this study, an in-house strain of S. calvus T-3018 was provided by Pfizer. Genome sequencing 
of this wild-type strain of S. calvus was carried out in China in 2014, and comparison of its genome 
sequence with that of the public strain of S. calvus revealed that S. calvus T-3018 does not 
possess a mutation within the bldA gene.  
As such, the first aim of the project was to establish nucleocidin 78a-producing cultures, from 
glycerol stocks of S. calvus T-3018. S. calvus T-3018 was grown on solid ISP4 medium for 20 
days (solid ISP2 medium was also trialed, however this did not provide sufficient nucleocidin 78 
production). A specific fermentation medium, developed by Pfizer, was then used for the 
growth of S. calvus for 18 days (see section 5.3.2).  
After centrifugation, the supernatant was lyophilised and production of nucleocidin 78a was 
assayed by mass spectrometry and 19F-NMR. Mass spectrometry indicated that nucleocidin 
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78a was produced, however in 19F-NMR experiments the chemical shifts of nucleocidin 78a 
and fluoride ion are close, and as the fluoride peak is very broad the nucleocidin 78a peak 
was obscured and could not be easily identified.  
In 1957, Thomas et al. reported that nucleocidin 78a could be dissolved in n-butanol.1 In 2009, 
successful extraction of antibiotics from S. calvus’ cultures was achieved using n-butanol by 
Fukuda et al.2 The smallest volume of n-butanol required for complete extraction of antibiotics 
was found to be one fifth of the volume of the culture broth.2  
Therefore, cultures of S. calvus were centrifuged and the supernatant extracted with n-butanol. 
The organic layer was concentrated and the 19F-NMR spectrum recorded. This method 
allowed for the separation, and the resolution, of nucleocidin 78a and fluoride ion peaks as 
shown in Figure 2. The production of nucleocidin 78a during these experiments was very low, 
and due to this the number of scans for 19F-NMR was increased to a minimum of 3600, over 
a 2 h acquisition time.  
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Figure 2. 19F-NMR spectrum of a butanol extract in D2O of S. calvus culture after 18 days. 
The experimental multiplicity (doublet of triplets), and coupling constants of nucleocidin 78a 
proved to be comparable to the reported coupling constants found in the literature, as 
presented in Figure 3.8  
 Experimental Literature8 
Multiplicity dt dt 
Chemical shift -119.86 ppm -121.64 ppm 
J 3’-F 19.0 Hz 17.2 Hz 
J 5’-F 7.3 Hz 7.5 Hz 
 
Figure 3. Comparison of 19F-NMR spectrum between Streptomyces calvus culture in D2O and synthetic 
nucleocidin 78a in D2O. 
 
 
fluoride ion 
nucleocidin 78a 
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LC-MS was then carried out on the butanol extract of the supernatant of S. calvus cultures to 
further confirm the production of nucleocidin 78a as shown in Figure 4. Moreover, purified 
nucleocidin 78a was provided by Pfizer and a 19F-NMR spiking experiment was performed, 
which confirmed undoubtedly the biosynthesis of nucleocidin 78a. These results confirmed 
that nucleocidin-producing cultures had been successfully established. 
 
Figure 4. LC-MS analysis of n-butanol extract showing the production of nucleocidin 78a in 
Streptomyces calvus culture. 
 
Not only was the amount of nucleocidin 78a produced from S. calvus T-3018 cultures very 
low, its production was also found to be very fickle. Indeed, most petri plates containing 
Streptomyces calvus did not show many spores. Cultures from petri plates containing spores 
did show enhanced nucleocidin 78a production. However, cultures from petri plates without 
spores could also support the production of nucleocidin 78a, although at much lower levels. It 
was also observed that the titres of nucleocidin 78a dissapeared with glycerol stock over time. 
Therefore, glycerol stocks of S. calvus T-3018 were regularly supplied by Pfizer.  
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Comparison of nucleocidin 78a and adenosine 111a reveal that they are structurally similar 
molecules. Both contain a ribose ring system as well as an adenine base. In addition to this, 
nucleocidin 78a contains a fluorine atom attached at the C-4’ of the ribose ring and a sulfamoyl 
group bound to the primary alcohol. Subsequently, it was hypothesised that adenosine could 
be either a putative substrate for a new fluorinating enzyme or an early intermediate in the 
biosynthesis of nucleocidin 78a. Therefore, the role and biosynthesis of adenosine 111a, in 
relation to nucleocidin 78a biosynthesis, were investigated. 
3.2. Biosynthesis of adenosine 111a 
 
3.2.1. The role of adenosine 111a 
 
Nucleosides are glycosylamines that contain nitrogenous bases such as: adenine, guanine, 
uracil, thymine and cytosine. This nucleobase is linked to a 5-carbon sugar such as ribose or 
deoxyribose via a β-N-glycosidic bound. All naturally occurring ribonucleosides are 
represented in Figure 5.  
 
Figure 5. Structures of ribonucleosides. 
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Certain kinases, possess the ability to phosphorylate nucleosides at the 5’-primary alcohol. 
After such phosphorylation, they are known as nucleotides, which are the building blocks of 
DNA and RNA. These nucleotides can be acquired either from the diet or biosynthesised by 
de novo pathways and are essential to almost all biological process within a cell.  
Nucleosides can be phosphorylated up to three times to form crucial nucleotides such as 
adenosine triphosphate (ATP), which provides the chemical energy needed for metabolism 
within cells; as the hydrolysis of ATP, forming adenosine diphosphate (ADP) and inorganic 
phosphate, allows for the release of energy that can be utilised in a variety of metabolic 
reactions.  
3.2.2. From glycerol 116a to adenosine 111a 
 
To establish that adenosine 111a is involved in the biosynthesis of nucleocidin 78a, the 
biosynthesis of adenosine 111a in S. calvus T-3018 was investigated. An overview of the 
numerous metabolic pathways producing adenosine 111a is described below. Since the 
strategy of this project was to conduct feeding experiments with labelled glycerols, the 
investigation was focused on the biosynthesis of adenosine 111a from glycerol 116a within 
the cell.   
One of these involves the S-adenosylmethionine (SAM 27a) cycle as described below in 
Scheme 1. In the SAM cycle, methionine 29 is first activated to generate SAM 27a, which then 
donates a methyl-group to various precursors which produce S-adenosylhomocysteine (SAH). 
SAH then undergoes cleavage to afford adenosine 111a and homocysteine. Finally, the 
regeneration of methionine from homocysteine requires vitamin B12 in the form of 
methylcobalamin.9  
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Scheme 1. SAM cycle producing adenosine 111a. 
Additionally, adenosine 111a can also be biosynthesised by a different metabolic pathway 
derived from glycerol 116a. Glycerol 116a is a prochiral molecule and a precursor of lipid 
triglycerides. This precursor can enter two different, parallel, metabolic pathways: glycolysis 
and the pentose phosphate pathway. Before entering into one of these two metabolic 
pathways, glycerol 116a must first be activated and transformed to a common intermediate 
known as glyceraldehyde-3-phosphate 118a, as described in Scheme 2. 
 
Scheme 2. Biosynthesis of glyceraldehyde-3-phosphate 118a from glycerol 116a. 
Firstly, phosphorylation of glycerol 116a by glycerol kinase to afford sn-glycerol-3-phosphate 117a 
is stereoselective, since glycerol 116a is always phosphorylated on the same pro-chiral arm (pro-
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R). Oxidation of the secondary alcohol of sn-glycerol-3-phosphate 117a is then achieved by a 
dehydrogenase enzyme, resulting in the formation of dihydroxyacetone phosphate 86a. Finally, 
this undergoes isomerisation by triosephosphate isomerase affording glyceraldehyde-3-
phosphate 118a. 
Glyceraldehyde-3-phosphate 118a can enter the pentose phosphate pathway to generate 
ribose-5-phosphate 119a as shown in Scheme 4, an advanced intermediate in the 
biosynthesis of adenosine 111a. The pentose phosphate pathway contains two different 
phases: an oxidative and a non-oxidative phase.10 The oxidative phase comprises the 
transformation of glucose-6-phosphate 120 to ribulose-5-phosphate 123a in three enzyme-
catalysed reactions as represented in Scheme 3. This phase begins with the oxidation of the 
hydroxyl group at C-1 of glucose-6-phosphate 120, generating 6-phosphogluconolactone 121 
and co-enzyme NADPH. 6-Phosphogluconolactonase is responsible for the hydrolysis of 6-
phosphogluconolactone 121 into 6-phosphogluconate 122. Finally, 6-phosphogluconate 122 
undergoes oxidative decarboxylation affording ribulose-5-phosphate 123a and NADPH.  
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Scheme 3. Oxidative phase of pentose phosphate pathway. 
The non-oxidative phase is responsible for the formation of 5-carbon sugars, as shown in 
Scheme 4. During this phase, two very important sugars are biosynthesised: erythrose-4-
phosphate 124 is a precursor of the aromatic amino acids and ribose-5-phosphate 119a is a 
precursor of nucleotides and nucleic acids. Glyceraldehyde-3-phosphate 118a can either react 
with fructose-6-phosphate 125 or sedoheptulose-7-phosphate 126 in reactions mediated by 
the same transketolase enzyme. Firstly, transfer of a 2-carbon fragment from fructose-6-
phosphate 125 to glyceraldehyde-3-phosphate 118a affords xylulose-5-phosphate 127a and 
erythrose-4-phosphate 124. Alternatively, transfer of a 2-carbon fragment from 
sedoheptulose-7-phosphate 126 to glyceraldehyde-3-phosphate 118a gives ribose-5-
phosphate 119a and xylulose-5-phosphate 127a. Epimerisation of xylulose-5-phosphate 127a 
to ribulose-5-phosphate 123a is catalysed by ribulose 5-phosphate 3-epimerase enzyme.11 
Finally, ribulose 5-phosphate isomerase catalyses the biotransformation of ribulose-5-
phosphate 123a to ribose-5-phosphate 119a, which is an important intermediate in the 
biosynthesis of adenosine 111a.12  
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Scheme 4. Non-oxidative phase of pentose phosphate pathway. 
After its production, ribose-5-phosphate 119a undergoes eleven enzymatic transformations to 
afford the important intermediate inosine monophosphate 128 (IMP). Conversion of IMP 128 
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to adenylosuccinate 129 is then catalysed by adenylosuccinate synthase.13 Adenylosuccinate 
129 undergoes β-elimination which causes its cleavage, generating AMP 130 and fumarate. 
Finally, IMP 128 can be regenerated from AMP 130 through the release ammonia mediated 
by AMP deaminase enzyme as described in Scheme 5.    
 
 
Scheme 5. Biosynthesis of AMP 130 from IMP 128. 
AMP 130 can either be phosphorylated to form adenosine diphosphate (ADP), and then again 
to form adenosine triphosphate (ATP) or be hydrolysed to give adenosine 111a. Indeed, 5’-
nucleotidase is an enzyme responsible for catalysing the phosphorolytic cleavage of 5’-
nucleotides such as AMP 130, as shown in Scheme 6.    
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Scheme 6. Conversion of AMP 130 to adenosine 111a by 5’-nucleotidase. 
3.3. Feeding experiments of [2-13C]-glycerol 116b and [1,1,2,3,3-
2H5]-glycerol 116c 
 
3.3.1. Isotopic incorporation of [2-13C]-glycerol 116b into nucleocidin 78a 
 
According to the pentose phosphate pathway (described previously), the carbon  C-2 of 
glycerol 116a should be incorporated as the carbon C-4’ of nucleocidin 78b, the carbon directly 
attached to fluorine. If this hypothesis proves to be true, a feeding experiment with [2-13C]-
glycerol 116b would reveal this incorporation by 19F-NMR, as coupling should be observed 
between the fluorine atom and the 13C-carbon. 
In order to determine the optimal time for the addition of isotopically labelled glycerol into 
Streptomyces calvus fermentations, a profile of nucleocidin production was carried out by 
performing a work-up of the cultures every two days. It was observed that nucleocidin 78a 
production begins after 9-10 days of incubation. The labelled glycerols were then added to 
different S. calvus fermentations (100 mL) after 4 days, followed by subsequent similar 
additions every two days until a total of 6 additions of either glycerol had been achieved. The 
final concentration of added glycerol was 10 mM in each case. After 18 days of fermentation, 
the cells were removed after centrifugation and the supernatant was extracted into n-butanol 
(20 mL). The organic layer was concentrated under reduced pressure, and the extract was 
analysed by 19F-NMR in order to detect nucleocidin 78a.14 The outcome of this feeding 
experiment can be rationnalised, as shown in Scheme 7. 
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Scheme 7. [2-13C]-Glycerol 116b incorporation into nucleocidin 78b. 
After a successful work-up, it was clear that the fluorine signal of nucleocidin 78a was 
accompanied by satellites due to 1JCF coupling, consistent with a population of nucleocidin 78b 
molecules enriched with 13C at the carbon C-4’ of the ribose ring. This experiment showed a 
high incorporation (25%), with a 13C-19F coupling constant of 232 Hz, as shown in Figure 4. 
The satellite signals are off-centre relative to the natural abundance 19F-NMR signal due to a 
heavy atom α-shift.15 This incorporation is entirely consistent with the prediction shown 
previously in Scheme 7. This experiment proved that the ribose ring of nucleocidin 78a is 
indeed biosynthesised via the pentose phosphate pathway. 
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Figure 6. 19F{1H}-NMR spectrum of feeding experiment with [2-13C]-glycerol 116b in D2O.  
Moreover, an additional organofluorine compound was observed at -118.1 ppm, which 
revealed the presence of a new fluorinated metabolite in very low quantity as shown in Figure 
6.14 Such a fluorometabolite was also observed in the recent study where nucleocidin 
production was elicited by reversing the bldA mutation.4 Coupled-fluorine NMR proved that 
nucleocidin 78a and this new metabolite shared the same multiplicity and very similar coupling 
constants, as shown in Figure 7. Therefore, it appears to be metabolically related to 
nucleocidin 78a either as a biosynthetic precursor, or as a metabolite.16  
 nucleocidin 78a new fluorometabolite 
Multiplicity dt dt 
Chemical shift -119.8 ppm -118.1 ppm 
J 3’-F 19.0 Hz 18.9 Hz 
J 5’-F 7.3 Hz 6.6 Hz 
 
Figure 7. Comparison of 19F-NMR spectrum between nucleocidin 78a and new fluorometabolite in D2O. 
 
new metabolite  
nucleocidin 78a  
labelled 
nucleocidin 78b 
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3.3.2. Isotopic incorporation of [1,1,2,3,3-2H5]-glycerol 116c into nucleocidin 78a 
 
After the successful pulse feeding experiments with [2-13C]-glycerol 116b, the commercially 
available [1,1,2,3,3-2H5]-glycerol 116c was then incubated with Streptomyces calvus cultures, 
using a similar protocol. The outcome of this feeding experiment can be rationalised, as shown in 
Scheme 8. Labelled glycerol 116c undergoes phosphorylation, followed by oxidation of the 
secondary alcohol leading to the loss of a deuterium atom in 86c. Isomerisation of tetradeuterated 
dihydroxyacetone phosphate 86c leads to glyceraldehyde-3-phosphate 118c and loss of another 
deuterium atom. The transketolation followed by epimerisation of 127c catalysed by ribulose 5-
phosphate 3-epimerase enzyme would result in the loss of a further deuterium atom, leaving only 
two deuterium atoms in ribose-5-phosphate 119c. Therefore, [1,1,2,3,3-2H5]-glycerol 116c should 
generate [5’,5’-2H2]-adenosine 111c. This experiment would confirm that the carbon C-5’ of 
nucleocidin 78a is derived from the carbon C-3 of glycerol 116a. Moreover, the chemical shift of 
the labelled nucleocidin 78c would show whether the two deuterium atoms are still both attached 
to the carbon C-5’ of nucleocidin 78a.  
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Scheme 8. [1,1,2,3,3-2H5]-Glycerol 116c incorporation into nucleocidin 78c. 
Addition of [1,1,2,3,3-2H5]-glycerol 116c to a final concentration of 10 mM into Streptomyces calvus 
fermentation was carried out, following the procedure described previously. The same work-up as 
previously mentioned was also performed. This experiment led to a 5% incorporation of deuterium 
into nucleocidin 78a, as shown in Fugure 8.14 The presence of the new fluorometabolite observed 
in [2-13C]-glycerol 116b experiment was not apparent in this case. 
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Figure 8. 19F{1H}-NMR spectrum of feeding experiment with [1,1,2,3,3-2H5]-glycerol 116c in D2O. 
 
Feeding experiments with [1,1,2,3,3-2H5]-glycerol 116c led to a 5% incorporation of deuterium 
into nucleocidin 78a, as indicated by an upfield isotope induced shift in the resultant 19F{1H}-
NMR spectrum, as shown in Figure 8. The magnitude of this upfield shift at 0.22 ppm is 
consistent with a single vicinal deuterium incorporated at the β-position to the fluorine atom. 
According to previous studies by Lambert and Greifenstein, the magnitude of this shift will 
change depending on the vicinal angle between the carbon-deuterium and the carbon-fluorine 
bonds.17 Indeed, it was established that if the D-C-C-F angle is included between 0° and 60°, 
the isotope shift is about 0.15 ppm. This isotope shift increases to 0.35 ppm when the dihedral 
angle is between 120° and 180°, as shown in Figure 9.18 This experiment confirmed that the 
origin of the carbon C-5’ of nucleocidin 78a is the carbon C-3 of glycerol 116a. The loss of one 
deuterium atom at the carbon C-5’ of nucleocidin 78d indicates that the mechanism of the 
biological fluorination might not be as straightforward as initially assumed. 
nucleocidin 78a  
labelled 
nucleocidin 78c 
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Figure 9. The D-C-C-F chemical shift isotope effect (Δδ) as a function of dihedral angle (ɸ) (figure taken 
from Lambert et al.18). 
 
Therefore, the upfield shift of 0.22 ppm in the feeding experiment with glycerol-1,1,2,3,3-d5 
116c confirmed the presence of only one deuterium atom at the carbon C-5’ of the ribose ring 
in nucleocidin 78d with a D-C-C-F angle around 90°, as shown in Figure 10. This result could 
be explained by oxidation-reduction processes leading to a loss of one deuterium atom. This 
hypothesis will be discussed in more details in the Chapter 4 in section 4.1.3. 
 
Figure 10. Structure of labelled nucleocidin 78d. 
 
102 
 
3.4. Feeding of (2S)-[1-2H2]-glycerol 116d and (2R)-[1-2H2]-glycerol 
to Streptomyces calvus 116e 
 
 
3.4.1. Feeding experiments in Streptomyces cattleya 
 
Previously, a series of isotopic labelling studies with deuterated labelled glycerols in Streptomyces 
cattleya was repeated. This involved the synthesis and feeding experiments of (2S)-[1-2H2]-
glycerol 116d and (2R)-[1-2H2]-glycerol 116e.19 These isotopically enriched glycerols 116d and 
116e were administered in distinct resting cell suspensions to cultures of S. cattleya. These 
experiments established that both hydrogens on the carbon C-5’ of the ribose ring of SAM 27a 
are retained in its conversion to fluoroacetate 63a and 4-fluoro-L-threonine 77a.20 Further studies, 
along with a more comprehensive understanding of the individual steps within the biosynthesis of 
fluoroacetate 63a and 4-fluoro-L-threonine 77a, indicate that the carbons C-5’ and C-4’ of SAM 
27c were converted to fluoroacetate 63b and, carbons C-3’ and C-4’ of fluorothreonine 77b as 
indicated in Scheme 9.15  
 
Scheme 9. Carbons C-5’ and C-4’ of SAM 27c are retained from (2R)-[1-2H2]-glycerol 116e in fluoroacetate 
63b and 4-fluoro-L-threonine 77b biosynthesis.20 
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3.4.2. Synthesis of (2S)-[1-2H2]-glycerol 116d and (2R)-[1-2H2]-glycerol 116e 
 
Feeding experiments with (2S)-[1-2H2]-glycerol 116d and (2R)-[1-2H2]-glycerol 116e in 
Streptomyces calvus would allow for further confirmation of the previous results shown above. 
Additionally, feeding experiment with (2S)-[1-2H2]-glycerol 116d may provide information 
concerning the origin of carbon  C-3’ of nucleocidin 78a.  
In order to repeat the feeding experiments performed by Nieschalk et al., the synthesis of (2S)-
[1-2H2]-glycerol 116d and (2R)-[1-2H2]-glycerol 116e was carried out using the procedure 
developed by Hill et al.19,20 Commercially available (S)-methyl 2,2-dimethyl-1,3-dioxolane-4-
carboxylate 131 and (R)-methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate 133 were both 
treated with LiAlD4 in dry ether, under reflux, for 1 h. Aqueous quenching of these reactions 
forms aluminium hydroxides which are responsible for the formation of emulsions, making 
extractions of the product problematic. In order to improve the work-up, a method established 
by Fieser was used for purification of acetonides 132 and 134.21 This involved addition of H2O 
to the reaction mixture at 0 °C, followed by aqueous sodium hydroxide (15%), and then a 
further addition of H2O. Finally, HCl mediated hydrolysis of both alcohols 132 and 134 gave 
the two [1-2H2]-glycerol enantiomers 116d and 116e in good yield and purity as shown in 
Scheme 10.  
 
Scheme 10. Synthesis of (2S)-[1-2H2]-glycerol 116d and (2R)-[1-2H2]-glycerol 116e. 
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Once both deuterated glycerols 116d and 116e were in hand, feeding experiments were 
carried out. Based on the biosynthetic pathway of adenosine 111a, the outcomes of each 
feeding experiment were anticipated. Feeding experiments using (2S)-[1-2H2]-glycerol 116d 
were predicted to generate dihydroxyacetone phosphate 86d. Isomerisation would then afford 
labelled glyceraldehyde-3-phosphate 118d with a loss of one deuterium atom as shown in 
Scheme 11. The conversion of glyceraldehyde-3-phosphate 118d to xylulose-5-phosphate 127d 
is catalysed by transketolase.This would result in [3-2H]-xylulose-5-phosphate 127d which would 
then undergo epimerisation with loss of the last deuterium affording ribulose-5-phosphate 123a, 
with exchange of the surviving deuterium with the bulk solvent.16,22 Ribulose-5-phosphate 123a 
is then metabolised to generate nucleocidin 78a without any isotope. Therefore, no incorporation 
of deuterium atoms should be observed after the (2S)-[1-2H2]-glycerol 116d feeding experiment.  
 
Scheme 11. Rationalisation of the feeding experiment with (2S)-[1-2H2]-glycerol 116d into nucleocidin 
78a.  
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On the other hand (2R)-[1-2H2]-glycerol 116e would be converted to [1-2H2]-glyceraldehyde-3-
phosphate 118e, which would then enter the pentose phosphate pathway and be transformed 
to [1-2H2]-ribose-5-phosphate 119c with retention of the two deuterium atoms. Like the feeding 
experiment with [1,1,2,3,3-2H5]-glycerol 116c, deuterated adenosine 111c would be formed 
from [1-2H2]-ribose-5-phosphate 119c, as shown in Scheme 12. Therefore, the same outcome 
observed during this feeding experiment should be observed for the feeding experiment with 
(2R)-[1-2H2]-glycerol 116e.  
 
Scheme 12. Rationalisation of the feeding experiment with (2R)-[1-2H2]-glycerol 116e into nucleocidin 
78d. 
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3.4.3. Pulse feeding experiment with dideuterated glycerols 116d and 116e 
 
As expected, feeding experiments with (2S)-[1-2H2]-glycerol 116d did not show isotopic 
incorporation into nucleocidin 78a. However, the presence of the new metabolite observed after 
the feeding experiment with [2-13C]-glycerol 116b was apparent after this feeding experiment.    
Pulse feeding experiments with (2R)-[1-2H2]-glycerol 116e led to an 8% incorporation of 
deuterium into nucleocidin 78a, which was determined by an upfield shift in the resultant 
19F{1H}-NMR spectrum, as shown in Figure 11. The magnitude of this upfield shift at 0.22 ppm 
is the same as that observed after the feeding experiment with [1,1,2,3,3-2H5]-glycerol 116c. 
This result confirmed the formation of a population of monodeuterated nucleocidin 78d 
molecules. Moreover, each feeding experiment with a labelled glycerol 116b-e was performed 
twice at least with the approximately the same yield of incorporation. 
Moreover, the presence of the second fluorometabolite was also observed. This 
fluorometabolite has the same chemical shift as that of the other organofluorine compound 
detected after the feeding experiments with (2S)-[1-2H2]-glycerol 116d and [2-13C]-glycerol 
116b, as shown in Figure 11. However, in feeding experiments with (2R)-[1-2H2]-glycerol 116e 
the level of the unknown metabolite was greater than that of nucleocidin 78a. It also showed 
a similar level of deuterium incorporation as nucleocidin 78a, with a 0.22 ppm shift 
corresponding to the presence also of only one deuterium atom.14 
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Figure 11. 19F-NMR spectroscopic analysis of extracts of S. calvus after the addition of glycerol 
isotopomers:  
(A) feeding experiment with (2S)-[1-2H2]-glycerol 116d.    
(B) feeding experiment with (2R)-[1-2H2]-glycerol 116e. 
(C) feeding experiment with [1,1,2,3,3-2H5]-glycerol 116c. 
(D) feeding experiment with [2-13C]-glycerol 116b. 
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3.5. Isotopically labelled adenosines 111c and 111d into 
nucleocidin 78a 
 
After initial studies investigating the incorporation of labelled glycerol into nucleocidin 78a, 
further feeding experiments using labelled adenosine were explored in order to test the 
hypothesis that adenosine 111a is an advanced intermediate in the biosynthesis of nucleocidin 
78a. Therefore, the syntheses of [5’,5’-2H2]-adenosine 111c and [3’-2H]-adenosine 111d were 
addressed for this purpose.  
3.5.1. Synthesis of [5’,5’-2H2]-adenosine 111c 
 
In 1982, Pang et al.23 reported the multistep synthesis of [5’,5’-2H2]-adenosine 111c from ethyl 
adenosine-5’-carboxylate. The synthesis of the latter was not reported, therefore, an 
alternative synthetic strategy was developed in this project for the preparation of [5’,5’-2H2]-
adenosine 111c. After protection of adenosine 111a, oxidation of acetonide 137 was 
envisaged to afford carboxylic acid 136. Formation of ester 135 including acetal removal could 
be performed in a one-step process. Finally, [5’,5’-2H2]-adenosine 111c would be obtained 
after ester 135 reduction, as shown in Scheme 13.  
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Scheme 13. Retrosynthetic strategy to [5’,5’-2H2]-adenosine 111c. 
Acetonide 137 was obtained by reacting adenosine 111a with acetone in the presence of 
perchloric acid. Purification of the reaction mixture by column chromatography afforded the 
product 137 in 65% yield.24 Oxidation of acetonide 137 to adenosine-5’-carboxylic acid 136 
following the procedure developed by Epp et al. was achieved in good yield.25 Treating the 
acetal protected nucleoside 137 with a catalytic amount of 2,2,6,6-tetramethyl-1-
piperidinyloxyl (TEMPO) and a stoichiometric amount of [bis(acetoxy)-iodo]benzene (BAIB) in 
a 1:1 ACN- H2O afforded the carboxylic acid 136 in 72% yield in high purity, as shown in 
Scheme 14.   
 
Scheme 14. Protection of adenosine 111a and oxidation of 137. 
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Acetonide 136 was treated with thionyl chloride in methanol to form an acyl chloride 
intermediate, which reacted with methanol affording the methyl ester 135. Indeed, hydrochloric 
acid is generated in the reaction which also causes acetal hydrolysis. This deprotection is 
important for improving the solubility of ester 135 for the following deuteration reaction. The 
methyl ester 135 was purified by column chromatography in good yield (81%). Finally, ester 
135 was dissolved in ethanol and sodium borodeuteride (NaBD4) was added to the reaction 
mixture, as shown in Scheme 15.23 Reduction of the methyl ester 133 generated [5’,5’-2H2]-
adenosine 111c which was purified by column chromatography in high purity for use in feeding 
experiments. Despite the fact that proton NMR showed high purity, mass spectrometry 
analysis revealed the presence of a trace of unlabelled adenosine 111a (2%). 
 
Scheme 15. Synthesis of [5’,5’-2H2]-adenosine 111c. 
The 1H-NMR spectrum of [5’,5’-2H2]-adenosine 111c was compared to that of adenosine 111a, 
as shown in Figure 12. This comparison showed an overall simplification of the coupling 
patterns. Indeed, the first significant observation is the disappearance of both peaks 
corresponding to H-5’ in adenosine 111a. Moreover, the multiplicity of OH-5’ peak changed to 
a singlet, instead of a doublet of doublets in adenosine 111a which is consistent with the 
presence of two deuterium atoms at the C-5’ position. Also there was a tremendous change 
of the coupling pattern for the H-4’ signal from a multiplet to a doublet. With all these 
observations, it was concluded that the synthesis of this adenosine isotopomer 111c had been 
successful.  
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Figure 12. Comparison of 1H-NMR spectrum of:                                                                                  
(A) adenosine 111a in DMSO-d6.                                                                                                               
(B) [5’,5’-2H2]-adenosine 111c in DMSO-d6. 
 
3.5.2. Synthesis of [3’-2H]-adenosine 111d 
 
The synthesis of monodeuterated [3’-2H]-adenosine 111d has been described in the literature 
by Robins et al in 1997.26 The strategy involved the protection of the 2’- and 5’-hydroxyl groups 
of adenosine 111a, and then oxidation of the free alcohol in 141 to give keto adenosine 140. 
Selective deprotection of the primary alcohol of the keto adenosine 140, followed by ketone 
reduction with NaBD4 would offer monodeuterated adenosine 138. Final deprotection of the 
2’-hydroxyl would then give [3’-2H]-adenosine 111d. 
H-1’ OH-2’ & OH-5’ OH-3’ H-2’ H-3’ H-4’ H-5’ & H-5’ 
A 
B 
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Scheme 16. Retrosynthetic strategy to [3’-2H]-adenosine 111d. 
O-TBS protection of 2’- and 5’-hydroxyl positions of adenosine 111a was achieved by treating 
adenosine 111a with 3 equivalents of tert-butyldimethylsilyl chloride in pyridine. The product 
2',5'-bis-O-(tert-butyldimethylsilyl)adenosine 141 was obtained as a mixture along with two 
side-products 3',5'-bis-O-(tert-butyldimethylsilyl)adenosine 142 and 2',3’,5'-tris-O-(tert-
butyldimethylsilyl)adenosine 143 in a 3:3:1 ratio. Each isomer was easily separated via column 
chromatography affording the desired product 141 in a relatively low yield (34%). The reaction 
outcome is summarised in Scheme 17.  
 
Scheme 17. Synthesis of the TBS protected adenosine 141. 
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In the literature, the oxidation of the free 2’-hydroxyl in adenosine 141 was carried out using 
two different reagents: Dess-Martin periodinane (DMP) and chromium trioxide.26 In our hands, 
oxidation of 141 employing DMP failed and only the starting material 141 was recovered. 
However, oxidation of 141 was successfully achieved using chromium trioxide, acetic 
anhydride and pyridine in DCM. The reaction mixture was filtered through glass microfibre and 
purified by flash column chromatography affording the desired product 140 in 50% yield, as 
shown in Scheme 18.  
 
Scheme 18. Oxidation of the TBS protected adenosine 141. 
In order to increase its solubility, selective deprotection of the 5’-hydroxyl group of the 
protected adenosine 140 was performed using trifluoroacetic acid (TFA) in H2O affording 2’-
O-(tert-butyldimethylsilyl)adenosine 139. Under these acidic conditions, primary alcohols are 
deprotected more easily than secondary. The reaction time was kept short to avoid unwanted 
deprotection of the 2’-hydroxyl group. Due to its instability, the keto adenosine 139 was not 
purified and was used immediately in the next reaction.   
 
Scheme 19. Deprotection of the TBS protected adenosine 140. 
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Unpurified protected adenosine 139 was treated with NaBD4 and acetic acid, generating 
sodium triacetoxyborodeuteride (NaBH(OAc)3/AcOH) in situ. The formation of sodium 
triacetoxyborodeuteride, an activated deuteride reducing agent, allowed for the reduction of 
the carbonyl group with incorporation of a deuterium atom at the carbon C-3’. A mixture of two 
deuterated diastereoisomers 138 and 144 was obtained in a 2:1 ratio, with the beta product 
138 as the major product. This product mixture was used in the following reaction without 
purification.  
 
Scheme 20. Reduction of the TBS protected adenosine 139 with NaBD4. 
Final deprotection of the 138 and 144 mixture was performed using tert-butylammonium 
fluoride 53 (TBAF) in dry THF, as shown below in Scheme 25. [3’-2H]-Adenosine 111d was 
purified by column chromatography (EtOAc/iPrOH/H2O, 7:2:1) allowing the separation of the 
two diastereoisomers.  
 
Scheme 21. Final step in the synthesis of [3’-2H]-adenosine 111d. 
The 1H-NMR spectrum of [3’-2H]-adenosine 111d was compared to that of adenosine 111a as 
shown below in Figure 13. The coupling patterns of monodeuterated 111d were simplified due 
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to the presence of the isotope. The major observation was the significant reduction of the peak 
corresponding to H-3’ in adenosine 111a. Moreover, the multiplicity of H-4’ peak changed from 
a multiplet to a triplet which confirmed the presence of one deuterium atom. The coupling 
patterns of monodeuterated 111d were simplified due to the presence of the isotope. Finally, 
there is a clear simplification of the coupling pattern of H-2’. Based on the above mentioned 
observations, it was concluded that the reduction of keto adenosine 139 with NaBD4 had 
proven successful. Despite the high purity of [3’-2H]-adenosine 111d shown by 1H-NMR, mass 
spectrometry analysis showed the presence of unlabelled adenosine 111a as a minor 
component (4%). 
 
Figure 13. Comparison of 1H-NMR spectrum of:                                                                                  
(A) adenosine 111a in DMSO-d6.                                                                                                            
(B) [3’-2H]-adenosine 111d in DMSO-d6. 
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3.5.3. Feeding experiments of labelled adenosines 111c and 111d 
 
Since previous feeding experiments could not confirm that the carbon C-3’ of nucleocidin 78a 
is derived from the carbon C-1 of glycerol 116a, a feeding experiment with [3’-2H]-adenosine 
111d was conducted. Moreover, a feeding experiment with [5’,5’-2H2]-adenosine 111c was 
performed in order to discover whether the loss of deuterium atom at the carbon C-5’ of 
nucleocidin 78a occurs before or after the formation of adenosine 111a. The anticipated 
isotopic incorporation sites for nucleocidin 78a are illustrated in Scheme 22.  
 
Scheme 22. Anticipated labelling patterns into nucleocidin 78a from [5’,5’-2H2]-adenosine 111c and [3’-
2H]-adenosine 111d. 
 
A feeding experiment with [5’,5’-2H2]-adenosine 111c was achieved following the same 
procedure developed previously for that of the labelled glycerols. However, the final 
concentration of [5’,5’-2H2]-adenosine 111c (4 mM) was lower than the concentration of the 
glycerols (10 mM) because of the higher toxicity of adenosine 111a.27 Unfortunately, no 
incorporation of isotope was observed into the resultant nucleocidin 78a in this experiment as 
judged by 19F{1H}-NMR, as shown below in Figure 14. Moreover, the production of nucleocidin 
78a was substantially diminished in the feeding experiment compared to the control 
experiment. 
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Figure 14. 19F{1H}-NMR spectrum of feeding experiment with [5’,5’-2H2]-adenosine 111c in D2O. 
 
Pulse feeding experiment with [3’-2H]-adenosine 111d was carried out, but unfortunately, the 
production of nucleocidin 78a had ceased during this experiment, as well as during the control 
experiment conducted in parallel. Therefore, these results could not successfully concluded.  
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3.6. Conclusion 
 
An in-house strain of Streptomyces calvus T-3018 which was known to produce nucleocidin 78a 
was acquired from Pfizer. Despite nucleocidin production being very fickle and with very low titres, 
nucleocidin 78a was observed by 19F-NMR after n-butanol extraction. Due to the structural 
similarity of adenosine 111a and nucleocidin 78a it was then hypothesised that adenosine 111a 
may be an intermediate in the biosynthesis of nucleocidin 78a. According to the pentose 
phosphate pathway, carbons C-4’ and C-5’ of the ribose ring of adenosine 111a are derived 
from glycerol 116a, as shown in Figure 15.  
Therefore, in order to investigate the biosynthesis of nucleocidin 78a, feeding experiments with 
different isotopomers of glycerol were carried out. Fermentation cultures of Streptomyces calvus 
were supplemented with [2-13C]-glycerol 116b and this experiment showed a 25% incorporation 
of 13C into carbon C-4’ of nucleocidin 78b. This incorporation was consistent with pentose 
phosphate pathway involvement in ribose ring synthesis.  
(2S)-[1-2H2]-Glycerol 116d and (2R)-[1-2H2]-glycerol 116e were synthesised following the 
procedure developed by Hill et al.19 Pulse feeding experiment with (2S)-[1-2H2]-glycerol 116d did 
not show any isotope incorporation into nucleocidin 78a. This is consistent with the loss of the two 
pro-S deuterium atoms during the pentose phosphate pathway. Pulse feeding experiments with 
[1,1,2,3,3-2H5]-glycerol 116c and (2R)-[1-2H2]-glycerol 116e showed incorporation into the carbon 
C-5’ of nucleocidin 78d, and with an upfield shift of 0.22 ppm. According to studies by Lambert 
and Greifenstein, the value of this chemical shift is consistent with the presence of only one 
deuterium atom attached at the carbon C-5’ of nucleocidin 78d as depicted in Scheme 23.17,18 The 
loss of one deuterium atom could be explained by an oxidation process ocurring after ribose ring 
assembly but prior to, or concominant with, fluorine introduction. 
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Scheme 23. Incorporation of labelled glycerols 116b and 116c into nucleocidin 78a.14 
 
The syntheses of [5’,5’-2H2]-adenosine 111c and [3’-2H]-adenosine 111d were achieved with 
high purity. Unfortunately, pulse feeding experiments with [5’,5’-2H2]-adenosine 111c resulted 
in a low production of nucleocidin 78a and no observable isotope incorporation. Moreover, 
feeding experiments with [3’-2H]-adenosine 111d could not be interpreted due to the lack of 
nucleocidin 78a production.  
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4. Exploring production of nucleocidin 78a in cell-free 
extracts of S. calvus 
 
4.1. Synthesis of putative substrates 
 
As previously described in Chapter 3, cell-free extract experiments of Streptomyces calvus 
were performed concomitantly alongside pulse feeding experiments using various isotopically 
labelled substrates. These experiments revealed that glycerol is incorporated into the ribose 
ring moiety of nucleocidin 78a. Moreover, pulse feeding experiments with (2R)-[1-2H2]-glycerol 
116e suggested that a hydrogen atom is lost at the carbon C-5’ prior to or concominant with 
fluorine introduction.1 In order to further elucidate the biosynthetic pathway of nucleocidin 78a 
in Streptomyces calvus, the synthesis of additional putative substrates was investigated for 
use in cell-free extract experiments. Subsequently, each putative substrate that was 
synthesised shared a relative structural homology with either adenosine 111a or nucleocidin 
78a as shown in Figure 1.  
 
Figure 1. Structures of the putative intermediates in the biosynthesis of nucleocidin 78a. 
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As mentioned previously, adenosine 111a was thought to be a potential early intermediate in 
the metabolic pathway of nucleocidin 78a. The synthesis of adenosine sulfate 160 and 
sulfamoyladenosine 161 was achieved, and each was used in separate cell-free extract 
experiments of S. calvus. Adenosine sulfate 160 and sulfamoyladenosine 161 were chosen 
as potential biosynthetic precursors for these experiments due to their structural similarity to 
that of nucleocidin 78a. The aldehyde 168 was considered as a putative substrate of the 
fluorinating enzyme, which would explain the loss of deuterium atom observed during the 
previous feeding experiments with [1,1,2,3,3-2H5]-glycerol 116c and (2R)-[1-2H2]-glycerol 116e. 
The proposed mechanism for the fluorination of the aldehyde 168 is described in detail in the 
section 4.1.3. Finally, the synthesis of fluoroadenosine 171 was performed and cell-free 
extracts were carried out in order to determine whether it is a fluorinated intermediate that can 
be biotransformed within the cell to nucleocidin 78a. The syntheses of these putative 
substrates are described below.  
4.1.1. Synthesis of adenosine sulfate 160 
 
4.1.1.1. Sulfation in nature 
 
Sulfation is a major industrial process which is used to manufacture a wide range of products 
such as pigments, drugs, detergents, pesticides, etc.2,3 In nature, sulfation is also very 
important and is utilised in a number different roles, for instance to generate reservoirs of 
bioactive molecules and to enhance the elimination of potential toxic agents.4 Indeed, sulfation 
is used in nature to regulate the bioactivity of biomolecules. Steroid sulfates for instance, which 
are not active in themselves, are hydrolysed by a sulfatase enzyme in order to become active.4 
Toxic xenobiotic molecules are another example of a class of compound which can be 
derivatised through sulfation.5  
During sulfation, the sulfate group must first be activated via the formation of adenosyl 
phosphosulfate 146 by an ATP sulfurylase enzyme. Phosphorylation of adenosyl 
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phosphosulfate 146 with ATP affords phosphoadenosine phosphosulfate 147, which is a 
sulfate group donor. Sulfotransferase enzymes are able to catalyse the transfer of the sulfate 
group from phosphoadenosine phosphosulfate 147 to an acceptor, such as an alcohol or 
amine, as shown in Scheme 1.6,7   
 
Scheme 1. Biological sulfation via formation of adenosyl phosphosulfate 146. 
4.1.1.2. Sulfating reagents 
 
The chemical introduction of a sulfate group into molecules has become the focus of many 
investigations. After sulfation, the physico-chemical properties of the compounds radically 
change. For instance, most sulfated molecules are water soluble which can make purification 
using conventional organic solvents more difficult. The stability of the sulfate group is also very 
low in acidic or under high temperature conditions.  
Sulfur trioxide (SO3) is a strong electrophilic reagent which quickly reacts with any molecule 
containing an electron donating group. In order to alleviate this issue of high reactivity, sulfur 
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trioxide is diluted or complexed with different agents such as H2O, giving sulfuric acid 149 
(H2SO4), or hydrochloric acid, affording chlorosulfonic acid 150.    
In the beginning of the 20th century, sulfation reactions were usually carried out with sulfuric 
acid 149, as shown in Scheme 2.8 Indeed, sulfation of alcohols was performed using sulfuric 
acid 149, but the yield is limited due to the release of H2O which forms during the reaction.9 
The subsequent use of Dean-Stark apparatus increased the yield by removing the water.  
 
Scheme 2. Sulfation of alcohols with sulfuric acid 149.  
In 1854, chlorosulfonic acid 150 was prepared using phosphorus pentachloride and 
concentrated sulfuric acid by Williamson et al.10 Three years later, chlorosulfonic acid 150 was 
produced using an alternative method by reacting hydrochloric acid with sulfur trioxide.11 Many 
different methods of production of chlorosulfonic acid 150 were then developed, such as via 
the reaction of carbon tetrachloride with sulfuric acid 149 or the action of phosphorus 
trichloride on sulfuric acid 149. Chlorosulfonic acid 150 is a strong acid and extremely 
hygroscopic due to its propensity to react with H2O to form sulfuric acid 149 and hydrochloric 
acid. Sulfation of alcohols carried out with chlorosulfonic acid 150 released hydrochloric acid, 
as shown in Scheme 3.12 
 
Scheme 3. Sulfation of alcohols with chlorosulfonic acid 150.  
In 1966, another sulfating method was established for the sulfation of alcohols with sulfuric 
acid 149 and dicyclohexylcarbodiimide 153 (DCC).13 The ratio and the order of addition of the 
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reactants were found to be important for achieving the desired sulfated product. Indeed, the 
alcohol, sulfuric acid 149 and DCC 153 were allowed to react in a 1:1:5 ratio. Moreover, the 
substrate was added to a solution of DCC 153 in DMF, which was followed by the addition of 
sulfuric acid 149. At first the mechanism was not clearly elucidated, but it was thought that 
sulfuric acid 149 reacts with DCC 153 forming the protonated DCC-H2SO4 intermediate 154. 
Finally, nucleophilic attack of the alcohol onto the sulfur atom would form the sulfate 152 
releasing dicyclohexylurea 155, as shown in scheme 4. 
 
Scheme 4. Mechanism of sulfation with sulfuric acid 149 and DCC 153.  
Although this reaction was in general successful, the relative insolubility of dicyclohexylurea 
155 rendered the purification of the product rather difficult and despite the fact that the major 
products with such reagents are mono sulphates, many side products were also observed.14 
Moreover, this mixture of sulfuric acid 149 and DCC 153 can only generate sulfates with 
specific substrates which are not sensitive to acidic conditions.  
In the 1980s, a new type of sulfating reagents was developed by complexing sulfur trioxide 
with amines such as trimethylamine, triethylamine, pyridine, etc.15 Due to the difficulty of 
handling sulfur trioxide as a gas or liquid, these sulfur trioxide-amine complexes were 
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preferred over sulfur trioxide. These organic complexes can be formed by bubbling sulfur 
trioxide through a solution of the desired organic base.16 The complexes are solids at room 
temperature and somewhat stable at high temperatures.  
 
Figure 2. Sulfur trioxide amine complexes.  
These sulfur trioxide amine complexes allowed for an easier purification when compared to 
the previous sulfating reagents. The sulfation of acidic hydroxyl groups was found to be 
optimal with use of the sulfur trioxide pyridine complex 156. However, sulfation of hindered 
substrates was easier with the less bulky sulfur trioxide amine complexes such as 157 and 
158.   
4.1.1.3. Preparation of adenosine sulfate 160 
 
Sulfation of acetonide protected adenosine analogues using sulfur trioxide pyridine complex 
156 has been previously described in a patent.17 Since acetonide adenosine 137 was acquired 
previously during the synthesis of [5’,5’-2H2]-adenosine 111c, as mentioned in Chapter 3, 
sulfation of this molecule was carried out with sulfur trioxide pyridine complex 156. 
Unfortunately, this sulfation reaction was not successful since only the starting material 137 
was recovered. The lack of reactivity in this instance may be due to steric hindrance. 
Therefore, the sulfating reagent was changed to sulfur trioxide trimethylamine complex 157 
and then to sulfur trioxide triethylamine complex 158, but in both cases a complex mixture was 
obtained which could not be purified by column chromatography. Increasing the temperature 
and the reaction time also did not show any improvement.     
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Scheme 5. Sulfation of acetonide 137 with different sulfur trioxide amine complexes. 
In 1956, sulfation of acetonide 137 using chlorosulfonic acid 150 followed by deprotection of 
the acetal with acetic acid was described.18 As such this procedure was followed, but a 
complex mixture was obtained and the product could not be purified by ion exchange column 
or HPLC.  
 
Scheme 6. Sulfation of acetonide 137 with chlorosulfonic acid 150. 
A method for the sulfation of adenosine 111a using chlorosulfonic acid 150 was developed by 
Egami et al.19 Adenosine 111a was treated with chlorosulfonic acid 150 in a mixture of dry 
pyridine and chloroform. After eluting through a short Discovery® DSC-NH2 SPE ion exchange 
column, the residue was then purified by semi-preparative HPLC, which was aided by the 
water solubility of adenosine sulfate 160. The use of a semi-preparative HPLC allowed for the 
isolation of the desired product 160 in high purity, which is essential for subsequent cell-free 
extract experiments. A reverse phase C-18 column was used with a flow rate of 10 mL/min 
and an isocratic mobile phase of 95% buffer A (0.05% TFA/H2O) and 5% buffer B (0.05% 
TFA/ACN). The adenosine sulfate 160 possessed a retention time of 7.4 minutes. The desired 
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fraction was collected, concentrated and freeze-dried affording a pure sample in 10% yield, 
as shown in Scheme 7.       
 
Scheme 7. Sulfation of adenosine 111a with chlorosulfonic acid 150. 
4.1.2. Synthesis of sulfamoyl adenosine 161 
 
In nature, the mechanism and enzymes responsible for the sulfamoylation reaction are yet to 
be elucidated. However, it is commonly thought that sulfamoylation in nature occurs in two 
distinct steps. It initiates with a sulfation reaction, as described previously in section 4.1.1.1, 
which is followed by the replacement of a hydroxyl group of the sulfonate with an amine group, 
performed by amidinotransferase enzymes, to generate the sulfamoyl group.20 
The synthesis of sulfamoyl adenosine 161 was described in the literature by Lukkarila et al as 
shown in Scheme 8.21 Sulfamoylation of the protected acetonide 137 was achieved using 
sodium hydride and sulfamoyl chloride 162 (75%). Final deprotection of the protected 
sulfamoyl adenosine 163 was carried out using a mixture of TFA and H2O in a 3:1 ratio 
affording sulfamoyl adenosine 161. The overall yield of these two reactions is 37.5%, primarily 
due to the relatively low yield of the last step (50%). This low yield can be explained by the 
harsh conditions (TFA/ H2O) destabilising the sulfamoyl group.    
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Scheme 8. Synthesis of sulfamoyl adenosine 161 by Lukkarila et al.21 
The procedure developed by Lukkarila et al. was not followed directly, but modified in order to 
increase the overall yield of sulfamoyl adenosine 161, as shown in Scheme 9. Instead of 
preparing acetonide 137, it was envisaged that the secondary hydroxyl groups of adenosine 
111a would be TBS protected giving adenosine 165. Sulfamoylation using a solution of 
amidosulfonyl chloride 162 in dry ACN would generate 164 and final deprotection would be 
achieved under milder conditions using TBAF 53 rather than a mixture TFA and H2O. TBAF 
53 should not interfere with the sulfamoyl group of sulfamoyl adenosine 164.   
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Scheme 9. Retrosynthetic strategy to sulfamoyl adenosine 161. 
Protection of adenosine 111a was carried out using TBSCl and imidazole in DMF.22 After work-
up, the residue was dissolved in 80% AcOH and stirred for 4 h at 100 °C. This second step 
allows for deprotection of any primary silyl ether. In the literature, the TBS protected adenosine 
165 was used without further purification.22 However, in this case the reaction mixture was 
purified by flash column chromatography to afford 165 in relatively low yield (40%).    
 
Scheme 10. Synthesis of the TBS protected adenosine 165. 
In order to perform the sulfamoylation of the protected adenosine 165, amidosulfonyl chloride 
162 was required. This was prepared as a 2 M solution of amidosulfonyl chloride 162 in dry 
ACN following the procedure developed by Townsend et al.23 Formic acid 166 was added to 
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a solution of chlorosulphonyl isocyanate 167 in dry ACN allowing for the formation of 
amidosulfonyl chloride 162 and the release of carbon dioxide and carbon monoxide. The 
reaction was considered to have proceeded quantitatively and as such the reaction mixture 
was used without further purification.     
 
Scheme 11. Synthesis of a 2 M solution of amidosulfonyl chloride 162 in dry ACN.  
A cold solution of amidosulfonyl chloride 162 in dry ACN was added to a solution of the 
protected adenosine 165 in DMA.24 The reaction was monitored by TLC and was stirred until 
the conversion was complete. Therefore, the reaction time was increased until complete 
conversion observed by TLC. The product was then purified by flash column chromatography 
affording the desired product 164 in quantitative yield.  
 
Scheme 12. Synthesis of the TBS protected sulfamoyl adenosine 164.  
Removal of the silyl ether protecting groups was achieved using TBAF 53 in THF.25 The 
resultant sulfamoyl adenosine 161 was water soluble and was purified by semi-preparative 
HPLC due to its water solubility. A reverse phase C-18 column was used with a flow rate of 
10 mL/min and an isocratic mobile phase of 95% buffer A (0.05% TFA/H2O) and 5% buffer B 
(0.05% TFA/ACN). Sulfamoyl adenosine 161 possessed a very short retention time of 5.6 
minutes due to its high polarity. The fraction containing the desired product 161 was collected, 
concentrated and freeze-dried affording a pure sample in 83% yield, as shown in Scheme 13.      
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Scheme 13. Synthesis of sulfamoyl adenosine 161.  
In conclusion, a new synthetic route affording sulfamoyl adenosine 161 was successfully 
developed. The overall yield of this procedure is better (33%) than the synthesis described by 
Lukkarila et al.21 This can be explained by the fact that the final deprotection with TBAF 53 is 
performed under milder conditions, which do not destabilise the sulfamoyl group of sulfamoyl 
adenosine 161, unlike the use of a mixture of TFA and H2O.  
4.1.3. Synthesis of aldehyde 168 
 
Previous pulse feeding experiments using [1,1,2,3,3-2H5]-glycerol 116c and (2R)-[1-2H2]-glycerol 
116e, described in Chapter 3, showed a loss of a deuterium atom upon their incorporation 
into nucleocidin 78a.1 In order to explain this loss of deuterium, one of the working hypotheses 
was that an oxidation of the primary hydroxyl group of adenosine 111a afforded the aldehyde 
168. This aldehyde emerged therefore as a putative substrate for the fluorinating enzyme in 
Streptomyces calvus. Aldehyde 168 has the potential to undergo tautomerisation, followed by 
a rearrangement to generate the oxonium species 170. Fluoride could then react with oxonium 
170 affording the fluoroadenosine 171. Finally, fluoroadenosine 171 would be further 
metabolised generating nucleocidin 78a, as shown in Scheme 14.   
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Scheme 14. Putative metabolic pathway of nucleocidin 78a.  
In order to test this working hypothesis, a synthesis of the aldehyde 168 was developed. Cell-
free extract experiments with this aldehyde 168 were then explored to determine whether this 
putative intermediate is a substrate of the fluorination enzyme.  
Two different strategies for the synthesis of the aldehyde 168 were reported by Liu et al.26 and 
by Wnuk et al.27, as illustrated in Scheme 15. Both strategies begin with the conversion of 
adenosine 111a to the acetonide 168, in which the primary hydroxyl-group is subjected to 
Moffat oxidation affording the aldehyde intermediate. Due to the instability of the aldehyde, 
the carbonyl group was then directly protected using N,N'-diphenylethylenediamine according 
to Liu et al. to give aminal 172,26 while Wnuk et al. reacted this aldehyde intermediate with 
hydroxylamine forming a stable oxime 174.27 Finally, hydrolysis of the oxime 174 and 
deprotection of the aminal 174 lead to the desired aldehyde 168.  
Both synthetic strategies offer access to the putative intermediate 168 in modest yield and in 
the same number of synthetic steps. However, Wnuk et al.’s method gives oxime 174, which 
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could be potentially difficult to deal with,28 and for this reason it was decided to first pursue Liu 
et al.’s synthetic strategy.  
 
Scheme 15. Retrosynthetic strategies to aldehyde 168.26,27 
Treatment of adenosine 111a with perchloric acid in acetone afforded acetonide 137 in good 
yield. For the protection of the amine, two methods were attempted. O-TMS protection of the 
primary hydroxyl group in acetonide 137 was achieved with TMSCl in pyridine for 1 h, followed 
by benzoylation of the amino-group with benzoyl chloride affording the 
monobenzoyladenosine 175 in 33% yield. Purification of 175 by column chromatography 
proved to be inefficient and time consuming. Due to the poor yield obtained, dibenzoylation of 
the amino-group was then explored using an excess of benzoyl chloride to afford the 
dibenzoylated amino-moiety in 70% yield. In this event, purification of protected adenosine 
173 was straightforward; therefore the dibenzoylation protection strategy was favoured, as 
shown in Scheme 16. 
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Scheme 16. Protection of adenosine 111a and benzoylation of acetonide 137. 
The protected adenosine 173 was subjected to Moffat oxidation (using N,N'-
dicyclohexylcarbodiimide 153 in dry DMSO) to afford the unstable aldehyde 176, which was 
immediately protected by adding N,N'-diphenylethylenediamine in methanol, to furnish the 
aminal 172 in 43% yield over 2 steps, as shown in Scheme 17.29-31  
 
Scheme 17. Oxidation of protected adenosine 173, followed by direct protection of the aldehyde 176. 
For deprotection of amine group, the aminal 172 was dissolved in dry methanol and ammonia 
gas was bubbled into the reaction mixture. After purification by column chromatography, free 
amine 177 was obtained in good yield as illustrated in Scheme 18. Treatment of 177 with a 
mixture of trifluoroacetic acid and H2O to simultaneously deprotect the diol and the aldehyde, 
gave a complex mixture as revealed by 1H-NMR. This mixture of trifluoroacetic acid and H2O 
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proved to be too harsh for the deprotection of 177; therefore, other acid reagents such as 
hydrochloric acid and sulfuric acid 149 were investigated, but these ultimately presented the 
same unsuccessful outcome. 
 
Scheme 18. Deprotection of protected aldehyde 172 and attempt to synthesise free aldehyde 168. 
In view of the difficulty in the final deprotection, the procedure developed by Wnuk et al. was 
explored.27 The protected adenosine 173 underwent Moffat oxidation affording aldehyde 176, 
which was immediately reacted with hydroxylamine hydrochloride. Unfortunately, the desired 
product 174, detected by mass spectrometry analysis, was too unstable and could not be 
isolated. 
 
Scheme 19. Oxidation of protected aldehyde 173 and attempt to synthesise oxime 174. 
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4.1.4. Synthesis of 4’-fluoroadenosine 171 
 
4.1.4.1. Preparation of fluoroadenosine 171 
 
4’-Fluoroadenosine 171 emerged as a possible advanced intermediate in the biosynthesis of 
nucleocidin 78a, which would require sulfation, and then amination, as shown in Scheme 20. 
 
Scheme 20. Putative metabolic pathway of 4’-fluoroadenosine 171 to nucleocidin 78a. 
In order to be able to test this hypothesis, the synthesis of 4’-fluoroadenosine 171 was carried 
out. The synthesis of this fluorinated adenosine 171 has been described in the literature.32-34 
In the procedures developed to date, the protected ribose 179 was sequentially 
photobrominated via N-bromosuccinimide under UV irradiation and then fluorinated affording 
the fluorinated ribose 180.  
In 1964, the formation of nucleosides via the silyl-Hilbert-Johnson reaction, also known as the 
Vorbrüggen reaction, was described under mild conditions. In order to synthesise nucleosides 
by this method, a protected sugar is reacted with a silylated heterocycle in the presence of a 
Lewis acid such as trimethylsilyl triflate (TMSOTf).35,36 However, silylated heterocycles are 
rather unstable due to hydrolysis and as a result are difficult to handle. Therefore, a one-step 
protocol was developed for the silylation of the heterocycle followed by nucleoside 
formation.37,38  
A modified Vorbrüggen reaction was devised using the fluorinated ribose 180, adenine, N,O-
bis(trimethylsilyl)trifluoro acetamide (BSTFA) and trimethylsilyl triflate, which gave the 
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protected fluoroadenosine 181.39 The deprotection of the protected fluoroadenosine 181 was 
then achieved using an excess of sodium carbonate.  
 
Scheme 21. Retrosynthetic strategy to 4’-fluoroadenosine 171. 
It was decided to pursue the method developed by Lee et al. for the synthesis of 4’-
fluoroadenosine 171.33 As such, the commercially available ribose 179 was first treated with 
N-bromosuccinimide in carbon tetrachloride under UV irradiation affording the brominated 
intermediates 182 and 183, as shown in Scheme 22.  
 
Scheme 22. Photobromination of the protected ribose 179. 
Due to the instability of the bromides 182 and 183, this product mixture was immediately 
treated with a solution of AgBF4, as illustrated in Scheme 23. Purification by column 
chromatography afforded an inseparable mixture of α-fluororibose 180 and β-fluororibose 184 
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in a 1:1 ratio. Separation of these two products by HPLC with a normal phase column could 
not be performed because of their similar retention times.   
 
Scheme 23. Fluorination of the bromide mixture of 182 and 183. 
The 4-fluororibose mixture of 180 and 184 underwent N-glycosylation giving a complex 
mixture which could not be purified by column chromatography, or by HPLC with a normal 
phase column or a reverse phase column. Therefore, the product mixture of 181 and 185 was 
immediately treated with sodium carbonate in methanol. Purification of the reaction mixture by 
HPLC afforded fluoroadenosines 171 and 186 as an inseparable mixture in a 1:1 ratio. A 
reverse phase C-18 column was used with a flow rate of 10 mL/min and an isocratic mobile 
phase of 95% buffer A (0.05% TFA/H2O) and 5% buffer B (0.05% TFA/ACN). The inseparable 
mixture of 171 and 186 had a retention time of 8.4 minutes. The fraction containing the 4’-
fluoroadenosines 171 and 186 was collected, concentrated and freeze-dried affording a 
sample of the two isomers, as shown in Figure 3. However, the yield over the two last steps 
was low (only 10%), as shown in Scheme 24, and it was found that this reaction could not be 
easily scaled up.  
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Scheme 24. Synthesis of the fluoroadenosine 171 and 186. 
 
Figure 3. 19F-NMR spectrum of the fluoroadenosine 171 and 186. 
 
 
fluororibofuranose 186 
4’-fluoroadenosine 171 
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4.1.4.2. Optimisation 
 
In order to optimise the overall yield of the synthesis of fluoroadenosine 171, fluorination at 
the carbon C-4’ was attempted of the protected adenosine 187 instead of at the protected 
ribose 179 stage. This new strategy does not require the N-glycosylation reaction, a step 
resulting in a low yield and difficult product purification. The synthesis of the 
tribenzoyladenosine 187 was achieved from adenosine 111a using benzoic anhydride in dry 
pyridine. The product was purified in a 30% yield, as illustrated in Scheme 25.40  
 
Scheme 25. Synthesis of the tribenzoyladenosine 187. 
Photobromination of the tribenzoyladenosine 187 resulted in an unpurified mixture of the 
bromides 188 and 189, as confirmed by a mass spectrometer. Unfortunately, the fluorination 
reaction with a solution of AgBF4 was unsuccessful, giving a complex mixture of nonfluorinated 
compounds, as shown in Scheme 26.  
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Scheme 26. Photobromination of the tribenzoyladenosine 187. 
In the light of this, an approach including the protection of adenosine 111a was explored. 
Therefore, the synthesis of the pentabenzoyladenosine 190 was carried out using benzoyl 
chloride in dry pyridine, as illustrated in Scheme 27.41 
 
Scheme 27. Synthesis of the pentabenzoyladenosine 190. 
As with the tribenzoyladenosine 190 substrate, photobromination of the 
pentabenzoyladenosine 190 gave the unpurified bromide mixture 191 and 192. Immediate 
fluorination of the bromide mixture 191 and 192 with AgBF4 gave a complex mixture, but there 
were no organic fluorine signals in the 19F-NMR.  
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Scheme 28. Photobromination of the pentabenzoyladenosine 190. 
It was then decided to explore the synthesis of fluoroadenosine 171 via an alternative route 
involving chloropurine riboside 195. This was chosen as it was anticipated that treatment with 
ammonia gas would remove the benzoyl groups and generate the adenine base at a later 
stage in the synthesis. Firstly, the synthesis of tribenzoylriboside 196 was carried out using 
chloropurine riboside 195 and benzoyl chloride in dry pyridine, as shown in Scheme 29.42  
 
Scheme 29. Synthesis of the tribenzoylriboside 196. 
After photobromination of the tribenzoylriboside 196, mass spectrometry indicated that 
bromoriboses 197 and 198 had formed. This mixture of 197 and 198 was treated with AgBF4 
and this gave a complex mixture with only traces of the anticipated fluororibosides 199 and 
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200 as judged by 19F-NMR. To conclude, a synthesis of fluoroadenosine 171 was achieved 
as a 1:1 mixture with its isomer 186. However, radical bromination followed by fluorination 
does not seem to function in the presence of the adenine base attached to the carbon C-1’ of 
the ribose ring. Separation of fluorinated sugars 171 and 186 proved to be very challenging 
despite the use of reverse phase and normal phase columns. 
 
Scheme 30. Photobromination of the tribenzoylriboside 196. 
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4.2. Cell-free extract experiments 
 
After the synthesis of several putative substrates for the fluorinating enzyme, it was necessary 
to carry out cell-free extract experiments with adenosine 111a, adenosine sulfate 160, 
sulfamoyladenosine 161 and 4’-fluoroadenosine 171. In 2002, cell-free extract experiments 
were achieved with resting cells of Streptomyces cattleya and these experiments allowed the 
identification of SAM 27a as the substrate for the fluorinase enzyme. Therefore, the same 
procedure as developed by O’Hagan et al. for the cell-free extract experiments of 
Streptomyces cattleya was followed for Streptomyces calvus.43-45  
After 7 days of fermentation, cultures of Streptomyces calvus were centrifuged. The cells were 
washed with Tris–HCl buffer, disrupted by ultrasoniaction and the cell debris removed by 
centrifugation. The supernatant was then used as the cell free extract for incubation 
experiments with a mixture of substrates and co-factors at 37 °C. After incubation, the protein 
was precipitated by heating and then removed by centrifugation. The supernatant was freeze-
dried and analysed by 19F-NMR. 
 
In all experiments, the buffer was supplemented with magnesium chloride which is used to 
stabilise ATP. ATP was added to the cell-free extracts as an energy source for the 
biosynthesis of nucleocidin 78a and as potential source of a substrate. Cell-free extracts were 
also incubated with co-factors such as NAD+ and NADP+ to accommodate the redox-enzyme 
oxidations within the cell-free extract. When necessary, the buffer of the cell-free extract was 
supplemented with ammonia or hydrated magnesium sulfate in order to facilitate enzymatic 
sulfamoylation of adenosine 111a or 4’-fluoroadenosine 171. In the case of the cell-free extract 
experiments with adenosine sulfate 160, only ammonia was added to facilitate the sulfamoyl 
group synthesis.  
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Two buffers were explored; Tris-HCl and phosphate buffer. Unfortunately, none of these 
experiments revealed the formation of nucleocidin 78a or any fluorinated intermediates by 19F-
NMR or mass spectrometry.  
 Experiment 1 Experiment 2 Experiment 3 Experiment 4 
Tris-HCl or 
phosphate buffer 
[20 mM, pH 7.0] + 
MgCl2 [10 mM] 
1260 µL 1290 µL 1320 µL 1260 µL 
NAD+ [100 mM] 30 µL 30 µL 30 µL 30 µL 
NADP+ [100 mM] 30 µL 30 µL 30 µL 30 µL 
ATP [100 mM] 30 µL 30 µL 30 µL 30 µL 
NH3 [100 mM] 30 µL 30 µL  30 µL 
MgSO4.7H2O       
[100 mM] 
30 µL   30 µL 
KF [100 mM] 30 µL 30 µL 30 µL 30 µL 
adenosine 
[50 mM] 
60 µL    
adenosine sulfate 
[50 mM] 
 60 µL   
sulfamoyladenosine 
[50 mM] 
  60 µL  
4’-fluoroadenosine 
[50 mM] 
   60 µL 
 
Figure 4. Incubation of cell-free extracts of S. calvus. 
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4.3. Conclusion 
 
Despite the high number of sulfating reagents available, it proved to be more difficult than 
expected to synthesise adenosine sulfate 160. In this study, adenosine 111a underwent 
sulfation using chlorosulfonic acid 150 in dry pyridine and chloroform to afford adenosine 
sulfate 160. Due to its water solubility and the high purity required for cell-free extract 
experiments, the desired product 160 was purified through a combination of ion exchange 
column and HPLC, sacrificing yield for purity.    
 
The synthesis of the sulfamoyladenosine 161 was described in the literature by Lukkarila et 
al.21 In place of the acetal protection of adenosine 111a, the 2’-OH and 3’-OH of adenosine 
111a was TBS protected in order to increase the overall yield. This strategy proved to be 
successful and the yield of the final deprotection was essentially quantitative.  
 
The synthesis of aldehyde 168 has been described in the literature by Liu et al.26 and by Wnuk 
et al.27 Unfortunately, due to its instability, the purification of carboxaldehyde 204 proved 
unsuccessful by HPLC and it could not be obtained for these studies.     
 
4’-Fluoroadenosine 171 is a candidate advanced intermediate in the biosynthesis of 
nucleocidin 78a. Therefore, the synthesis of fluoroadenosine 171 was achieved as described 
in the literature.32-34 Purification by HPLC proved to be very difficult and gave an inseparable 
mixture of α and β fluoroadenosine 171 and 186 in a 1:1 ratio.  
 
Cell-free extract experiments were carried out with the previous synthesised putative 
substrates 160, 161, 171 and adenosine 111a following the procedures developed by 
O’Hagan.43-45 Unfortunately, none of these cell-free extract experiments suggested the 
formation of nucleocidin 78a or any fluorinated intermediates by 19F-NMR and mass 
spectrometry. However, these results do not disprove any of these compounds as putative 
substrates since no control experiment could be performed on the integrity of the biosynthetic 
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enzymes in the cell-free extract. The proteins of Streptomyces calvus’ cells may lose their 
activity during the preparation of the cell-free extract experiments.  
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5. Thesis conclusions 
 
5.1. New fluorinated natural product from Streptomyces sp. MA37 
 
In 2014, four different bacteria were each found to possess a gene with high homology to the 
gene encoding the fluorinase enzyme in Streptomyces cattleya.1,2 Among these four bacteria, 
a soil bacterium named Streptomyces sp. MA37 was isolated. Fermentations of S. sp. MA37 
in the presence of inorganic fluoride showed the production of fluoroacetate 63a and 
fluorothreonine 77a, two fluorometabolites also observed in Streptomyces cattleya.  
Genome studies proved that both soil bacteria share the same metabolic pathway for the 
biosynthesis fluoroacetate 63a and fluorothreonine 77a.1 Production of seven new unidentified 
fluorometabolites was also observed, each in lower concentrations than both fluoroacetate 
63a and fluorothreonine 77a. Moreover, when analysed by 19F-NMR, each of these new 
fluorinated natural products share the same multiplicity with different coupling constants to 
fluorothreonine 77a.  
Therefore, it was suggested that these new fluorometabolites have the same metabolic origin 
as fluoroacetate 63a and 4-fluoro-L-threonine 77a but within this biosynthetic pathway there 
exists a branch point creating two competing metabolic pathways. Genome studies of S. sp. 
MA37 showed that several genes share high homology with genes responsible for the 
biosynthesis of chlorosalinosporamide A 11 in Salinospora tropica.3  
In accordance to the metabolic pathway of salinosporamide A 11, a related hypothetical 
metabolic pathway was proposed to explain the production of these new fluorometabolites, as 
depicted in Scheme 1. 
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Scheme 1. Proposed metabolic pathway of new fluorometabolites in S. sp. MA37. 
 
Over-expression of the gene Fdr C, encoding for a chain dehydrogenase was carried out in 
E. coli by Dr. Ma. In order to perform the enzyme assays, the synthesis of the substrate FDR 
88 was conducted following the procedure developed by Li et al.4 The absolute 
stereochemistry of the enzyme product was confirmed by total synthesis of FHPA 98. GC-MS 
of the enzyme product and the synthetic 98 showed that they both shared the same retention 
time and fragmentation pattern, proving that they are the same compound.5 
An additional spiking experiment confirmed that FHPA 98 is a fluorinated natural product 
produced by Streptomyces sp. MA37. Importantly, it is the first novel fluorometabolite to be 
identified in over two decades. However, further investigation is required for the identification 
of the other fluorinated natural products.  
 
Scheme 2. Enzymatic synthesis of FHPA 98 as a new fluorometabolite. 
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5.2. Metabolism studies of nucleocidin 78a in Streptomyces 
calvus 
 
Nucleocidin 78a was the first fluorinated natural product isolated from the soil bacterium 
Streptomyces calvus. Since its initial isolation in 1957, the production of nucleocidin 78a has 
been lost in publically available strains.6-9 Due to its particular structure, with the fluorine atom 
attached at the carbon C-4’ of the ribose ring, the originally isolated fluorinase enzyme cannot 
reasonably be involved in the fluorination of nucleocidin 78a. Therefore, the discovery and 
isolation of the second native fluorinating enzyme became the focus of this study.  
 
4.  
Figure 1. Structure of nucleocidin 78a. 
A strain of Streptomyces calvus T-3018 which was known to produce nucleocidin 78a in very 
low yield was provided by the Pfizer company. The presence of nucleocidin 78a could be observed 
by 19F-NMR after a n-butanol extraction of the liquid medium. Identification of nucleocidin 78a was 
carried by both LC-MS and spiking experiment with a pure sample provided by Pfizer.  
Due to its structural similarity, adenosine 111a was thought to be an advanced intermediate in the 
biosynthesis of nucleocidin 78a. Therefore, the biosynthesis of adenosine 111a from glycerol via 
the pentose phosphate pathway 116a was investigated. Pulse feeding experiments with [2-13C]-
glycerol 116b proved that the carbon C-4’ of nucleocidin 78a is derived from the carbon C-2 of 
glycerol 116a. Incubation of [1,1,2,3,3-2H5]-Glycerol 116c and (2R)-[1-2H2]-glycerol 116e in 
separate Streptomyces calvus fermentations showed incorporation with a loss of a deuterium 
atom at the carbon C-5’ of nucleocidin 78a. This loss suggested that the fluorination mechanism 
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might be more complex than initially expected. A summary of the results of the feeding 
experiments performed is described in Scheme 3.10 
 
Scheme 3. Incorporation of labelled glycerols 116b and 116c into nucleocidin 78a.10 
 
Concurrently, the synthesis of putative intermediates in the metabolic pathway was achieved, 
as shown in Figure 2. Adenosine sulfate 160 and sulfamoyladenosine 161 were synthesised 
due to their high structural similarities with nucleocidin 78a. The synthesis of fluoroadenosine 
171 was also performed, because it was thought to be an advanced fluorinated intermediate 
in the biosynthesis of nucleocidin 78a. Unfortunately, production of nucleocidin 78a or new 
fluorinated intermediates could not be observed during any cell-free extract experiments.   
 
Figure 2. Structure of putative intermediates for cell-free extract experiments. 
Recent genome studies of a gene cluster which is thought to be involved in the biosynthesis 
of nucleocidin 78a revealed the presence of a radical-SAM enzyme.8,9 These radical-SAM 
enzymes are known to be sensitive to oxygen, which could explain the lack of nucleocidin 
production in the previous cell-free extract experiments. Knock-out experiments and over-
expression of the gene encoding for this radical-SAM enzyme is currently in progress.  
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6. Experimental 
 
6.1. General experimental 
 
Air and moisture sensitive reactions were carried out under an argon atmosphere in flame-
dried glassware. Room temperature refers to 18-25 °C. All evaporations and concentrations 
were performed under reduced pressure (in vacuo). All reagents (from Acros UK, Alfa Aesar 
UK, Fischer UK, Fluorochem UK or Sigma Aldrich UK) were of synthetic grade and were used 
without further purification. Anhydrous solvents (Et2O, THF) were obtained from MBraun MB 
SPS-800 solvent purification system by passage through two drying columns and dispensed 
under an argon atmosphere. Anhydrous MeOH and ACN were distilled from calcium hydride 
in a recycling still. Anhydrous pyridine was distilled from potassium hydroxide using standard 
protocols.1  
The course of reactions was monitored by thin-layer chromatography (TLC) using aluminium 
plates coated with silica gel (60F245 Merck). TLC plates were observed under UV light (254 
nm and 266 nm) before being stained with anisaldehyde-sulfuric acid or alkaline potassium 
permanganate and developed by heating. Column chromatography was performed on Merck 
Geduran silica gel 60 (250-400 mesh) under a positive pressure of compressed air eluting with 
solvents (reported as v/v) as supplied. Reverse phase column chromatography was performed 
using Extract Clean C18-HC prepacked cartridges. 
NMR spectra were recorded at 298 K on Bruker Avance 300, Avance II 400, Avance 500 or 
Avance III HD 500 instruments. 1H and 13C-NMR spectra were recorded using deuterated 
solvent as the lock and the residual solvent as the internal standard. 19F-NMR spectra were 
referenced to CFCl3 as an external standard. Chemical shifts are reported in parts per million 
(ppm) and coupling constants (J) are reported in Hertz (Hz). The abbreviations for the 
multiplicity of the proton, carbon and fluorine signals are as follows: s singlet, d doublet, dd 
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doublet of doublets, ddd doublet of doublet of doublets, dddd doublet of doublet of doublet of 
doublets, dt doublet of triplets, q quartet, m multiplet, br s broad singlet. Compounds are 
numbered according to customary purine numbering. When necessary, resonances were 
assigned using two-dimensional experiments (COSY, HSQC, HMBC, TOCSY). 
Optical rotations were measured with a Perkin Elmer 341 polarimeter in a 10.0 cm cell at the 
wavelength of the sodium D-line (λ = 589 nm). Specific rotations are reported in implied units 
of 10-1 deg cm2 g-1 and concentrations (c) are reported in g/100 mL. High resolution 
electrospray ionisation mass spectra were obtained on a Micromass LCT or ThermoFisher 
Excalibur Orbitrap spectrometers operating in positive or negative mode, from solutions in 
CHCl3, MeOH, ACN or H2O by the Mass Spectrometry Service at the University of St Andrews. 
MALDI MS was acquired using a 4800 MALDI TOF/TOF Analyser (ABSciex) equipped with a 
Nd:YAG 355 nm laser and calibrated using a mixture of peptides by the Mass Spectrometry 
Service at the University of St Andrews.  
Infrared spectra were acquired on a Perkin Elmer Spectrum GX FTIR apparatus spectrometer 
either as KBr pellets, or as a thin film between NaCl plates, or on a Shimadzu IRAffinity-1S 
spectrometer with a diamond ATR attachment. Absorption maxima are reported in units of 
wavenumbers (cm-1). Melting points were recorded on an Electrothermal IA9100 melting point 
apparatus, or on a Griffin MPA 350.BM2.5 melting point apparatus and are uncorrected.  
X-ray diffraction data were collected on a Mercury 70 diffractometer using graphite 
monochromated Mo-Kα radiation at 100 K by means of phi and omega scans. Structures were 
solved by direct methods and refined by full-matrix least squares techniques. 
HPLC analyses/semi-preparations were performed using either a Varian Prostar (Varian 400 
autosampler, Varian Prostar 230 solvent delivery system, Varian Prostar 235 UV-vis detector) 
or a Shimadzu Prominence (SIL-20A HT autosampler, CL-20AT ternary pump, DGU-20A3R 
solvent degasser, SPD 20A UV detector and CBM-20A controller module) with reverse phase 
160 
 
column. All solvents used were HPLC grade and were degassed prior to use by bubbling 
nitrogen through the solvents. 
LC-MS analysis was performed on a Waters 2795 HPLC coupled in parallel to a Waters 2996 
photodiode array detector and Micromass LCT TOF mass spectrometer in ESI positive mode 
using the column indicated in the individual experiment. Samples were freeze dried from 
frozen solutions in H2O in a Christ Alpha 1-2 LO Plus freeze drier. 
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6.2. Compounds preparation 
 
6.2.1. Methyl 2,3-O-isopropyliden-β-D-ribofuranoside 102 
 
 
2,2-Dimethyloxypropane (20 mL, 16.3 mmol, 0.24 eq.) and perchloric acid 70% (4 mL, 66.6 
mmol, 1 eq.) was added dropwise to a suspension of D-ribose 103 (10 g, 66.6 mmol, 1 eq.) in 
acetone (80 mL) cooled to 0 °C. The resulting reaction mixture was stirred for 2 h at room 
temperature and then MeOH (14 mL) was added and the mixture was stirred at room 
temperature for 16 h. A saturated solution of K2CO3 (10 mL) was added and the mixture was 
partitioned between H2O (150 mL) and DCM (70 mL). The aqueous phase was extracted with 
DCM (3 × 70 mL). The combined organic phases were dried (Na2SO4), filtered and the filtrate 
was concentrated. The crude mixture was purified by column chromatography (PE/EtOAc 9:1) 
to afford methyl 2,3-O-isopropyliden-β-D-ribofuranoside 102 (5.9 g, 44%) as a yellow oil. 
Rf = 0.46 (EtOAc/PE 1:1); [α]20D : −73.5° (c 1.0, CHCl3) (lit.,2 −78.5°, c 1.0, CHCl3); 1H-NMR 
(CDCl3, 300 MHz) δH 4.94 (1H, s, H-1), 4.80 (1H, d, J = 6.0 Hz, H-3), 4.55 (1H, d, J = 6.0 Hz, 
H-2), 4.40 (1H, t, J = 3.1 Hz, H-4), 3.68-3.56 (2H, m, CH2-5), 3.40 (3H, s, OCH3), 1.45 (3H, s, 
CH3), 1.29 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 112.2 (C(CH3)2), 110.0 (CH, C-1), 88.4 
(CH, C-4), 85.9 (CH, C-2), 81.5 (CH, C-3), 64.0 (CH2, C-5), 55.6 (CH3, OCH3), 26.4 (CH3), 
24.7 (CH3); IR Qmax (neat): 3458, 2988, 2932, 2836, 1457, 1380, 1275, 1207, 1163, 1097, 1044, 
964, 870 cm-1; HRMS m/z (ES+) (calculated C9H16O5Na+ = 227.0895) found 227.0899 [M+Na]+. 
Data are in agreement with literature.2 
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6.2.2. Methyl 2,3-O-(1-methylethylidene)-5-O-                                                               
(p-toluenesulfonyl)-β-ribofuranoside 101 
 
 
4-Toluenesulfonyl chloride (4.77 g, 25.0 mmol, 1.5 eq.) was added portionwise to a solution 
of methyl 2,3-O-isopropyliden-β-D-ribofuranoside 102 in dry pyridine (10 mL) at 0 °C and the 
reaction mixture was stirred for 3 h at room temperature. H2O (4 mL) was carefully added to 
the reaction mixture and the stirring was continued for further 30 min. The mixture was 
extracted with CHCl3 (3 × 15 mL) and the combined organic phases were washed with an 
aqueous solution of CuSO4 (30 mL), saturated bicarbonate solution (30 mL), H2O (30 mL) and 
dried (Na2SO4). The filtrate was concentrated in vacuo and the crude mixture was purified by 
column chromatography (PE/EtOAc 2:1) to afford methyl 2,3-O-(1-methylethylidene)-5-O-(p-
toluenesulfonyl)-β-ribofuranoside 101 (4.92 g, 83%) as a colourless oil. 
Rf = 0.67 (EtOAc/PE 1:1); [α]20D : −49.5° (c 1.0, CHCl3) (lit.,2 −48.7°, c 1.0, CHCl3); 1H-NMR 
(CDCl3, 300 MHz) δH 7.80 (2H, d, J = 8.3 Hz, ArH), 7.35 (2H, d, J = 8.3 Hz, ArH), 4.92 (1H, s, 
H-1), 4.58 (1H, d, J = 5.9 Hz, H-3), 4.52 (1H, d, J = 5.9 Hz, H-2), 4.30 (1H, t, J = 7.1 Hz, H-4), 
4.04-3.97 (2H, m, CH2-5), 3.22 (3H, s, OCH3), 2.45 (3H, s, Ar-CH3), 1.44 (3H, s, CH3), 1.28 
(3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 145.2 (Ar-C), 132.9 (Ar-C), 130.1 (Ar-CH), 128.1 
(Ar-CH), 112.8 (C(CH3)2), 109.6 (CH, C-1), 85.0 (CH, C-2), 83.7 (CH, C-4), 81.5 (CH, C-3), 
69.3 (CH2, C-5), 55.2 (CH3, OCH3), 26.5 (CH3), 25.0 (CH3), 21.8 (CH3, Ar-CH3); IR Qmax (neat): 
2952, 1596, 1450, 1375, 869 cm-1; HRMS m/z (ES+) (calculated C16H22O7NaS+ = 381.0984) 
found 381.0980 [M+Na]+. Data are in agreement with literature.3 
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6.2.3. 2-Pyridinesulfonyl fluoride 104 (PyFluor) 
 
 
A multi-neck flask fitted with an addition funnel and a thermometer was charged with sulfuric 
acid 149 (80 mL) and 2-mercaptopyridine (5.55 g, 50 mmol, 1 eq.) and left open to the 
atmosphere. The reaction mixture was cooled to 0 °C and 13% aqueous sodium hypochlorite 
(238 mL) was added dropwise over 4 h while stirring vigorously and maintaining an internal 
reaction temperature below 10 °C. Upon complete addition, the reaction mixture was extracted 
twice with ethyl acetate (2 × 125 mL). The combined organic extracts were concentrated to 
afford crude 2-pyridinesulfonyl chloride, which was immediately added to a mixture containing 
1:3 (v/v) ACN:H2O (80 mL) and potassium bifluoride (19.55 g, 250 mmol, 5 eq.). This solution 
was stirred vigorously for 20 min and was then extracted twice with EtOAc (75 mL). The 
organic extracts were dried over sodium sulfate and filtered through a   5 g silica plug, eluting 
with EtOAc. The filtrate was purified by column chromatography (PE/EtOAc 2:1) to afford 2-
pyridinesulfonyl fluoride 104 (5.0 g, 62%) as a colourless crystalline solid. 
Rf = 0.44 (PE/EtOAc 2:1); m.p. 27-30 °C (lit.,4 23-26 °C); 1H-NMR (CHCl3, 300 MHz) δH 8.85 
(1H, d, J = 4.9 Hz, ArH), 8.15 (1H, d, J = 8.0 Hz, ArH), 8.08 (1H, tt, J = 7.8 Hz, J = 1.6 Hz, 
ArH), 7.70 (1H, ddd, J = 7.7 Hz, J = 4.8 Hz, J = 1.0 Hz, ArH); 13C-NMR (CHCl3, 100 MHz) δC 
151.9 (Ar-C, d, J = 30.5 Hz), 151.5 (Ar-CH, d, J = 1.1 Hz), 139.1 (Ar-CH), 130.0 (Ar-CH), 124.1 
(Ar-CH, d, J = 2.2 Hz); 19F-NMR (CHCl3, 376 MHz) δF -145.7; HRMS m/z (ES+) (calculated 
C5H4FNNaO2S+ = 183.9839) found 183.9840 [M+Na]+. Data are in agreement with literature.4 
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6.2.4. Methyl 5-deoxy-5-fluoro-2,3-O-isopropylidene-β-D-ribofuranoside 100 
 
 
PyFluor 104 (0.81 g, 5.0 mmol, 1.1 eq.) and MTBD (1.3 mL, 9.0 mmol, 2 eq.) was added to a 
solution of 2,3-O-isopropyliden-β-D-ribofuranoside 102 (0.92 g, 4.5 mmol, 1 eq.) in toluene   
(12 mL). The reaction mixture was stirred at room temperature overnight then quenched by 
addition of a saturated aqueous solution of bicarbonate (15 mL) and the mixture was stirred 
for an additional 30 min. The organic phase was isolated and the aqueous layer was extracted 
with EtOAc (3 × 15 mL). The combined organic phases were dried (MgSO4) and the solvent 
was evaporated. The crude mixture was then purified by column chromatography (PE/Et2O 
1:1) to afford methyl 5-deoxy-5-fluoro-2,3-O-isopropylidene-β-D-ribofuranoside 100 (0.76 g, 
82%) as a colorless oil. 
Rf = 0.61 (Et2O/PE 1:1); [α]20D : −90.0° (c 1.0, CHCl3) (lit.,5 −91.9°, c 1.0, CHCl3); 1H-NMR 
(CDCl3, 300 MHz) δH 4.98 (1H, d, J = 2.4 Hz, H-1), 4.69 (1H, d, J = 6.0 Hz, H-3), 4.59 (1H, d, 
J = 6.0 Hz, H-2), 4.49-4.24 (3H, m, H-4 & CH2), 3.32 (3H, s, OCH3), 1.48 (3H, s, CH3), 1.32 
(3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 112.8 (C(CH3)2), 109.4 (CH, C-1), 85.2 (CH,        
C-2), 84.6 (CH, d, J = 22.2 Hz, C-4), 83.1 (CH, d, J = 172.4 Hz, C-5), 81.2 (CH, d, J = 4.3 Hz, 
C-3), 55.0 (CH3, OCH3), 26.5 (CH3), 25.0 (CH3); 19F-NMR (CDCl3, 376 MHz) δF -225.2 _ -225.7 
(1F, m); IR Qmax (neat): 2940, 2837, 1457, 1384, 1212, 1088, 871 cm-1; HRMS m/z (ES+) 
(calculated C9H15FNaO4+ = 229.0847) found 229.0847 [M+Na]+. Data are in agreement with 
literature.3 
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6.2.5. 5-Fluoro-5-deoxy-ribose 88 (FDR) 
 
 
A solution of methyl 5-deoxy-5-fluoro-2,3-O-isopropylidene-β-D-ribofuranoside 100 (556 mg, 
2.69 mmol, 1 eq.) in aqueous H2SO4 149 (20 mM, 6 mL) was stirred at 98 °C for 2 h. The 
reaction mixture was cooled to room temperature and the pH was adjusted to pH 7 by addition 
of BaCO3. The suspension was centrifuged and the supernatant was passed through a syringe 
filter (0.22 µm). The resultant solution was lyophilised for 16 h, affording 5-fluoro-5-deoxy-
ribose 88 (360 mg, 88%) as a yellow oil. 
1H-NMR (D2O, 300 MHz) δH 5.37 (0.3H, d, J =  4.0 Hz, α anomer, H-1), 5.23 (0.7H, d,                    
J = 1.5 Hz, β anomer, H-1), other signals could not be interpreted due to overlapping;              
13C-NMR (D2O, 100 MHz) δC 101.5 (CH, β anomer, C-1), 96.8 (CH, α anomer, C-1), 83.7 (CH2, 
d, J = 168.6 Hz, β anomer, C-5), 83.2 (CH2, d, J = 167.2 Hz, α anomer, C-5), 81.3 (CH, d,         
J = 17.4 Hz, α anomer, C-4), 80.9 (CH, d, J = 18.2 Hz, β anomer, C-4), 75.3 (CH, β anomer, 
C-2), 71.0 (CH, α anomer, C-2), 69.8 (CH, d, J = 6.9 Hz, β anomer, C-3), 69.6 (CH, d,                     
J = 6.5 Hz, α anomer, C-3); 19F-NMR (D2O, 376 MHz) δF -229.4 (0.7F, dt, J = 47.3 Hz, 25.7 
Hz, β anomer), -231.7 (0.3F, dt, J = 47.3 Hz, 25.7 Hz, α anomer); HRMS m/z (ES-) (calculated 
C5H8FO4- = 151.0412) found 151.0407 [M-H]-. Data are in agreement with literature.3 
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6.2.6. 2,3-O-Isopropylidene-D-ribose 110 
 
 
2,2-Dimethoxypropane (2.5 mL, 20.6 mmol, 1.03 eq.) and 4-toluene sulfonic acid (0.19 g,       
1.0 mmol, 0.05 eq.) were added to a cooled suspension of D-ribose 103 (3.0 g, 20.0 mmol,      
1 eq.) in acetone (30 mL). After stirring at room temperature for 1 h, the clear mixture was 
neutralised with saturated aqueous sodium bicarbonate solution and filtered through pad of a 
celite. The filtrate was concentrated and the residue was dissolved in EtOAc (60 mL), and then 
washed with H2O (15 mL). The aqueous layer was extracted with EtOAc (2 × 30 mL). The 
combined organic layer was dried (MgSO4), filtered and the filtrate was concentrated. The 
product was purified by column chromatography (EtOAc) to afford 2,3-O-isopropylidene-D-
ribose 110 (0.91 g, 24%) as a colourless oil. 
Rf = 0.38 (EtOAc); [α]20D : −29.8° (c 0.5, CHCl3) (lit.,7 −24.7°, c 1.1, CHCl3); 1H-NMR (CDCl3, 
300 MHz) δH 5.31 (1H, s, H-1), 4.73 (1H, d, J = 5.9 Hz, H-2), 4.47 (1H, d, J = 5.9 Hz, H-3), 
4.30 (1H, t, J = 3.1 Hz,     H-4), 3.68-3.55 (2H, m, CH2), 1.38 (3H, s, CH3), 1.21 (3H, s, CH3); 
13C-NMR (CDCl3, 100 MHz) δC 112.2 (C(CH3)2), 103.1 (CH, C-1), 88.0 (CH, C-4), 87.0 (CH, 
C-3), 81.8 (CH,   C-2), 63.8 (CH2, C-5), 26.5 (CH3), 24.9 (CH3); IR Qmax (neat): 3419, 2987, 
2942, 1458, 1377, 1212, 1067, 870 cm-1; HRMS m/z (ES+) (calculated C8H14NaO5+ = 
213.0733) found 213.0728 [M+Na]+. Data are in agreement with literature.6 
 
 
 
 
167 
 
6.2.7. 2,3-O-Isopropylidene-D-ribono-1,4-lactone 109 
 
 
K2CO3 (1.99 g, 14.4 mmol, 3 eq.) and iodine (3.65 g, 14.4 mmol, 3 eq.) were added to the 
solution of 2,3-O-isopropylidene-D-ribose 110 (0.91 g, 4.8 mmol, 1 eq.) in DCM (15 mL). The 
reaction mixture was stirred at room temperature for 4 h, then quenched by addition of a 
saturated aqueous solution of Na2SO3 (10 mL) and vigorous stirring for a further 30 min. The 
organic phase was isolated and the aqueous phase was extracted with EtOAc (3 × 20 mL). 
The combined organic phases were dried (MgSO4) and solvent was evaporated. The crude 
mixture was then purified by column chromatography (EtOAc) to afford 2,3-O-isopropylidene-
D-ribono-1,4-lactone 109 (0.88 g, 97%) as a white solid. 
Rf = 0.38 (EtOAc); [α]20D : −62.8° (c 0.25, CHCl3) (lit.,8 −62.3°, c 0.05, CHCl3); m.p.                  
129-133 °C (lit.,8 136-137 °C); 1H-NMR (CDCl3, 300 MHz) δH 4.84 (1H, d, J = 5.6 Hz, H-2), 
4.78 (1H, d, J = 5.6 Hz, H-3), 4.63 (1H, br s, H-4), 4.00 (1H, d, J = 11.9 Hz, H-5), 3.82 (1H, d, 
J = 11.9 Hz, H-5), 1.48 (3H, s, CH3), 1.39 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 175.5 
(C=O), 113.3 (C(CH3)2), 82.6 (CH, C-4), 78.4 (CH, C-3), 75.8 (CH, C-2), 62.2 (CH2,  C-5), 26.9 
(CH3), 25.6 (CH3); IR Qmax (neat): 3460, 1763, 1377, 1221, 1196, 1153, 968, 854, 808, 773 cm-
1; HRMS m/z (ES+) (calculated C8H12NaO5+ = 211.0577) found 211.0572 [M+Na]+. Data are in 
agreement with literature.8 
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6.2.8. 5-Deoxy-5-fluoro-2,3-O-isopropylidene-D-ribono-1,4-lactone 108 
 
 
PyFluor 104 (0.06 g, 0.36 mmol, 1.1 eq.) and MTBD (0.10 mL, 0.66 mmol, 2 eq.) were added 
to a solution of 2,3-O-isopropylidene-D-ribono-1,4-lactone 109 (62 mg, 0.33 mmol, 1 eq.) in 
toluene (2 mL). The reaction mixture was stirred at room temperature overnight, then 
quenched by addition of a saturated aqueous solution of bicarbonate (5 mL) and vigorous 
stirring for a further 30 min. The organic phase was isolated and the aqueous phase was 
extracted with EtOAc (3 × 10 mL). The combined organic phases were dried (MgSO4) and the 
solvent evaporated. The crude mixture was concentrated and purified by column 
chromatography (PE/EtOAc 3:1) to afford 5-deoxy-5-fluoro-2,3-O-isopropylidene-D-ribono-
1,4-lactone 108 (55 mg, 87%) as colourless needle-like crystals. 
Rf = 0.55 (EtOAc/PE 1:1); [α]20D : −74.4° (c 0.25, CHCl3) (lit.,8 −82.8°, c 0.005, CHCl3); m.p. 
65-68 °C (lit.,8 60-62 °C); 1H-NMR (CDCl3, 300 MHz) δH 4.82 (1H, d, J = 5.4 Hz, H-2), 4.79 
(1H, dd, J = 5.6 Hz, 3.3 Hz, H-3), 4.75-4.59 (3H, m, H-4 & CH2), 1.41 (3H, s, CH3), 1.41 (3H, 
s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 169.9 (C=O), 115.4 (C(CH3)2), 82.6 (CH2, d,                       
J = 172.0 Hz, C-5), 80.4 (CH, d, J = 18.2 Hz, C-4), 77.4 (CH, d, J = 4.9 Hz, C-3), 75.3 (CH, d, 
J = 3.8 Hz, C-2), 26.9 (CH3), 25.75 (CH3); 19F-NMR (CDCl3, 376 MHz) δF -235.5 (1F, dddd,       
J = 48.5 Hz, 45.3 Hz, 34.4 Hz, 3.3 Hz); IR Qmax (neat):  3545, 2995, 1788, 1383, 1269, 1055, 
847 cm-1; HRMS m/z (ES+) (calculated C8H11FNaO4+ = 213.0534) found 213.0526 [M+Na]+. 
Data are in agreement with literature.8 
 
 
 
169 
 
6.2.9. 5-Deoxy-5-fluoro-D-ribono-1,4-lactone 97 
 
 
A solution of 5-deoxy-5-fluoro-2,3-O-isopropylidene-D-ribono-1,4-lactone 108 (120 mg,        
0.63 mmol, 1eq.) in a mixture of TFA/H2O (5 mL, 9:1) was stirred at room temperature for 5 h. 
The reaction mixture was co-evaporated five times with Et2O (5 mL), affording 5-deoxy-5-
fluoro-D-ribono-1,4-lactone 97 (90.5 mg, 96%) as white solid. 
[α]20D : +7.6˚ (c 0.25, H2O); m.p. 81-85 °C; 1H-NMR (D2O, 300 MHz) δH4.63-4.60 (1H, m), 
4.58-4.48 (3H,m), 4.38 (1H,d, J= 5.5 Hz, H-2); 13C-NMR (D2O, 100 MHz)δC 178.0 (C=O), 84.2 
(CH, d, J= 17.8 Hz, C-4), 82.2 (CH2, d, J= 168.5 Hz, C-5), 68.9 (CH, d, J= 2.1 Hz, C-2), 68.6 
(CH, d, J= 5.1 Hz, C-3);19F-NMR (D2O, 376 MHz) δF -231.6 (1F, td, J= 46.7 Hz, 33.2 Hz); IR 
Qmax (neat): 3429, 3280, 1751, 1190, 1140, 966, 895, 781 cm-1; HRMS m/z (ES+) (calculated 
C5H7FNaO4+ = 173.0221) found 173.0219 [M+Na]+. 
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6.2.10. (2R,3S,4S)-5-Fluoro-2,3,4-trihydroxypentanoic acid 98 
 
 
LiOH (27.8 mg, 0.66 mmol, 1.1 eq.) was added to a solution of 5-deoxy-5-fluoro-D-ribono-1,4-
lactone 97 (90.5 mg, 0.6 mmol, 1 eq.) in H2O (3 mL). The resultant mixture was stirred at room 
temperature for 72 h. The pH was then adjusted to 7 by addition of diluted HCl and the reaction 
mixture was concentrated, affording (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid 98 
(100 mg, 100%) as a white solid in quantitative yield. 
[α]20D : -4.0˚ (c 0.25, H2O); m.p. 165-168 °C; 1H-NMR (D2O, 300 MHz) δH4.61-4.41 (2H, m, 
CH2), 4.04 (1H,d, J= 3.1 Hz,   H-2), 3.94-3.82 (2H,m, H-3 & H-4); 13C-NMR (D2O, 100 MHz) 
δC 177.9 (C=O), 85.0 (CH2, d,  J= 164.6 Hz, C-5), 73.4 (CH, C-2), 72.2 (CH, d, J= 7.3 Hz,        
C-3), 69.8 (CH, d, J= 17.8 Hz, C-4);19F-NMR (D2O, 376 MHz) δF -233.5 (1F, td, J= 47.4 Hz, 
24.5 Hz); IR Qmax (neat): 3209, 1604, 1408, 1336, 1096, 1036, 949, 910, 810  cm-1; HRMS m/z 
(ES-) (calculated C5H8FO5- = 167.0361) found 167.0358 [M-H]-. 
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6.2.11. (S)-2,2-Dimethyl-4-hydroxy[2H2]methyl-1,3-dioxolane 132 
 
 
A solution solution of (S)-methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate 131 (1.8 mL,       
12.5 mmol, 1eq.) in anhydrous diethyl ether (10 mL) was added dropwise to a suspension of 
LiAlD4 (1.0 g, 23.8 mmol, 1.9 eq.) in anhydrous diethyl ether (8.5 mL). The mixture was stirred 
under reflux for 1 h and then diluted with diethyl ether. After cooling the reaction mixture to     
0 °C, H2O (1 mL) was slowly added, followed by aqueous NaOH (15% w/v, 1 mL) and H2O (3 
mL) again. The solution was allowed to reach room temperature and was stirred for 15 min. 
The solution was dried over MgSO4 and filtered to remove salts. The solvent was then 
evaporated affording (S)-2,2-dimethyl-4-hydroxy[2H2]methyl-1,3-dioxolane 132 (1.58 g, 94%) 
as a yellow oil. 
Rf = 0.44 (EtOAc/PE 1:1); [α]20D : -16.4° (c 1.0, CHCl3) (lit.,9 −14.9°, undiluted); 1H-NMR 
(CDCl3, 300 MHz) δH 4.21 (1H, t, J = 6.6 Hz, CH), 4.02 (1H, dd, J = 8.2 Hz, 6.6 Hz, CH2), 3.77 
(1H, dd, J = 8.2 Hz, 6.6 Hz, CH2), 2.24 (1H, br s, OH), 1.42 (3H, s, CH3), 1.35 (3H, s, CH3); 
13C-NMR (CDCl3,  100 MHz) δC 109.5 (C(CH3)2), 76.1 (CH), 65.8 (CH2), 63.1 (CD2, p,                    
J = 21.3 Hz), 26.8 (CH3), 25.4 (CH3); IR Qmax (neat): 3454, 1395, 1380, 1049, 837  cm-1; HRMS 
m/z (ES+) (calculated C6H11D2O3+ = 135.0985) found 135.0984 [M+H]+. Data are in agreement 
with literature.9 
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6.2.12. (S)-1,1-Dideuteroglycerol 116d 
 
 
HCl (38%, 0.1 mL) was slowly added to a solution of (S)-2,2-dimethyl-4-hydroxy[2H2]methyl-
1,3-dioxolane 132 (1.58 g, 11.8 mmol, 1 eq.) in H2O (1.9 mL) and the reaction mixture was 
stirred at room temperature for 3 h. The solution was then concentrated affording (S)-1,1-
dideuteroglycerol 116d (0.87 g, 78%) as a yellow oil. 
1H-NMR (D2O, 300 MHz) δH 3.71 (1H, dd, J = 6.6 Hz, 4.4 Hz, CH), 3.59 (1H, dd, J = 11.9 Hz, 
4.4 Hz, CH2), 3.49 (1H, dd, J = 11.9 Hz, 6.6 Hz, CH2); 13C-NMR (D2O, 100 MHz) δC 72.3 (CH), 
62.8 (CH2), 62.4 (CD2, p, J = 22.7 Hz); HRMS m/z (ES+) (calculated C3H7D2O3+ = 95.0672) 
found 95.0672 [M+H]+. Data are in agreement with literature.9 
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6.2.13. (R)-2,2-Dimethyl-4-hydroxy[2H2]methyl-1,3-dioxolane 134 
 
 
A solution of (R)-methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate 133 (0.9 mL, 6.3 mmol, 
1eq.) in anhydrous diethyl ether (5 mL) was added dropwise to a stirred suspension of LiAlD4   
(0.5 g, 12.6 mmol, 2 eq.) in anhydrous diethyl ether (4.5 mL). The mixture was stirred under 
reflux for 1 h and then diluted with diethyl ether. After cooling to 0 °C, H2O (0.5 mL) was slowly 
added to the reaction, followed by a solution of aqueous NaOH (15% w/v, 1 mL) and H2O     
(1.5 mL). The solution was allowed to reach room temperature and was stirred for 15 min. The 
solution was dried over MgSO4 and filtered to remove salts. The solvent was then evaporated 
affording (R)-2,2-dimethyl-4-hydroxy[2H2]methyl-1,3-dioxolane 134 (0.5 g, 60%) as a colorless 
oil. 
Rf = 0.43 (EtOAc/PE 1:1); [α]20D : +15.9˚ (c 1.0, CHCl3) (lit.,9 −15.2°, undiluted); 1H-NMR 
(CDCl3, 300 MHz) δH 4.20 (1H, t, J = 6.6 Hz, CH), 4.01 (1H, dd, J = 8.2 Hz,  6.6 Hz, CH2), 3.76 
(1H, dd, J = 8.2 Hz,   6.6 Hz, CH2), 2.29 (1H, br s, OH), 1.41 (3H, s, CH3), 1.35 (3H, s, CH3); 
13C-NMR (CDCl3,  100 MHz) δC 109.5 (C(CH3)2), 76.1 (CH), 65.8 (CH2), 63.1 (CD2, p,                    
J = 21.8 Hz), 26.8 (CH3), 25.4 (CH3); IR Qmax (neat): 3455, 1395, 1382, 1050, 837 cm-1; HRMS 
m/z (ES+) (calculated C6H11D2O3+ = 135.0985) found 135.0984 [M+H]+. Data are in agreement 
with literature.9 
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6.2.14. (R)-1,1-Dideuteroglycerol 116e 
 
 
HCl (38%, 0.1 mL) was slowly added to a solution of (R)-2,2-dimethyl-4-hydroxy[2H2]methyl-
1,3-dioxolane 134 (0.50 g, 3.7 mmol, 1 eq.) in H2O (1.1 mL) and the reaction mixture was 
stirred at room temperature for 3 h. The solution was then concentrated affording (R)-1,1-
dideuteroglycerol 116e (0.25 g, 70%) as a colorless oil. 
1H-NMR (D2O, 300 MHz) δH 3.71 (1H, dd, J = 6.5 Hz, 4.4 Hz, CH), 3.59 (1H, dd, J = 11.9 Hz, 
4.4 Hz, CH2), 3.49 (1H, dd, J = 11.9 Hz, 6.5 Hz, CH2); 13C-NMR (D2O, 100 MHz) δC 74.1 (CH), 
64.0 (CH2), 63.6 (CD2, p, J = 22.5 Hz); HRMS m/z (ES+) (calculated C3H7D2O3+ = 95.0672) 
found 95.0672 [M+H]+. Data are in agreement with literature.9 
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6.2.15. 2’,3’-O-Isopropylidene-adenosine 137 
 
 
Perchloric acid (1.13 mL, 18.71 mmol, 2 eq.) was added over 3 min to a suspension of 
adenosine 111a (2.5 g, 9.35 mmol, 1 eq.) in acetone (50 mL) cooled to 0 °C. The reaction 
mixture was allowed to reach room temperature and stirred for 6 h. Aqueous ammonia   (35% 
v/v, 25 mL) was added in 2.5 mL portions after the solution was cooled to 0 °C. The mixture 
was then concentrated to a white powder and stored at -20 °C overnight. The white solid was 
washed with diethyl ether (20 mL) and the residue was purified by silica gel column 
chromatography (CHCl3/MeOH 4:1) to afford 2’,3’-O-isopropylidene-adenosine 137 (1.86  g, 
65%) as a white powder. 
Rf = 0.66 (CHCl3/MeOH 4:1); [α]20D : -64.2° (c 1.0, H2O) (lit.,10 −65°, c 1.0, H2O); m.p.              
214-215 °C (lit.,11 218-220 °C from DCM); 1H-NMR (CDCl3, 300 MHz) δH 8.32 (1H, s,  H-8), 
7.84 (1H, s, H-2), 5.85 (1H, d, J = 5.0 Hz, H-1’), 5.73 (2H,   br s, NH2), 5.24-5.18 (1H, m,           
H-2’), 5.14-5.09 (1H, m, H-3’), 4.56-4.53 (1H, m, H-4’), 4.02-3.94 (1H, m, H-5’), 3.85-9.74 (1H, 
m, H-5’), 1.65 (3H, s, CH3), 1.38 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 156.0   (Ar-C), 
152.8 (Ar-CH, C-8), 148.8 (Ar-C), 140.5 (Ar- CH, C-2), 121.5 (Ar-C), 114.3 (C(CH3)2), 94.6 
(CH, C-1’), 86.2 (CH, C-4’), 83.1 (CH, C-2’), 81.9 (CH, C-3’), 63.6 (CH2, C-5’), 27.8 (CH3), 25.4 
(CH3); IR Qmax (neat): 3720, 3110, 1688, 1605, 1210, 1090, 716 cm-1; HRMS m/z (ES+) 
(calculated C13H17N5NaO4+ = 330.1173) found 330.1173 [M+Na]+. Data are in agreement with 
literature.12 
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6.2.16. 2’,3’-O-Isopropylideneadenosine-4’-dehydroxymethyl-                                                                       
4’-carboxylic acid 136 
 
 
BAIB (2.3 g, 7.16 mmol, 2.2 eq.) and TEMPO (0.10 g, 0.65 mmol, 0.2 eq.) were added to a 
solution of 2’,3’-O-isopropylidene-adenosine 137 (1.0 g, 3.25 mmol, 1 eq.) in H2O (5 mL) and 
ACN (5 mL). The reaction mixture was stirred at room temperature for 3 h. The solvents were 
then removed by filtration and the solid was washed with Et2O (3 × 20 mL) to afford 2’,3’-O-
isopropylideneadenosine-4’-dehydroxymethyl-4’-carboxylic acid 136 (0.75 g, 72%) as a white 
solid. 
[α]20D : -94.1° (c 1.0, CHCl3); m.p. 251-255 °C (lit.,13 250-253 °C); 1H-NMR (CDCl3, 300 MHz) 
δH 8.24 (1H, s, H-8), 8.08 (1H, s, H-2), 7.28 (2H, br s, NH2), 6.33 (1H, s, H-1’), 5.54 (1H, dd,   
J = 6.0 Hz, 1.9 Hz, H-3’), 5.46 (1H, d, J = 6.0 Hz, H-2’), 4.68 (1H, d, J = 1.9 Hz, H-4’), 1.52 
(3H, s, CH3), 1.35 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 170.7 (CO2H), 156.4 (Ar-C), 
152.4 (Ar-CH, C-2), 149.1 (Ar-C), 140.4 (Ar- CH, C-8), 119.2 (Ar-C), 113.0 (C(CH3)2), 89.5 
(CH, C-1’), 85.4 (CH, C-3’), 83.8 (CH, C-2’), 83.4 (CH, C-4’), 26.5 (CH3), 24.9 (CH3); IR Qmax 
(neat): 3051, 1694, 1600, 1554, 1124, 1080 cm-1; HRMS m/z (ES+) (calculated C13H16N5O5+ = 
322.1146) found 322.1146 [M+H]+. Data are in agreement with literature.13  
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6.2.17. Adenosine-5’-carboxylic acid methyl ester 135 
 
 
2’,3’-O-Isopropylideneadenosine-4’-dehydroxymethyl-4’-carboxylic acid 136 (1.0 g, 3.1 mmol, 
1 eq.) was suspended in MeOH (70 mL) and cooled to 0 °C. After 30 min stirring, SOCl2          
(1.1 mL, 15.6 mmol, 5 eq.) was added dropwise. The reaction mixture was stirred at room 
temperature overnight. Solvent and SOCl2 were removed under reduced pressure and co-
evaporated with toluene (3 × 20 mL). The residue was purified by silica gel column 
chromatography (DCM/MeOH 9:1) to afford adenosine-5’-carboxylic acid methyl ester 135 
(0.74 g, 81%) as a yellow powder. 
Rf = 0.36 (DCM/MeOH 9:1); [α]20D : -24.7° (c 2.3, CHCl3) (lit.,14 −23°, c 2.34, HCl); m.p.          
200-207 °C (lit.,14 220-222 °C); 1H-NMR (CDCl3, 300 MHz) δH 8.59 (1H, s, H-8), 8.21 (1H, s, 
H-2), 6.21 (1H, d, J = 6.0 Hz, H-1’), 4.64-4.60 (2H, m, H-2’ & H-3’), 4.46 (1H, dd, J = 4.6 Hz, 
3.0 Hz, H-4’), 3.82 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 171.1 (C=O), 156.5 (Ar-C), 
152.6 (Ar-CH, C-2), 148.9 (Ar-C), 139.9 (Ar- CH, C-8), 119.2  (Ar-C), 88.1 (CH, C-1’), 82.8 
(CH, C-3’), 75.0 (CH, C-2’), 73.6 (CH, C-4’), 51.7 (CH3); IR Qmax (KBr): 3431, 2921, 1734, 1667, 
1601, 1584, 1485, 1334, 1301, 1284, 1200, 1099, 1068, 901, 660 cm-1; HRMS m/z (ES+) 
(calculated C11H14N5O5+ = 296.0989) found 296.0989 [M+H]+. Data are in agreement with 
literature.14  
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6.2.18. 5’,5’-Dideuterioadenosine 111c 
 
 
Adenosine-5’-carboxylic acid methyl ester 135 (0.65 g, 2.2 mmol, 1 eq.) was suspended in 
EtOH (16 mL) and cooled to 0 °C. NaBD4 (0.46 g, 11.0 mmol, 5 eq.) was added in portions 
over 20 min. The reaction mixture was then heated to 110 °C and stirred for 2 d. The reaction 
mixture was cooled and concentrated, before being dissolved in H2O (30 mL) and the pH 
adjusted to pH 6.5 with HCl (1 M). The resulting solution was concentrated and the residue 
was purified by silica gel column chromatography (EtOAc/iPrOH/H2O 7:2:1) to afford 5’,5’-
dideuterioadenosine 111c (0.49  g, 82%) as a white powder. 
Rf = 0.28 (EtOAc/iPrOH/H2O 7:2:1); [α]20D : −61.4° (c 1.0, H2O); m.p. 233-236 °C (lit.,15 234-
236 °C from H2O); 1H-NMR (DMSO-d6, 300 MHz) δH 8.32 (1H, s, H-8), 8.18 (1H, s, H-2), 5.97 
(1H, d, J = 6.5 Hz, H-1’), 4.75 (1H, t, J = 5.8 Hz, H-2’), 4.63 (2H, br s, NH2), 4.33 (1H, dd,           
J = 5.0 Hz, J = 2.5 Hz, H-3’), 4.17 (1H, d, J = 2.5 Hz, H-4’); 13C-NMR (DMSO-d6, 100 MHz) δC 
156.2 (Ar-C), 152.1 (Ar-CH, C-8), 149.5 (Ar-C), 141.3 (Ar- CH, C-2), 119.0   (Ar-C), 88.9 (CH, 
C-1’), 85.1 (CH, C-4’), 72.8 (CH, C-3’), 70.1 (CH, C-2’), 62.9 (CH2, p, J = 21.2 Hz, C-5’); IR 
Qmax (KBr): 3432, 2920, 1667, 1605, 1584, 1481, 1331, 1299, 1200, 1103, 1070, 900, 660      
cm-1; HRMS m/z (ES+) (calculated C10H12D2N5O4+ = 270.1166) found 269.1098 [2%] and 
270.1169 [M+H]+.  
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6.2.19. 2’,5’-Bis-O-(tert-butyldimethylsilyl)-β-D-adenosine 141 
 
 
TBSCl (6.8 g, 45.0 mmol, 3 eq.) was added to a solution of adenosine 111a (4 g, 15.0 mmol,     
1 eq.) in pyridine (32 mL). After 2 d stirring at room temperature, the reaction mixture was 
diluted with DCM (30 mL), washed with H2O (3 × 20 mL), dried over MgSO4, filtered and 
concentrated. The residue was purified by column chromatography (EtOAc/Et2O 1:2) to afford 
2’,5’-bis-O-(tert-butyldimethylsilyl)-β-D-adenosine 141 (2.5 g, 34%) as a white solid. 
Rf = 0.38 (EtOAc/Et2O 1:2); m.p. 175-178 °C (lit.,16 172-175 °C); 1H-NMR (CDCl3, 300 MHz) 
δH 8.37 (1H, s, H-8), 8.24 (1H, s, H-2), 6.13 (1H, d, J = 5.1 Hz, H-1’), 5.65 (2H, s, NH2), 4.67 
(1H, t, J = 5.0 Hz, H-2’), 4.31 (1H, t, J = 3.6 Hz, H-3’), 4.23 (1H, q, J = 2.7 Hz, H-4’), 4.04 (1H, 
dd, J = 11.5 Hz, 2.7 Hz, H-5’), 3.88 (1H, dd, J = 11.5 Hz, 2.5 Hz, H-5’), 2.77 (1H, d,                           
J = 4.2 Hz, OH-3’), 0.98 (9H, s, (CH3)3), 0.87 (9H, s, (CH3)3), 0.18 (3H, s, CH3), 0.16 (3H, s, 
CH3), -0.03 (3H, s, CH3), -0.09 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 155.5 (Ar-C), 
153.1 (Ar-CH, C-2), 150.0 (Ar-C), 138.9 (Ar-CH, C-8), 119.8 (Ar-C), 87.9 (CH, C-1’), 85.2 (CH, 
C-4’), 77.1 (CH, C-2’), 71.3 (CH, C-3’), 63.1 (CH2, C-5’), 26.0 (CH3, (CH3)3), 25.6 (CH3, (CH3)3), 
18.5 (SiC-(CH3)3), 18.0 (SiC-(CH3)3), -5.00 (CH3, Si-CH3), -5.2 (CH3, Si-CH3), -5.3 (CH3, Si-
CH3),  -5.5 (CH3, Si-CH3); IR Qmax (KBr): 3376, 3330, 3180, 2937, 2857, 1651, 1595, 1473, 
1329, 1255, 1140, 1105, 835, 781 cm-1; HRMS m/z (ES+) (calculated C22H42N5O4Si2+ = 
496.2770) found 496.2757 [M+H]+. Data are in agreement with literature.17  
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6.2.20. 9-[2’,5’-Bis-O-(tert-butyldimethylsilyl)-β-D-erythro-pentofuranos-3’-
ulosyl]adenine 140 
 
 
Pyridine (1.98 mL, 24.0 mmol, 4 eq.) and Ac2O (1.14 mL, 12.0 mmol, 2eq.) were sequentially 
added to an ice cold suspension of CrO3 (1.2 g, 12.0 mmol, 2 eq.) in DCM (90 mL), and stirring 
at room temperature under argon atmosphere was continued until a homogeneous solution 
was obtained. A solution of 2’,5’-bis-O-(tert-butyldimethylsilyl)-β-D-adenosine 141 (3 g,            
6.0 mmol, 1 eq.) in DCM (90 mL) was added dropwise and stirring was continued for 2 h. The 
reaction mixture was poured into cold EtOAc (150 mL) and the resulting precipitate was filtered 
(glass microfibre filter). The filtrate was concentrated and the residue was purified by column 
chromatography (EtOAc) to afford 9-[2’,5’-bis-O-(tert-butyldimethylsilyl)-β-D-erythro-
pentofuranos-3’-ulosyl]adenine 140 (1.48 g, 50%) as a white solid. 
Rf = 0.31 (EtOAc); m.p. 176-180 °C (lit.,16 177-178 °C); 1H-NMR (CDCl3, 300 MHz) δH 8.39 
(1H, s, H-8), 8.17 (1H, s, H-2), 6.16 (1H, d, J = 8.3 Hz, H-1’), 5.72 (2H, s, NH2), 4.96 (1H, d, J 
= 8.3 Hz, H-2’), 4.35-4.31 (1H, m, H-4’), 4.00 (2H, d, J = 2.3 Hz, H-5’), 0.95 (9H, s, (CH3)3), 
0.75 (9H, s, (CH3)3), 0.13 (3H, s, CH3), 0.10 (3H, s, CH3), -0.01 (3H, s, CH3), -0.18 (3H, s, 
CH3); 13C-NMR (CDCl3, 100 MHz) δC 208.6 (C=O, C-3’), 155.4 (Ar-C), 153.4 (Ar-CH, C-2), 
150.4 (Ar-C), 138.6 (Ar-CH, C-8), 119.8 (Ar-C), 85.0 (CH, C-1’), 82.4 (CH, C-4’), 77.9 (CH, C-
2’), 62.5 (CH2, C-5’), 25.9 (CH3, (CH3)3), 25.3 (CH3, (CH3)3), 18.3 (SiC-(CH3)3), 18.0 (SiC-
(CH3)3), -4.8 (CH3, Si-CH3), -5.4 (CH3, Si-CH3), -5.6 (CH3, Si-CH3), -5.7 (CH3, Si-CH3); IR Qmax 
(KBr): 3330, 3188, 2931, 2859, 1788, 1651, 1595, 1475, 1308, 1250, 1114, 1057, 970 cm-1; 
HRMS m/z (ES+) (calculated C22H40N5O4Si2+ = 494.2613) found 494.2602 [M+H]+. Data are in 
agreement with literature.18  
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6.2.21. 9-[2-O-(Tert-butyldimethylsilyl)-β-D-erythro-                                                                                                    
pentofuran-3-ulosyl]adenine 139 
 
 
9-[2’,5’-Bis-O-(tert-butyldimethylsilyl)-β-D-erythro-pentofuranos-3’-ulosyl]adenine 140 (1 g,    
2.0 mmol, 1 eq.) was dissolved in a mixture of TFA (24.3 mL) and H2O (2.7 mL). After 30 min 
stirring at 0 °C, the yellow solution was poured into a mixture of EtOAc (60 mL), cyclohexane 
(40 mL), and aqueous saturated bicarbonate solution (100 mL). The phases were separated 
and the aqueous phase was extracted with a mixture of EtOAc (60 mL) and cyclohexane        
(40 mL). The combined organic phases were washed with H2O (60 mL), dried over Na2SO4, 
filtered and concentrated to afford 9-[2-O-(tert-butyldimethylsilyl)-β-D-erythro-pentofuran-3-
ulosyl]adenine 139 as viscous yellow oil, which was used in the following reaction without 
further purification.  
1H-NMR (CDCl3, 300 MHz) δH 8.68 (1H, s, H-8), 8.65 (1H, s, H-2), 6.21 (1H, d, J = 7.8 Hz,  H-
1’), 4.88 (1H, d, J = 7.8 Hz, H-2’), 4.50 (1H, t, J = 1.8 Hz,  H-4’), 4.11 (2H, m, H-5’), 0.77 (9H, 
s, (CH3)3), 0.04 (3H, s, CH3), -0.17 (3H, s, CH3). Data are in agreement with literature.18  
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6.2.22. 2’-O-(Tert-butyldimethylsilyl)-[3’-2H]-adenosine 138 and 2’-O-(tert-
butyldimethylsilyl)-[3’-2H]-β-D-xylofurannosyl-9 adenine 144 
 
 
NaBD4 (268 mg, 6.4 mmol, 2 eq.) was added carefully to a solution of 9-[2-O-(tert-
butyldimethylsilyl)-β-D-erythro-pentofuran-3-ulosyl]adenine 139 (1.2 g, 3.2 mmol, 1 eq.) in 
AcOH (60 mL) cooled to 0 °C. The resulting solution was stirred overnight at room 
temperature. EtOAc (50 mL) was added to the reaction mixture and the phases were 
separated. The aqueous phase was extracted with EtOAc (3 × 50 mL), dried over MgSO4, 
filtered and concentrated to afford a mixture of 2’-O-(tert-butyldimethylsilyl)-[3’-2H]-adenosine 
138 and 2’-O-(tert-butyldimethylsilyl)-[3’-2H]-β-D-xylofurannosyl-9 adenine 144 in a ratio of 2:1, 
which was used in the following reaction without further purification.  
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6.2.23. 3’-Deuterioadenosine 111d 
 
 
TBAF 53 (1 M in dry THF, 4.8 mL, 4.8 mmol, 1.5 eq.) was added dropwise to a solution of 2’-
O-(tert-butyldimethylsilyl)-[3’-2H]-adenosine 138 and 2’-O-(tert-butyldimethylsilyl)-[3’-2H]-β-D-
xylofurannosyl-9 adenine 144  in dry THF (100 mL). The reaction mixture was stirred at room 
temperature for 2 h. The volatiles were removed in vacuo and the residue was purified by 
column chromatography (EtOAc/iPrOH/H2O 7:2:1) to afford 3’-deuterioadenosine 111d         
(177 mg, 33% over 3 steps) as a white powder.  
Rf = 0.28 (EtOAc/iPrOH/H2O 7:2:1); [α]20D : −59.9° (c 1.0, H2O); m.p. 233-237 °C; 1H-NMR 
(DMSO-d6, 300 MHz) δH 8.35 (1H, s, H-8), 8.14 (1H, s, H-2), 7.36 (2H, s, NH2), 5.88 (1H, d, J 
= 6.2 Hz, H-1’), 5.51 – 5.40 (2H, m, OH-2’ & OH-5’), 5.19 (1H, s, OH-3’), 4.60 (1H, t,                        
J = 5.5 Hz, H-2’), 3.96 (1H, t, J = 3.6 Hz, H-4’), 3.67 (1H, dt, J = 12.2 Hz, 4.0 Hz, H-5’), 3.55 
(1H, ddd, J = 12.2 Hz, 7.2 Hz, 3.6 Hz, H-5’); 13C-NMR (DMSO-d6, 100 MHz) δC 156.6 (Ar-C), 
152.8 (Ar-CH, C-2), 149.6 (Ar-C), 140.4 (Ar-CH, C-8), 119.8 (Ar-C), 88.4 (CH, C-1’), 86.3 (CH, 
C-4’), 73.9 (CH, C-2’), 70.9 (CD, t, J = 21.3 Hz, C-3’), 62.1 (CH2, C-5’); IR Qmax (KBr): 3430, 
2920, 1666, 1605, 1580, 1486, 1330, 1300, 1200, 1100, 1069, 901, 660; HRMS m/z (ES+) 
(calculated C10H13DN5O4+ = 269.1103) found 268.0877 [4%] and 269.1097 [M+H]+. Data are 
in agreement with literature.18  
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6.2.24. Adenosine sulfate 160 
 
 
A solution of chlorosulfonic acid 150 (30 µL, 0.45 mmol, 1.2 eq.) in CHCl3 (0.2 mL) was slowly 
added to a solution of adenosine 111a (100 mg, 0.37 mmol, 1 eq.) in dry pyridine (5 mL) at     
0 °C. The reaction was stirred at room temperature overnight. The reaction mixture was 
concentrated under reduced pressure, and the residue was passed through a short Discovery® 
DSC-NH2 SPE ion exchange column. The white solid was purified by semi-preparative HPLC 
(Phenomenex Kingsorb C18 (250 × 21.20 mm, 5µ)), using the HPLC conditions: Mobile phase 
A: 0.05% TFA/H2O, B: 0.05% TFA/ACN; an isocratic mobile phase of: 95% A and 5% B for 30 
min. Under these conditions, the product eluted between 6.9 to 7.9 min. Evaporation of the 
solvents from this fraction, followed by freeze-drying afforded adenosine sulfate 160 (10 mg, 
6%) as a white solid.  
[α]20D : -11.6° (c 0.5, H2O); m.p. 98-101 °C; 1H-NMR (D2O, 300 MHz) δH 8.34 (1H, s, H-8), 
8.18 (1H, s, H-2), 6.26 (1H, d, J = 6.6 Hz, H-1’), 5.38 (1H, t, J = 6.2 Hz, H-2’), 5.16 (1H, dd,  J 
= 5.6 Hz, J = 2.9 Hz, H-3’), 4.59-4.51 (1H, m, H-4’), 4.27 (2H, m, H-5’); 13C-NMR (D2O,  100 
MHz) δC 154.7 (Ar-C), 151.6 (Ar-CH, C-8), 149.2 (Ar-C), 140.4 (Ar-CH, C-2), 118.6 (Ar-C), 
85.0 (CH, C-1’), 81.5 (CH, C-4’), 76.6 (CH, C-2’), 75.3 (CH, C-3’), 67.2 (CH2, C-5’); IR Qmax 
(neat): 3400, 2955, 1686, 1601, 1568, 1499, 1349, 1318, 1288, 1199, 1142, 1101, 901, 660 
cm-1; HRMS m/z (ES-) (calculated C10H12N5O7S- = 346.0463) found 346.0463 [M-H]-. Data are 
in agreement with literature.19  
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6.2.25. 2’,3’-O-Bis(tert-butyldimethylsilyl)-adenosine 165 
 
 
To a solution of adenosine 111a (5.0 g, 18.7 mmol, 1.0 eq.) and imidazole (11.5 g,                 
168.3 mmol, 9.0 eq.) in DMF (25 mL) was added TBSCl (9.9 g, 65.5 mmol, 3.5 eq.) in DMF 
(25 mL). The resulting solution was stirred at room temperature overnight, then diluted with 
DCM (150 mL) and washed with saturated bicarbonate solution (3 × 80 mL). The combined 
organic layers were washed with brine (3 × 80 mL), dried over MgSO4, filtered and 
concentrated. The resulting liquid was dissolved into 80% AcOH (25 mL) and stirred at           
100 °C for 4 h. The reaction mixture was concentrated and the residue was co-evaporated 
with toluene (3 × 40 mL). The residue was purified by silica gel column chromatography 
(EtOAc) to afford 2’,3’-O-bis(tert-butyldimethylsilyl)-adenosine 165 (3.7 g, 40%) as a white 
solid. 
Rf = 0.48 (EtOAc); [α]20D : -113.8° (c 1.0, CHCl3); m.p. 242-247 °C (lit.,20 180 °C from EtOH); 
1H-NMR (CDCl3, 300 MHz) δH 8.31 (1H, s, H-8), 7.80 (1H, s, H-2), 6.69 (1H, dd, J = 12.4 Hz, 
J = 1.6 Hz, H-4’), 5.75 (1H, d, J = 7.9 Hz, H-1’), 5.71 (2H, br s, NH2), 5.01 (1H, dd, J = 8.0 Hz, 
J = 4.6 Hz, H-2’), 4.30 (1H, d, J = 4.6 Hz, H-3’), 4.13 (1H, s, OH), 3.91 (1H, d, J = 13.0 Hz,     
H-5’), 3.67 (1H, t, J = 12.6 Hz,  H-5’), 0.92 (9H, s, (CH3)3), 0.71 (9H, s, (CH3)3), 0.10 (3H, s, 
CH3), 0.08 (3H, s, CH3), -0.17 (3H, s, CH3), -0.65 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 
153.0 (Ar-C), 148.9 (Ar-CH, C-8), 148.7 (Ar-C), 141.3 (Ar- CH, C-2), 119.2   (Ar-C), 91.2 (CH, 
C-1’), 89.8 (CH, C-4’), 74.2 (CH, C-3’), 74.0 (CH, C-2’), 63.2 (CH2, C-5’), 26.0 ((CH3)3), 25.8 
((CH3)3), 18.8 (C(CH3)3), 18.2 (C(CH3)3), -4.4 (CH3), -4.4 (CH3), -4.5 (CH3), -5.9 (CH3); IR Qmax 
(neat): 3421, 3331, 3156, 2948, 2910, 1650, 1634, 1470, 1330, 1274, 1138, 1111, 821, 778 
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cm-1; HRMS m/z (ES+) (calculated C22H42N5O4Si2+ = 496.2770) found 496.2770 [M+H]+. Data 
are in agreement with literature.21 
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6.2.26. Amidosulfonyl chloride 162 
 
 
Formic acid 166 (0.75 mL, 20 mmol, 1 eq.) was added dropwise to a solution of chlorosulfonyl 
isocyanate 167 (1.74 mL, 20 mmol, 1 eq.) in dry ACN (10 mL) at 0 °C. The reaction mixture 
was stirred at room temperature overnight. The resulting solution of amidosulfonyl chloride 
162 was used in the following reaction without any further purification.  
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6.2.27. 2’,3’-O-Bis(tert-butyldimethylsilyl)-5’-O-(sulfamoyl)adenosine 164 
 
 
A chilled solution of amidosulfonyl chloride 162 (2 M in dry ACN, 0.12 mL, 0.23 mmol, 2.3 eq.) 
was added to an ice cold solution of 2’,3’-O-bis(tert-butyldimethylsilyl)-adenosine 165 (50 mg, 
0.1 mmol,  1 eq.). After stirring at room temperature for 1 h, the reaction mixture was cooled 
to 0 °C and quenched by subsequent additions of Et3N (1 mL) and MeOH (4 mL). The volatiles 
were removed in vacuo and the residue was taken up into EtOAc (10 mL), extracted with 
aqueous saturated bicarbonate solution (2 × 10 mL), and brine (2 × 10 mL). The organic layer 
was dried over Na2SO4, filtered and evaporated. The residue was purified by silica gel column 
chromatography (EtOAc) to afford 2’,3’-O-bis(tert-butyldimethylsilyl)-5’-O-
(sulfamoyl)adenosine 164 (57 mg, quantitative) as a white solid. 
Rf = 0.55 (EtOAc); [α]20D : -149.6° (c 1.0, CHCl3); m.p. 118-130 °C; 1H-NMR (CDCl3, 300 MHz) 
δH 8.36 (1H, s,   H-8), 8.15 (1H, s, H-2), 7.65 (2H, br s, NH2), 7.32 (2H, br s, NH2), 5.95 (1H, 
d, J = 6.8 Hz, H-1’), 4.96 (1H, dd, J = 6.7 Hz, J = 4.5 Hz, H-2’), 4.42-4.36 (2H, m, H-3’ & H-5’), 
4.31 (1H, dd, J = 11.0 Hz, J = 5.8 Hz, H-5’), 4.17 (1H, td, J = 5.5 Hz, J = 1.9 Hz, H-4’), 0.92 
(9H, s, (CH3)3), 0.70 (9H, s, (CH3)3), 0.14 (3H, s, CH3), 0.12 (3H, s, CH3), -0.09 (3H, s, CH3),  
-0.38 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 156.1 (Ar-C), 152.7 (Ar-CH, C-2), 149.5 
(Ar-C), 139.8 (Ar-CH, C-8), 119.3 (Ar-C), 87.0 (CH, C-1’), 82.8 (CH, C-4’), 73.7 (CH, C-2’), 
72.5 (CH, C-3’), 68.0 (CH2, C-5’), 25.7 ((CH3)3), 25.5 ((CH3)3), 17.8 (C(CH3)3), 17.5 (C(CH3)3), 
-4.7 (CH3), -4.78 (CH3), -4.84 (CH3), -5.6 (CH3); IR Qmax (neat): 2930, 2857, 1645, 1601, 1472, 
1362, 1252, 1163, 995, 939, 835, 775 cm-1; HRMS m/z (ES-) (calculated C22H41N6O6SSi2- = 
573.2352) found 573.2351 [M-H]-. Data are in agreement with literature.22 
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6.2.28. 5’-Sulfamoyladenosine 161 
 
 
TBAF 53 (1 M in THF, 0.87 mL, 0.87 mmol, 2.5 eq.) was added dropwise to a solution of 2’,3’-
O-bis(tert-butyldimethylsilyl)-5’-O-(sulfamoyl)adenosine 164 (201 mg, 0.35 mmol, 1 eq.) in dry 
THF (10 mL). The reaction mixture was stirred at room temperature for 1 h, and the solvent 
was then evaporated. The residue was purified by semi-preparative HPLC, using this HPLC 
condition: Mobile phase A: 0.05% TFA/H2O, B: 0.05% TFA/ACN; Gradient: 95% A and 5% B. 
Under these conditions, the product eluted between 5.2 to 6.0 min. Evaporation of the solvents 
from this fraction, followed by freeze-drying afforded 5’-sulfamoyladenosine 161 (100 mg, 
83%) as a white solid.  
[α]20D : -31.9° (c 1.0, H2O) (lit.,23 -33.6° c 1.0, DMF); m.p. 109-120 °C (lit.,24 98-112 °C);            
1H-NMR (CDCl3, 300 MHz) δH 8.30 (1H, s, H-8), 8.21 (1H, s, H-2), 6.07 (1H, d, J = 5.1 Hz,       
H-1’), 4.66 (1H, t, J = 5.1 Hz, H-2’), 4.46-4.28 (4H, m, H-3’ & H-4’ & H-5’); 13C-NMR (CDCl3, 
100 MHz) δC 157.4 (Ar-C), 154.0 (Ar-CH, C-8), 150.7 (Ar-C), 140.8 (Ar-CH, C-2), 120.4          
(Ar-C), 89.9 (CH, C-1’), 83.7 (CH, C-4’), 75.6 (CH, C-2’), 71.9 (CH, C-3’), 70.0 (CH2, C-5’); IR 
Qmax (neat): 3251, 1682, 1630, 1447, 1375, 1211, 1192, 1069, 853, 635 cm-1; HRMS m/z (ES+) 
(calculated C10H14N6O6S+ = 347.0768) found 347.0761 [M+H]+. Data are in agreement with 
literature.24  
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6.2.29. N6-Monobenzyl-2’,3’-O-isopropylidene-adenosine 175 
 
 
2’,3’-O-Isopropylidene-adenosine (200 mg, 0.65 mmol, 1 eq.) 137 was co-evaporated twice 
with anhydrous pyridine and dissolved in pyridine (4 mL) followed by addition of trimethylsilyl 
chloride (0.44 mL, 3.46 mmol, 5.3 eq.) at 0 °C. After 30 min stirring at room temperature, 
benzoyl chloride (0.10 mL, 0.86 mmol, 1.3 eq.) was added and stirring was continued for 3 h 
at room temperature. The reaction mixture was cooled down to 0 °C and diluted with H2O        
(1.5 mL). The reaction mixture was treated with a concentrated aqueous ammonia solution    
(2 mL) and stirred for 30 min at room temperature. The mixture was concentrated and the 
residue was purified by column chromatography (EtOAc) to afford N6-monobenzyl-2’,3’-O-
isopropylidene-adenosine 175 (88.8 mg, 33%) as a white powder. 
Rf = 0.33 (DCM/MeOH 9:1); [α]20D : -92.8° (c 1.0, CHCl3) (lit.,25 -83.0° c 2.4, DCM); m.p.        
136-138 °C (lit.,25 146-148 °C); 1H-NMR (CDCl3, 300 MHz) δH 9.30 (1H, br s, NH), 8.74 (1H, 
s, H-8), 8.09 (s, 1H, H-2), 8.06-7.44 (5H, m, ArH), 5.95 (1H, d, J = 4.5 Hz,   H-1’), 5.26-5.16 
(1H, m, H-2’), 5.14-5.03 (1H, m, H-3’), 4.55-4.49 (1H, m, H-4’), 4.03-3.90 (1H, m, H-5’), 3.86-
3.72 (1H, m, H-5’), 1.63 (3H, s, CH3), 1.37 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 164.8 
(C, C=O), 152.4 (CH, C-8), 150.6 (C, Ar), 150.4 (C, Ar), 142.7 (CH, C-2), 133.5 (C, Ar), 133.0 
(C, ArH), 129.0 (C, ArH), 128.0 (C, ArH), 124.4 (C, Ar), 114.4 (C, C(CH3)2), 94.1 (CH, C-1’), 
86.4 (CH, C-4’), 83.3 (CH, C-2’), 81.7 (CH, C-3’), 63.3 (CH2, C-5’), 27.7 (CH3), 25.3 (CH3); IR 
Qmax (neat): 3350, 1709, 1605, 1590, 1465, 1329, 1255, 1210, 1057, 701 cm-1; HRMS m/z 
(ES+) (calculated C20H21N5NaO5+ = 434.1435) found 434.1425 [M+Na]+. Data are in agreement 
with literature.26 
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6.2.30. N6,N6-Dibenzoyl-2’,3’-O-isopropylidene-adenosine 173 
 
 
2’,3’-O-Isopropylidene-adenosine 137 (2.0 g, 6.52 mmol, 1eq.) was co-evaporated twice with 
anhydrous pyridine and dissolved in pyridine (24 mL) followed by the addition of trimethylsilyl 
chloride (2.48 mL, 19.56 mmol, 3 eq.) at 0 °C. The reaction mixture was stirred for 2 h at room 
temperature. The mixture was cooled to 0 °C and benzoyl chloride (1.67 mL, 14.36 mmol,     
2.2 eq.) was slowly added. The reaction mixture was stirred for 2 h at room temperature before 
being quenched with H2O (8 mL) and concentrated. The mixture was reconstituted with CHCl3 
(60 mL) and washed with diluted H2SO4 149 solution (2 × 40 mL), saturated aqueous sodium 
bicarbonate solution (40 mL), and H2O (40 mL). The organic layer was dried over MgSO4 and 
concentrated. The mixture was purified by column chromatography (EtOAc) to afford N6,N6-
dibenzoyl-2’,3’-O-isopropylidene-adenosine 173 (2.35 g, 70%) as a white foam. 
Rf = 0.59 (EtOAc); [α]20D : -68.3˚ (c 0.60, CHCl3); m.p. 124-125 °C (lit.,11 129-133 °C); 1H-NMR 
(CDCl3, 300 MHz) δH 8.62 (1H, s, H-8), 8.19 (1H, s, H-2), 7.90-7.31 (10H, m, Ar-CH), 5.97 
(1H, d, J = 4.6 Hz, H-1’), 5.26-5.14 (1H, m, H-2’), 5.07-4.99 (1H, m, H-3’), 4.52-4.48 (1H, m, 
H-4’), 3.98-3.85 (1H, m, H-5’), 3.81-3.67 (1H, m, H-5’), 1.63 (3H, s, CH3), 1.36 (3H, s, CH3); 
13C-NMR (CDCl3, 100 MHz) δC 172.2 (C=O), 152.6 (Ar-C), 151.9 (Ar-C), 151.8 (Ar-CH, C-8), 
144.5 (Ar-CH, C-2), 133.9 (Ar-C), 133.2 (Ar-CH), 129.6 (Ar-CH), 128.9 (Ar-CH), 128.6 (Ar-C), 
114.4 (C(CH3)2), 93.9 (CH, C-1’), 86.3 (CH, C-4’), 83.3 (CH, C-2’), 81.6 (CH, C-3’), 63.2 (CH2, 
C-5’), 27.6 (CH3), 25.3 (CH3); IR Qmax (neat): 2989, 1700, 1600, 1576, 1238, 1077, 830, 694, 
641 cm-1; HRMS m/z (ES+) (calculated C27H25N5NaO6+ = 538.1697) found 538.1692 [M+Na]+. 
Data are in agreement with literature.11 
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6.2.31. N6,N6-Dibenzoyl-5’-deoxy-2’,3’-O-isopropylidene-5’,5’-(N,N’-
diphenylethylenediamino)adenosine 172 
 
 
Dichloroacetic acid (96 µL, 1.17 mmol, 0.5 eq.) was added dropwise to a solution of N6,N6-
dibenzoyl-2’,3’-O-isopropylidene-adenosine 173 (1.2 g, 2.33 mmol, 1 eq.) and DCC 153       
(1.44 g, 6.99 mmol, 3 eq.) in anhydrous DMSO (15 mL) at 0 °C. The mixture was allowed to 
warm to room temperature and was stirred overnight. A solution of oxalic acid (587 mg,         
4.66 mmol, 2 eq.) in methanol (2.5 mL) was slowly added. After 30 min stirring at room 
temperature, the mixture was filtered and the residue was washed with cold methanol. N,N’-
diphenylethylenediamine (569 mg, 2.68 mmol, 1.2 eq.) was added to the combined filtrate and 
washings and the resulting solution was gently stirred at room temperature for additional 3 h. 
H2O (5 mL) was added and after storage at 0 °C crystals were obtained. The mother liquor 
was partitioned between H2O (40 mL) and CHCl3 (40 mL) and the organic phase was washed 
with H2O (2 × 40 mL), dried over MgSO4 and concentrated. The crude mixture was purified by 
column chromatography (EtOAc/PE 1:1) to afford N6,N6-dibenzoyl-5’-deoxy-2’,3’-O-
isopropylidene-5’,5’-(N,N’-diphenylethylenediamino)adenosine 172 (708 mg, 43%) as a white 
solid. 
Rf = 0.41 (EtOAc/PE 1:1); [α]20D : +45.4° (c 1.10, CHCl3); m.p. 139-141 °C (lit.,27 135-138 °C); 
1H-NMR (CDCl3, 300 MHz) δH 8.47 (1H, s, H-8), 7.96 (1H, s, H-2), 7.90-7.85 (4H, m, ArH), 
7.54-7.47 (2H, m, ArH), 7.41-7.33 (4H, m, ArH), 7.24-7.12 (4H, m, ArH), 6.83-6.70 (4H, m, 
ArH), 6.64 (2H, d, J = 8.1 Hz, ArH), 6.13 (1H, d, J = 2.0 Hz, H-1’), 5.73 (1H, d,  J = 2.5 Hz,     
N-CH-N), 5.19-5.12 (2H, m, H-2’, H-3’), 4.63-4.59 (1H, m, H-4’), 3.74-3.45 (4H, m, N-CH2-
CH2-N), 1.51 (3H, s, CH3), 1.32 (3H, s, CH3); 13C-NMR (CDCl3, 100 MHz) δC 172.4 (C=O), 
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152.5 (Ar-CH, C-8), 146.4 (Ar-C), 143.8 (Ar-CH, C-2), 134.2 (Ar-C), 133.2 (Ar-CH), 129.6      
(Ar-CH), 129.5 (Ar-CH), 129.4 (Ar-CH), 128.9 (Ar-C), 118.6 (Ar-C), 118.5 (Ar-C), 115.3 
(C(CH3)2), 113.8 (Ar-CH), 113.6 (Ar-CH), 88.7 (CH, C-1’), 87.1 (CH, C-4’), 83.8 (CH, C-2’), 
80.2 (CH, C-3’), 73.4 (N-CH-N), 47.6 (CH2), 47.2 (CH2), 27.5 (CH3), 25.8 (CH3); IR Qmax (neat): 
1710, 1602, 1501, 1238, 1077, 750, 511 cm-1; HRMS m/z (ES+) (calculated C41H37N7NaO5+ = 
730.2748) found 730.2756 [M+Na]+. Data are in agreement with literature.27 
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6.2.32. 5’-Deoxy-2’,3’-O-isopropylidene-5’,5’-(N,N’-
diphenylethylenediamino)adenosine 177 
 
 
A solution of N6,N6-dibenzoyl-5’-deoxy-2’,3’-O-isopropylidene-5’,5’-(N,N’-
diphenylethylenediamino) adenosine 172 (540 mg, 0.76 mmol, 1 eq.) in anhydrous methanol  
(5 mL) was transferred into a heavy-walled tube. Ammonia was bubbled through the solution 
for 2 h at 0 °C. The tube was sealed and the mixture stirred at 60 °C for 18 h. The mixture was 
cooled to room temperature and carefully opened, followed by degassing with argon for 2 h 
before being concentrated. The product was purified by column chromatography (EtOAc) to 
afford 5’-deoxy-2’,3’-O-isopropylidene-5’,5’-(N,N’-diphenylethylenediamino)adenosine 177 
(316 mg, 83%) as a white powder.  
Rf = 0.18 (EtOAc); [α]20D : +51.1° (c 1.10, CHCl3); m.p. 249-250 °C (lit.,27 255-258 °C);              
1H-NMR (CDCl3, 300 MHz) δH 8.31 (1H, s, H-8), 7.60 (1H, s, H-2), 7.25-7.14 (4H, m, ArH), 
6.88-6.73 (4H, m, ArH), 6.69-6.63 (2H, m, ArH), 6.11 (1H, d, J = 2.3 Hz, H-1’), 5.96 (2H, br s, 
NH2), 5.78 (1H, d, J = 3.3 Hz, N-CH-N), 5.20-5.11 (2H, m, H-2’, H-3’), 4.62-4.57 (1H, m, H-4’), 
3.79-3.55 (4H, m, N-CH2-CH2-N), 1.50 (3H, s, CH3), 1.32 (3H, s, CH3); 13C-NMR (CDCl3,        
100 MHz) δC 155.7 (Ar-C), 153.4 (Ar-CH, C-8), 146.8 (Ar-C), 139.5 (Ar-CH, C-2), 129.4          
(Ar-C), 119.9 (Ar-C), 118.4 (Ar-CH), 114.9 (C(CH3)2), 113.8 (Ar-CH), 113.6 (Ar-CH), 88.7 (CH, 
C-1’), 87.2 (CH,  C-4’), 84.0 (CH, C-2’), 80.4 (CH, C-3’), 73.7 (N-CH-N), 47.9 (CH2), 46.8 (CH2), 
27.5 (CH3), 25.8 (CH3); IR Qmax (neat): 3351, 1600, 1528, 1238, 1077, 741, 519 cm-1; HRMS 
m/z (ES+) (calculated C27H30N7O3+ = 500.2405) found 500.2397 [M+H]+. Data are in agreement 
with literature.28 
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6.2.33. 1-O-Acetyl-2,3,5-tri-O-benzoyl-4-fluoro-β-D-ribofuranose 180 and 1-O-
acetyl-2,3,5-tri-O-benzoyl-4-fluoro-α-L-lyxofuranose 184  
 
 
N-bromosuccinimide (534 mg, 3 mmol, 3 eq.) was added to a solution of 1-O-acetyl-2,3,5-tri-
benzoyl-β-D-ribofuranose 179 (504 mg, 1 mmol, 1 eq.) in carbon tetrachloride (6 mL) and the 
mixture was stirred under irradiation with a sun lamp (275 W) at 90 °C for 5 h. The reaction 
mixture was diluted with DCM (10 mL) and washed with aqueous sodium thiosulfate (10 mL), 
aqueous sodium bicarbonate (10 mL) and H2O (10 mL), and dried over anhydrous sodium 
sulfate. Concentration of the solvent gave a crude product mixture of the 4-bromo-β-D-
ribofuranose 182 and 4-bromo-α-L-lyxofuranose 183. In a round bottom flask silver 
tetrafluoroborate was prepared from the reaction of silver fluoride (189 mg, 1.5 mmol, 1.5 eq.) 
with borontrifluoride-diethyl ether (377 μL, 3.0 mmol, 3 eq.) in anhydrous diethyl ether (10 mL) 
for 1 h at room temperature. An ethyl acetate (5 mL) solution of the bromide mixture was 
added to the suspension of AgBF4 and the mixture was stirred for 1 h at 0 °C. The reaction 
mixture was diluted with diethyl ether (20 mL), washed with aqueous saturated sodium 
bicarbonate (15 mL), H2O (15 mL) and brine (15 mL), and dried over anhydrous sodium 
sulfate. The solvents were removed under reduced pressure and the residue was subjected 
to silica gel column chromatography (PE/EtOAc 2:1) to give an inseparable mixture of 1-O-
acetyl-2,3,5-tri-O-benzoyl-4-fluoro-α-L-lyxofuranose 184 and 1-O-acetyl-2,3,5-tri-O-benzoyl-
4-fluoro-β-D-ribofuranose 180 (199 mg, 38%) in a ratio of 1:1 as a colourless gum.   
1-O-Acetyl-2,3,5-tri-O-benzoyl-4-fluoro-β-D-ribofuranose 180; Rf = 0.34 (EtOAc/PE 2:1);   
1H-NMR (CDCl3, 300 MHz) δH signals were not interpreted due to overlapping; 13C-NMR 
(CDCl3, 100 MHz) δC signals were not interpreted due to overlapping; 19F-NMR (CDCl3,          
376 MHz) δF  -114.89 (1F, ddd, J = 17.9 Hz, 10.5 Hz, 4.5 Hz); HRMS m/z (ES+) (calculated 
C28H23FNaO9+ = 545.1218) found 545.1230 [M+Na]+. 
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1-O-Acetyl-2,3,5-tri-O-benzoyl-4-fluoro-α-L-lyxofuranose 184; Rf = 0.34 (EtOAc/PE 2:1);   
1H-NMR (CDCl3, 300 MHz) δH signals were not interpreted due to the overlap; 13C-NMR 
(CDCl3, 100 MHz) δC signals were not interpreted due to the overlap; 19F-NMR (CDCl3,            
376 MHz) δF  -104.30 - -104.49 (1F, m); HRMS m/z (ES+) (calculated C28H23FNaO9+ = 
545.1218) found 545.1230 [M+Na]+. 
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6.2.34. 9-(2’,3’,5’-Tri-O-benzoyl-4’-fluoro-β-D-ribofuranosyl)adenine 181 and 9-
(2’,3’,5’-tri-O-benzoyl-4’-fluoro-α-L-lyxofuranosyl)adenine 185 
 
 
To a suspension of adenine 82 (58 mg, 0.43 mmol, 5 eq.) in ACN (4 mL) was added N,O-
bis(trimethylsilyl)trifluoro acetamide (228 μL, 0.86 mmol, 10 eq.) and the mixture was stirred 
for 2 h at 50 °C to give silylated adenine. The 1-O-acetyl-2,3,5-tri-O-benzoyl-4-fluoro-β-D-
ribofuranose 180/1-O-acetyl-2,3,5-tri-O-benzoyl-4-fluoro-α-L-lyxofuranose 184 (45 mg,      
0.086 mmol, 1 eq.) mixture and TMSOTf (72 μL, 0.43 mmol, 5 eq.) were then added to the 
silylated adenine solution and the resulting mixture was stirred overnight at 90 °C. The reaction 
was quenched by adding saturated aqueous sodium bicarbonate (8 mL). The aqueous phase 
was extracted with ethyl acetate (10 mL) and the combined organic layers were washed with 
brine (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to afford a 
mixture of 9-(2’,3’,5’-tri-O-benzoyl-4’-fluoro-β-D-ribofuranosyl)adenine 181 and 9-(2’,3’,5’-tri-
O-benzoyl-4’-fluoro-α-L-lyxofuranosyl)adenine 185, which was used in the following reaction 
without further purification.  
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6.2.35. 4’-Fluoro adenosine 171 and 1-O-acetyl-2,3,5-tri-O-benzoyl-4-fluoro-β-D-
ribofuranose 186 
 
 
To a MeOH (5 mL) solution of 9-(2’,3’,5’-tri-O-benzoyl-4’-fluoro-β-D-ribofuranosyl)adenine 181 
and 9-(2’,3’,5’-tri-O-benzoyl-4’-fluoro-α-L-lyxofuranosyl)adenine 185 (51 mg, 0.086 mmol,         
1 eq.) was added sodium carbonate (91 mg, 0.86 mmol, 10 eq.) and the reaction mixture was 
stirred for 1 h at room temperature. The reaction mixture was filtered through sintered glass 
and concentrated. The mixture was passed through a short C-18 RP silica gel column 
(H2O:ACN (9:1)). Fractions containing 171 and 186 were combined and concentrated in 
vacuo. The residues were purified by semi-preparative HPLC (Phenomenex Kingsorb C18 
(250 × 21.20 mm, 5µ)), using the HPLC conditions: Mobile phase A: 0.05% TFA/ H2O; B: 
0.05% TFA/ACN; an isocratic mobile phase of: 95% A and 5% B for 25 min. Under these 
conditions, the product eluted between 8.1 to 8.7 min. Evaporation of the solvents from this 
fraction, followed by freeze-drying afforded a mixture of 4’-fluoro adenosine 171 and 1-O-
acetyl-2,3,5-tri-O-benzoyl-4-fluoro-β-D-ribofuranose 186 (2.5 mg, 10%) in a ratio of 1:1 as a 
white solid.  
4’-Fluoro adenosine 171; 1H-NMR (DMSO-d6, 300 MHz) δH 8.55 (1H, s, H-8), 8.26 (1H, s,    
H-2), 6.14 (1H, d, J = 4.5 Hz, H-1’), 4.40 (1H, dd, J = 14.9 Hz, J = 7.2 Hz, H-3’), 4.33 (1H, m, 
H-2’), 3.78 (2H, m, H-5’); 19F-NMR (CDCl3, 376 MHz) δF -127.5 (1F, dt, J = 17.1 Hz, 6.6 Hz); 
HRMS m/z (ES+) (calculated C10H13FN5O4+ = 286.0946) found 286.0947 [M+H]+. Data are in 
agreement with literature.29  
1-O-Acetyl-2,3,5-tri-O-benzoyl-4-fluoro-β-D-ribofuranose 186; 1H-NMR (DMSO-d6,          
300 MHz) δH 8.44 (1H, s, H-8), 8.22 (1H, s, H-2), 6.56 (1H, d, J = 4.8 Hz, H-1’), 5.67 (1H, t,     
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J = 6.4 Hz, H-2’), 5.42 (1H, dd, J = 5.5 Hz, J = 3.0 Hz, H-3’), 4.51 (2H, m, H-5’); 19F-NMR 
(CDCl3, 376 MHz) δF -111.8 - -112.2 (1F, m); HRMS m/z (ES+) (calculated C10H13FN5O4+ = 
286.0946) found 286.0947 [M+H]+.  
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6.2.36. 2’,3’,5’-Tri-O-benzoyladenosine 187 
 
 
Benzoic anhydride (2.26 g, 10.0 mmol, 5 eq.) and 4-(N,N-dimethylamino)pyridine (61 mg,    
0.05 mmol, 0.025 eq.) were added to a suspension of adenosine 111a (535 mg,   2.0 mmol,   
1 eq.) in dry pyridine (20 mL). After 2 h stirring at room temperature, the mixture was 
concentrated to half-volume, diluted with CHCl3 (30 mL) and washed three times with 5% 
NaHCO3 (3 × 20 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to 
dryness under reduced pressure. The residue was purified by silica gel column 
chromatography (EtOAc) to afford 2’,3’,5’-tri-O-benzoyladenosine 187 (345 mg, 30%) as a 
white solid.    
Rf = 0.42 (EtOAc); [α]20D : -72.4° (c 1.0, CHCl3) (lit.,30 -73.7° c 1.0, CHCl3); m.p. 97-99 °C (lit.,30 
90-94 °C from H2O); 1H-NMR (CHCl3, 300 MHz) δH 8.29 (1H, s, H-8), 8.13-7.92 (7H, m, ArH), 
7.63-7.34 (9H, m, ArH), 6.42 (H, d, J = 5.1 Hz, H-1’), 6.38 (1H, t, J = 5.3 Hz, H-2’), 6.25 (1H, 
t, J = 5.3 Hz, H-3’), 5.61 (2H, br s, NH2), 4.90 (1H, dd, J = 12.1 Hz, J = 3.3 Hz, H-5’), 4.85-4.80 
(1H, m, H-4’), 4.71 (1H, dd, J = 12.1 Hz, J = 4.3 Hz, H-5’); 13C-NMR (CHCl3, 100 MHz) δC 
166.6 (C=O), 165.7 (C=O), 165.5 (C=O), 156.0 (Ar-CH, C-2), 154.2 (Ar-C), 153.9 (Ar-CH,        
C-8), 150.0 (Ar-C), 139.6 (Ar-CH), 139.4 (Ar-CH), 134.3 (Ar-CH), 133.6 (Ar-CH), 133.3           
(Ar-CH), 130.6 (Ar-CH), 130.1 (Ar-CH), 130.1 (Ar-CH), 129.8 (Ar-CH), 129.3 (Ar-C), 128.9    
(Ar-C), 128.5 (Ar-C), 119.3 (Ar-C), 87.1 (CH,   C-1’), 80.8 (CH, C-2’), 75.1 (CH, C-4’), 71.5 
(CH, C-3’), 63.9 (CH2, C-5’); IR Qmax (KBr): 3200, 2920, 1729, 1640, 1595, 1328, 1231, 1047, 
899, 658 cm-1; HRMS m/z (ES+) (calculated C31H26N5O7+ = 580.1827) found 580.1828 [M+H]+. 
Data are in agreement with literature.31  
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6.2.37. 6-N,N-2’,3’,5’-Tri-O-pentabenzoyladenosine 190 
 
 
Adenosine 111a (2.0 g, 7.5 mmol, 1 eq.) was suspended in dry pyridine (20 mL). To the 
suspension was added benzoyl chloride (6.1 mL, 52.3 mmol, 7 eq.), and the mixture was 
stirred at 65 °C for 4 h. Ethanol (20 mL) was added to the reaction mixture and the solvents 
were removed in vacuo. Residue was diluted with DCM (300 mL), washed H2O (3 × 200 mL) 
and brine (200 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to 
dryness under reduced pressure. The residue was purified by silica gel column 
chromatography (EtOAc/PE 1:1) to afford 6-N,N-2’,3’,5’-tri-O-pentabenzoyladenosine 190   
(1.2 g, 20%) as a colorless foam.    
Rf = 0.39 (EtOAc/PE 1:1); [α]20D : -79.7° (c 1.0, CHCl3); m.p. 182-185 °C (lit.,32 185-187 °C); 
1H-NMR (CHCl3, 300 MHz) δH 8.51 (1H, s, H-8), 8.22 (1H, s, H-2), 8.11-8.07 (2H, m, ArH), 
8.02-7.97 (2H, m, ArH), 7.96-7.91 (2H, m, ArH), 7.87-7.82 (4H, m, ArH), 7.61-7.32 (15H, m, 
ArH), 6.47 (H, d, J = 5.2 Hz, H-1’), 6.39 (1H, t, J = 5.5 Hz, H-2’), 6.26 (1H, t, J = 5.3 Hz, H-3’), 
4.90 (1H, dd, J = 12.1 Hz, J = 3.2 Hz, H-5’), 4.86-4-82 (1H, m, H-4’), 4.71 (1H, dd,                             
J = 12.1 Hz, J = 4.3 Hz, H-5’); 13C-NMR (CHCl3, 100 MHz) δC 171.4 (C=O), 167.7 (C=O), 166.6 
(C=O), 165.7 (C=O), 165.5 (C=O), 155.1  (Ar-CH, C-2), 154.0 (Ar-C), 153.6 (Ar-CH, C-8), 
150.2 (Ar-C), 139.6 (Ar-CH), 139.4 (Ar-CH), 134.3 (Ar-CH), 134.1 (Ar-CH), 134.0 (Ar-CH), 
133.6 (Ar-CH), 133.3 (Ar-CH), 132.6 (Ar-CH), 131.9 (Ar-CH), 131.1 (Ar-CH), 130-128 signals 
were not interpreted due to the overlap, 127.5 (Ar-C), 119.6 (Ar-C), 86.9 (CH,  C-1’), 80.8 (CH, 
C-2’), 73.7 (CH, C-4’), 71.2 (CH, C-3’), 63.2 (CH2, C-5’); IR Qmax (neat): 1730, 1655, 1601, 
1357, 1230, 1048, 902, 666 cm-1; HRMS m/z (ES+) (calculated C45H33N5NaO9+ = 810.2170) 
found 810.2169 [M+Na]+. Data are in agreement with literature.33 
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6.2.38. 6-Chloro-9-(2’,3’,5’-tri-O-benzoyl-β-D-pentofuranosyl)purine 196 
 
 
Benzoyl chloride (1.05 mL, 8.2 mmol, 4.1 eq.) was added to a suspension of 6-chloropurine 
riboside 195 (573 mg, 2.0 mmol, 1 eq.) in dry pyridine (12 mL) and the mixture was stirred at 
room temperature overnight. Ethanol (12 mL) was added to the reaction mixture and the 
solvents were removed in vacuo. The residue was diluted in DCM (100 mL) and washed with 
brine (3 × 100 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to 
dryness under reduced pressure. The residue was purified by silica gel column 
chromatography (EtOAc/PE 1:2) to afford 2’,3’,5’-tri-O-benzoyladenosine 196 (345 mg, 30%) 
as a white solid.    
Rf = 0.36 (EtOAc/PE 1:2); [α]20D : -65.5˚ (c 0.8, CHCl3) (lit.,34 -63.8° c 0.085, CHCl3); m.p. 115-
119 °C (lit.,34 114-115 °C); 1H-NMR (CHCl3, 300 MHz) δH 8.60 (1H, s, H-8), 8.27 (1H, s, H-2), 
8.10-7.89 (7H, m, ArH), 7.64-7.51 (3H, m, ArH), 7.50-7.33 (5H, m, ArH), 6.45 (H, d,                         
J = 5.1 Hz, H-1’), 6.41 (1H, t, J = 5.2 Hz, H-2’), 6.25 (1H, t, J = 5.2 Hz, H-3’), 4.94 (1H, dd,        
J = 12.1 Hz, J = 3.2 Hz, H-5’), 4.88-4-82 (1H, m, H-4’), 4.70 (1H, dd, J = 12.1 Hz, J = 4.1 Hz, 
H-5’); 13C-NMR (CHCl3, 100 MHz) δC 167.1 (C=O), 166.4 (C=O), 166.0 (C=O), 156.1 (Ar-CH, 
C-2), 154.7 (Ar-C), 154.1 (Ar-CH, C-8), 151.0   (Ar-C), 147.2 (Ar-CH), 144.9 (Ar-CH), 135.2 
(Ar-CH), 134.0 (Ar-CH), 133.7 (Ar-CH), 132.8 (Ar-CH), 130.5 (Ar-CH), 130.1 (Ar-CH), 130.0 
(Ar-CH), 129.3 (Ar-C), 128.7 (Ar-C), 128.5  (Ar-C), 121.3 (Ar-C), 80.9 (CH, C-1’), 75.7 (CH,   
C-2’), 70.5 (CH, C-4’), 69.2 (CH, C-3’), 65.3 (CH2, C-5’); IR Qmax (neat): 1749, 1604, 1585, 
1550, 1288, 1118, 742 cm-1; HRMS m/z (ES+) (calculated C31H23ClN4NaO7+ = 621.1147) found 
602.1147 [M+Na]+. Data are in agreement with literature.35  
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6.3. Biological methods 
 
6.3.1. General method 
 
Reagents were obtained from commercial sources (Acros Organic, Sigma, Fisher) and used 
without further purification.  
All microbiological works were carried out using standard sterile techniques under a 
Gallenkamp laminar flowhood. Experiments involving cell-free extract solutions were carried 
out at 4 °C or on ice. Glassware, equipment and consumable for biological works were 
sterilised by autoclaving, flaming or spraying with 70% ethanol, as appropriate prior to use. 
Media were sterilised by autoclaving. Cell cultures were incubated in a temperature controlled 
Gallenkamp orbit incubator or an Innova 2000 platform shaker. Centrifugation was carried out 
on a Beckman Avanti centrifuge. Micro-centrifugation was carried out on a Hettich Mikro 200 
bench-top centrifuge. Sonication was performed with a Vibra Cell apparatus from Sonics & 
Materials Inc. 
Optical density was measured at 600 nm using a Jenway 6300 Spectrophotometer. Protein 
concentrations were determined by a Nanodrop ND1000 Spectrophotometer. 
19F-NMR spectra were recorded with proton-decoupling in 10% D2O in H2O at 298 K on a 
Burker Avance 500 MHz spectrometer and calibrated with an external reference (CFCl3).  
6.3.2. Cultures of Streptomyces calvus 
 
Streptomyces calvus was grown on solid agar plates composed of soluble starch (10 g), 
dipotassium phosphate (1 g), magnesium sulfate VSP (1 g), sodium chloride (1 g), ammonium 
sulfate (2 g), calcium carbonate (2 g), ferrous sulfate (1 mg), manganous chloride (1 mg), zinc 
sulfate (1 mg), agar (20 g) and deionised H2O (1 L). The medium ISP4 was sterilised by 
autoclave before use. The plates were maintained at 30 °C where the bacteria mature after a 
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period of 20 days. The spores were collected by means of sterilised cotton swabs and stored 
at -80 °C in a 50% glycerol solution (Seed culture).36 
 
A mass of the mycelium of S. calvus was obtained by inoculating a sterilised, defined medium 
(100 mL) with the spores obtained above (Seed culture, use 1 to 5 µl per flask) and allowed 
to grow at 28 °C for 12 days in a 500 mL conical flask with shaking at 180 rpm. The defined 
medium is composed of tap H2O (1 L), corn steep liquor (12.5 g), mannitol (10 g), sodium 
chloride (2 g), Hoagland’s salt solution (1 mL), magnesium sulfate (0.25 g), monopotassium 
phosphate (1.5 g), potassium fluoride (7.5 mL, 0.5 M) and diammonium phosphate (2 g).  
 
Hoagland’s salt solution contains deionised H2O (1 L), H3PO3 (0.611 g), MnCl2.4H2O (0.389 
g), CuSO4 (0.056 g), ZnSO4.7H2O (0.056 g), Al2(SO4)3 (0.056 g), NiSO4.6H2O (0.056  g), 
Co(NO3)2.6H2O (0.056 g), (NH4)6Mo7O24.4H2O (0.056 g), TiO2 (0.056 g), LiCl (0.028 g), 
SnCl2.2H2O (0.028 g), KI (0.028 g) and KBr (0.028 g), and was sterilised by autoclaving. 
After 18 days of fermentation, the cells were discarded by centrifugation and the supernatant 
was extracted with n-butanol (20 mL). The organic layer was concentrated under reduced 
pressure. The extract was analysed by 19F-NMR (3600 scans). 
6.3.3. Pulse feeding experiments 
 
Cultures of S. calvus (100 mL) were shaken at 30 °C and labelled glycerol was added after 4 
days; the same quantity of labelled glycerol was added every two days for a total of 6 additions. 
The final concentration of labelled glycerol was between 8-10 mM. After 21 days of 
fermentation, the cells were discarded by centrifugation and the supernatant was extracted 
into n-butanol (20 mL). The organic layer was concentrated under reduced pressure. The 
extract was analysed by 19F-NMR (3600 scans) to detect nucleocidin. 
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6.3.4. Cell-free extract experiments 
 
The cells of Streptomyces sp. MA 37 were harvested by centrifugation (20 min, 13 000 rpm, 
4 °C) after an 8 day fermentation. The cell pellets were washed three times using Tris–HCl 
buffer (20 mM, pH 7.5) supplemented with 10 mM MgCl2 to remove remnant culture media. 
The cells were re-suspended in the same buffer (0.1 g wet-cell weight per mL). The cells were 
disrupted by ultrasonication (60% duty cycle for 30–60 s). Cell debris were removed by 
centrifugation (30 min, 13 000 rpm, 4 °C) and the resultant clear supernatant was used as the 
cell free extract for incubation experiments. The cell free extracts (1 mL) were supplemented 
with or without 5-FDR at 37 °C for 6 hours. At the end of the incubation period, protein was 
precipitated by heating the vial to 90 °C for 3 min and the protein was then removed by 
centrifugation. The supernatant was collected for 19F-NMR analysis.37  
 
The cells of Streptomyces calvus were harvested by centrifugation (20 min, 13 000 rpm,      4 
°C) after 7 day fermentation. The cell pellets were washed three times using Tris–HCl buffer 
(20 mM, pH 7.0) supplemented with 15 mM MgCl2 or phosphate buffer (15 mM, pH 7.0) 
supplemented with 15 mM MgCl2 to remove remnant culture media. The cells were re-
suspended in the same buffer used previously (0.1 g wet-cell weight per mL). The cells were 
disrupted by ultrasonication (60% duty cycle for 30–60 s). Cell debris was removed by 
centrifugation (30 min, 13 000 rpm, 4 °C) and the resultant clear supernatant was used as the 
cell free extract for incubation experiments. The cell free extracts (3 mL) were supplemented 
with a mix of substrates and co-factors at 37 °C overnight. At the end of the incubation period, 
protein was precipitated by heating the vial to 90 °C for 3 min and the protein was then 
removed by centrifugation. The supernatant was collected for 19F-NMR analysis.  
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